Neuroendocrine Alterations in Chronic Fatigue Syndrome by Majeed, Tahir
NEUROENDOCRINE ALTERATIONS IN 
CHRONIC FATIGUE SYNDROME.
BY
TAHIR MAJEED
A thesis submitted for the degree of Doctor of Philosophy 
in the Department of Neurology, Faculty of Medicine, 
University of Glasgow.
January, 1996.
University Department of Neurology 
Institute of Neurological Sciences 
Southern General Hospital 
Glasgow G51 4TF
© Tahir Majeed 1996
ProQuest Number: 13818532
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13818532
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
'fCrU
lojfl
/
GLASGOW
UNIVERSITY
LIBRARY
DECLARATION
I hereby declare that the work presented in this thesis is original and was 
conducted solely by the author, except where collaboration with others is 
acknowledged.
DEDICATION
To my parents.
Thank you for the love, 
prayers, encouragement and 
sacrifice that enabled me 
to go through this study.
ACKNOWLEDGEMENTS
I would like to express my sincere gratitude to Professor P O Behan, my supervisor 
for his patience, guidance, helpful criticism, advice and encouragement.
I would also like to thank Professor P G E Kennedy for his support and advice over 
the past two years.
I am also grateful to Dr John Gow and Dr W M H Behan for constant help and 
kindness throughout the course of this work, Dr Stig Hansen and Dr Peter Julu, 
Department of Clinical Physics, for statistical help.
Finally, I am thankful to all patients, their relatives and friends who were keen to 
participate in this study and eager to help with these experiments.
This work was funded by the Barclay Research Trust at Glasgow University.
ABBREVIATIONS
ACh Acetylcholine
AChE Acetylcholinesterase
ACTH Adrenocorticotropin hormone
ADX Adrenalectomy
AMP Adenosine monophosphate
ANOVA Analysis of variance
ATP Adenosine triphosphate
AVP Arginine vasopressin
CAT Choline acetyltransferase
CDC Centers for Disease Control
CFS Chronic fatigue syndrome
cGMP Cyclic guanocine monophosphate
CNS Central nervous system
COMT Catechol-O-methyltransferase
CPK Creatine phosphokinase
CRF Corticotropin releasing factor
CRH Coriticotropin releasing hormone
CRNA Complementary RNA
Cu Copper
DA Dopamine
V
DAG Diacylglycerol
D2 receptor Dopamine receptor
DEX Dexamethasone
DNA Deoxyribonucleic acid
DOPA Dihydroxyphenylalanine
EA Early antigen
EBV Epstein Barr virus
ER Endoplasmic reticulum
ESR Erythrocyte sedimentation rate
FSH Follicle stimulating hormone
G Nucleotide regulatory protein
GABA Gamma aminobutyric acid
GABA-T GABA a oxoglutarate transaminase
GAD Glutamic acid decarboxylase
GH Growth hormone
GHRH Growth hormone releasing hormone
Gi Inhibitory nucleotide regulatory protein
GnRH Gonadotropin releasing hormone
GR Glucocorticoid receptor
Gs Protein Stimulatory nucleotide regulatory protein
HHV Human herpes virus
HIAA Hydroxyindoleacetic acid
HIV Human immune deficiency virus
HLA Human leucocytic antigen
HPA Hypothalamic-pituitary-adrenal axis
HTL-V Human T cell lymphotropic vims
5-HT 5-hydroxytryptamine
IgA Immunoglobulin A
IgD Immunoglobulin D
IgG Immunoglobulin G
IGF Insulin-like growth factor
IgM Immunoglobulin M
IP3 Inositol triphosphate
IPSP Inhibitory postsynaptic potential
LCMV Lymphocytic choriomeningitis vims
LH Luteinizing hormone
LHRH Luteinizing hormone releasing hormone
MHC Major histocompatibility complex
MHPG Methoxy hydroxyphenethyleneglycol
MR Mineralocorticoid receptor
mRNA Messenger RNA
NA Noradrenaline
NE Norepinephrine
NK Natural killer cell
NMR Nuclear magnetic resonance
NREM Non-rapid eye movement
PCR Polymerase chain reaction
PIP2 Phosphatidylinositol diphosphate
PLC Phospholipase C
PKC Protein kinase C
PRF Prolactin releasing factor
PRL Prolactin
REM Rapid eye movement
Ri Inhibitory receptor
RNA Ribonucleic acid
Rs Stimulatory receptor
SEM Standard error of mean
SRIF Somatotropin release-inhibiting factor
SS Somatostatin
SSADH Succinic semi-aldehyde dehydrogenase
TRH Thyrotropin releasing hormone
TSH Thyroid stimulating hormone
VIP Vasoactive -intestinal peptide
VMA Vanillylmandelic acid
ol Alpha
i3 Beta
A Delta
iv
PUBLICATIONS
Majeed T, Dinan TG, Thakore J, Gray C, Behan PO (1995). Defective 
dexamethasone induced growth hormone release in chronic fatigue syndrome: 
Evidence for glucocorticoid receptor resistance and lack of plasticity? J Irish Coll 
Phys & Surg 24(1), 20-24.
Majeed T, Behan PO (1995). Clinical overview of chronic fatigue syndrome. EOS J 
Immunol Immunopharmacol Vol xv n 1-2, 8-14.
Majeed T, De Simone C, Famularo G, Marcellini S, Behan PO (1995). Abnormalities 
of carnitine metabolism in chronic fatigue syndrome. Eur J Neurol 2, 1-4.
Majeed T, Dinan TG, Behan PO (1995). Pyridostigmine-induced growth hormone 
responses; evidence for cholinergic supersensitivity in chronic fatigue syndrome 
(Abs.). Proceedings of First World Congress on Chronic Fatigue Syndrome and 
Related Disorders, Brussels 1995.
Majeed T, Dinan TG, Behan PO (1995). Baclofen-induced growth hormone release: 
does the GABA play any role in the pathophysiology of chronic fatigue syndrome? 
(Abs.) Proceedings of First World Congress on Chronic Fatigue Syndrome and 
Related Disorders, Brussels 1995.
Majeed T, Dinan TG, Behan PO (1995). Ipsapirone-induced ACTH release - 
evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients 
with chronic fatigue syndrome. (Abs.) Proceedings of First World Congress on 
Chronic Fatigue Syndrome and Related Disorders, Brussels 1995.
Majeed T, Dinan TG, Behan PO (1995). Desipramine-induced growth hormone 
release in chronic fatigue syndrome: evidence for reduced a-adrenoceptor 
responsiveness (Abs.). Proceedings of First World Congress on Chronic Fatigue 
Syndrome and Related Disorders, Brussels 1995.
TITLE i
DECLARATION ii
DEDICATIONS iii
ACKNOWLEDGEMENTS iv
LIST OF ABBREVIATIONS v
PUBLICATIONS x
CONTENTS xi
LIST OF FIGURES xv
LIST OF TABLES xviii
SUMMARY xix
A GENERAL OVERVIEW OF CHRONIC FATIGUE SYNDROME
1.1 DEFINITION 2
1.2 A CRITIQUE OF PRESENT DEFINITIONS. 6
1.3 CRITERIA USED FOR DEFINING PATIENTS STUDIED
IN THIS THESIS. 11
1.4 HISTORY 12
1.5 GENERAL DATA 18
1.5.1 Prevalence 18
1.5.2 Geographical Distribution 18
1.5.3 Gender 18
1.5.4 Genetics 19
1.6 AETIOLOGY 19
1.6.1 Infection 19
1.6.2 Metabolic 24
1.6.3 Immunology 27
1.6.4 Psychiatry 29
1.6.5 Autonomic nervous system 30
1.7 CLINICAL FEATURES 31
1.7.1 Mode of Presentation 31
1.7.2 Precipitating Factors 32
1.7.3 Symptoms 32
1.8 EVIDENCE FOR HYPOTHALAMIC INVOLVEMENT 42
1.8.1 Clinical Data 42
1.8.2 Laboratory Evidence 43
GENERAL NEUROENDOCRINOLOGICAL DATA 46
2.1 INTRODUCTION 47
2.1.1 Hormones 47
2.1.2 Chemical Nature of Hormones 49
2.1.2.1 Peptide Hormones 49
2.1.2.2 Steroid Hormones 50
2.2 HYPOTHALAMIC-HYPOPHYSEAL AXIS 56
vii
2.2.1 The Hypothalamus 57
2.2.2 The Pituitary 60
2.3 ASSESSMENT OF NEUROTRANSMITTER
(BRAIN RECEPTOR) FUNCTIONS 73
2.3.1 Neurotransmitters 73
2.3.1.1 Acetylcholine 73
2.3.1.2 Gamma-aminobutyric acid 76
2.3.1.3 Serotonin 78
2.3.1.4 Dopamine 82
2.3.1.5 Noradrenaline 86
2.3.2 Neuroendocrine Challenge Tests 89
2.4 OUTLINE AND AIMS OF STUDIES 91
GENERAL METHODS AND SUBJECTS 93
3.1 SUBJECTS 94
3.2 PROCEDURE 95
3.3 HORMONAL ASSAYS 95
3.4 STATISTICAL ANALYSIS 96
3.5 DRUGS ADMINISTERED 97
3.6 STUDY 1: 5-HT MEDIATED PROLACTIN RELEASE 100
3.7 STUDY 2: SEROTONIN MEDIATED ACTIVATION OF
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS 101
3.8 STUDY 3: DEXAMETHASONE INDUCED GROWTH 
HORMONE RELEASE 103
3.9 STUDY 4: DESIPRAMINE INDUCED GROWTH
HORMONE RELEASE 105
3.10 STUDY 5: PYRIDOSTIGMINE INDUCED GROWTH
HORMONE RELEASE 106
3.11 STUDY 6: GROWTH HORMONE RELEASE IN
RESPONSE TO DOPAMINE AGONIST 
BROMOCRIPTINE 109
3.12 STUDY 7: BACLOFEN INDUCED GROWTH
HORMONE RELEASE 110
RESULTS 113
4.1 STUDY 1 114
4.2 STUDY 2 117
4.3 STUDY 3 122
4.4 STUDY 4 129
4.5 STUDY 5 132
4.6 STUDY 6 135
4.7 STUDY 7 138
DISCUSSION AND CONCLUSION 141
REFERENCES 165
xiv
LIST OF FIG URES
2.1 Cyclic AMP (cAMP) as a second messenger in the action
of polypeptide and glycoprotein hormones. 51
2.2 Biosynthetic pathways for steroid hormones and their
chemical structures. 52
2.3 The Mechanisms of action of a steroid hormone (H) on the
target cells. 54
2.4 Diagram of the nuclei within the hypothalamus. 58
2.5 The structure of the pituitary gland seen in sagittal view. 62
2.6 The posterior pituitary or neurohypophysis stores and
secretes hormones produced in neuron cell bodies within 
the supraoptic and paraventricular nuclei of the hypothalamus 
and are transported to the posterior pituitary by nerve fibres
of the hypothalamo-hypophyseal tract. 63
2.7 Control of growth hormone secretion and its action. 66
2.8 Control of prolactin secretion. 69
2.9 Regulation of synthesis and secretion of adrenal
corticosteroids. 71
2.10 Synthesis, storage, release and destruction of
acetylcholine. 75
2.11a Horizontal projections of ascending serotinin pathways. 79
2.1 lb Schematic diagram of central serotonergic cell groups and
projections in sagittal sections from rat brain. 80
2.12a Sagittal projection of dopamine pathways in rats. 83
w
2.12b
2.13
4.1.1
4.1.2
4.2.1
4.2.2
4.2.3
4.2.4
4.3.1
4.3.2
4.3.3
Horizontal projections of the ascending dopamine and 
noradrenaline pathways. 84
Noradrenaline projections by histochemistry; sagittal 
projections of the ascending noradrenaline pathways. 87
Prolactin responses (Aprolactin) to buspirone challenge 
in CFS and healthy controls. 115
Prolactin responses as a function of time after buspirone 
administration. 116
Baseline ACTH levels in patients with CFS and in healthy 
comparison subjects. 118
Baseline cortisol levels in patients with CFS and in healthy 
comparison subjects. 119
ACTH responses to ipsapirone challenge in CFS and 
healthy controls. 120
ACTH responses (A ACTH) to ipsapirone challenge in 
CFS and in healthy comparison subjects. 121
Phase 1. Growth hormone responses (A GH) to 
dexamethasone (DEX) in controls, patients with CFS 
and in patients with depression. 124
Phase 1. Mean plasma GH responses as a function of 
time after DEX in patients with CFS, depressives and 
matched controls. 125
Phase 2. Growth hormone responses (A GH) to 
dexamethasone (DEX) in controls, patients with CFS 
and in patients with depression. 126
w i
127
128
130
131
133
134
136
137
139
140
Phase 2. Mean plasma GH responses as a function of 
time after DEX in patients with CFS, depressives and 
matched controls.
Mean cortisol levels in patients with CFS, depressives 
and healthy comparison subjects before and after 
metyrapone.
GH responses (A GH) to desipramine in controls and 
patients with CFS.
GH responses as a function of time after desipramine in 
patients with CFS and matched controls.
GH responses (A GH) to pyridostigmine in controls and 
patients with CFS.
GH responses as a function of time after pyridostigmine in 
patients with CFS and matched controls.
GH responses as a function of time after bromocriptine to 
patients with CFS and matched controls.
GH responses (A GH) to bromocriptine in controls and 
patients with CFS.
GH responses (A GH) to baclofen in patients with CFS 
and in controls.
GH responses as a function of time after baclofen to 
patients with CFS and matched controls.
xvii
Table 1 
Table 2
LIST OF TABLES
Comparison of case definitions of chronic fatigue syndrome. 10 
Anterior pituitary hormones and their regulation. 64
wiii
SUMMARY
Chronic fatigue syndrome (CFS) is an illness that occurs worldwide. Over the years 
the syndrome has had various labels, ranging from the Victorian one of neurasthenia 
to the putative neurological diagnosis of benign myalgic encephalomyelitis (Acheson 
1959). A working case definition was published by the Centers for Disease Control in 
1988 (Holmes et al) and revised in 1994 (Fukuda et al).
In the initial studies of patients with CFS, impaired activation of hypothalamic- 
pituitary-adrenal (HPA) axis (Demitrack et al 1991) and monoaminergic dysfunction 
(Demitrack et al 1992; Bakheit et al 1992) was reported. Dynamic neuroendocrine 
challenge tests provide one of the only methods for examining neurotransmitter 
function in vivo in humans (Checkley 1980). In the following studies these tests were 
used to examine different neurotransmitter systems and their influence on the 
functional activity of the HP A, hypothalamic-somatotroph and hypothalamic-prolactin 
axes.
In the first study, serotonin (5-HT) function in CFS was evaluated using the specific 
5-HT1A receptor agonist, buspirone. It was found that prolactin responses to this 
agent were augmented in patients with chronic fatigue syndrome compared to healthy 
controls. This finding does not support the view that CFS is a form of depressive 
disorder because in depression, prolactin responses to this 5-HT 1A agonist (Bakheit 
et al 1992) and to d-fenfluramine (Cleare et al 1995) are blunted reflecting decreased
Y1Y
5-HT neurotransmission. The study is therefore of importance in suggesting that 
CFS unlike depression, may be associated with increased 5-HT function.
The second study is based on the hypothesis that abnormalities in the HPA-axis 
(Demitrack et al 1991) arise from a disturbance in serotinergic neurotransmission. 
ACTH and cortisol responses to the selective 5-HT 1A receptor agonist ipsapirone 
were examined: no differences in baseline ACTH and cortisol levels were found but 
in CFS, there was significant attenuation of ACTH release.
Study 3 was designed to demonstrate the functional integrity of the hypothalamic- 
somatotroph axis and its interaction with the HPA-axis. Growth hormone (GH) 
responses to dexamethasone were examined in two phases, before and after the 
administration of metyrapone, an inhibitor of 11-/5 hydroxylation, given to block 
steroid synthesis and upregulate brain steroid receptors. Blunted responses were 
recorded in each phase in patients with CFS and depression compared to healthy 
controls. It is concluded that the abnormality found is compatible with a decrease 
response and/or a lack of plasticity in cerebral glucocorticoid receptors.
In study 4, noradrenergic function was examined by measuring GH responses to the 
monoamine reuptake inhibitor, desipramine; blunted responses were found in patients 
with CFS, compared to healthy individuals. It is concluded that the attenuated 
response is due to decreased sensitivity of the a l - postsynaptic adrenoceptor, 
secondary to a hyperadrenergic state, indicating that central noradrenergic function is 
decreased in patients with CFS.
X X
In study 5, growth hormone responses to anticholinesterase, pyridostigmine were 
examined: augmented responses were found in the CFS group, compared to the 
healthy individuals. This enhanced response reflects increased sensitivity of 
acetylcholine (ACh) neurotransmitter function in CFS.
In studies 6 & 7, growth hormone responses to the dopamine agonist, bromocriptine, 
and to the GABA (B) agonist, baclofen, were measured in order to assess dopamine 
(DA) and GABA neurotransmitter function. The responses in patients with CFS were 
the same as in the healthy controls. It is concluded that dopamine (DA) and GABA 
neurotransmitter systems are not involved in the pathophysiology of CFS.
In summary, the neuroendocrine investigations revealed positive findings of a) 
upregulation of 5-HT receptors with increased 5-HT function, b) impaired activation 
of the HPA-axis to serotonin input, c) cerebral steroid receptor resistance and d) 
reciprocal dysfunction in noradrenaline (NE) and acetylcholine (ACh)-mediated 
endocrine responses. These findings suggest that CFS is an organic illness with 
definite neuroendocrine abnormalities. Some of the neuroendocrine abnormalities are 
similar to those reported in depression, suggesting the reason why these two illnesses 
may share common symptoms.
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GENERAL OVERVIEW OF CHRONIC FATIGUE SYNDROME
1.1 DEFINITION
Fukuda et al (1994) described a case definition of chronic fatigue syndrome (CFS) 
from the Centers for Disease Control (CDC) Atlanta, USA, revising the previous 
working model published in 1988 (Holmes et al 1988). According to the new 
definition, CFS is >
A. Clinically evaluated, unexplained, persistent or relapsing chronic fatigue that is
of new or definite onset; is not the result of ongoing exertion: is not
substantially alleviated by rest: and results in substantial reduction in previous 
levels of occupational, educational, social or personal activities.
B. The concurrent occurrence of four or more of the following symptoms, all of 
which must have persisted or recurred during six or more consecutive months 
of illness and must not have predated the fatigue:
a. Self-reported impairment in short-term memory or concentration if 
severe enough to cause substantial reduction in previous levels of 
occupational, educational, social or personal activities, b. Sore 
throat, c. Tender cervical or axillary lymph nodes, d. Muscle pain,
e. Multi-joint pain without joint swelling or redness, f. Headaches of 
a new type, pattern, or severity, g. Unrefreshing sleep, h. 
Postexertional malaise lasting more than 24 hours.
This Working Case Definition, has to be used for research in clinical practice until 
more is known about the exact pathogenesis of CFS.
2
In the United Kingdom several different definitions were used, prior to the American 
CDC (1994) case description. United Kingdom researchers met in Oxford in 1990 
for the purpose of proposing a working case definition for the United Kingdom 
(Sharpe et al 1991). A number of clinical syndromes had been described in the past 
which included chronic infectious mononucleosis (Isaacs, 1948), Icelandic disease 
(Sigurdsson 1950), Royal Free disease (Acheson 1955), benign myalgic 
encephalomyelitis (Galpine and Brady, 1957), epidemic neuromyasthenia (Henderson 
and Shelokov 1959), postviral fatigue syndrome (Behan et al 1985), fibrositis 
fibromyalgia (Pritchard 1988; Yunus 1989) and chronic fatigue syndrome (Holmes et 
al 1988).
The UK experts proposed division into two broad groups i.e. - Chronic Fatigue 
Syndrome, and Postinfectious Fatigue Syndrome.
CFS was characterized by the following features:
a. Fatigue must be the principal symptom.
b. The syndrome must be definite in onset.
c. Be severe, disabling and have an effect on physical and mental (cognitive) 
functioning.
d. Fatigue must have been present for more than 50% of the time for at least 
six months.
e. Symptoms, including myalgia, mood and sleep disturbances could be 
present.
f. Patients with medical conditions known to produce chronic fatigue and 
patients with a current diagnosis of schizophrenia, manic depressive 
illness, substance abuse, eating disorders or proven organic brain disease, 
were to be excluded. However, other psychiatric disorders such as 
depressive illness and anxiety disorders were not grounds for exclusion.
3
Postinfectious syndrome must:
Fulfil criteria for CFS and have in addition
a Definite evidence of infection at onset or presentation,
b The syndrome had to be present for a minimum of six months
after the onset of infection, 
c The infection had to have been corroborated by laboratory
evidence.
In 1988, in America Holmes and colleagues at the CDC in Atlanta attempted to
define the syndrome. To meet their case definition for CFS, a case must fulfil both
major and minor criteria (Holmes et al 1988).
Major Criteria: -
a. The new onset of persistent or relapsing, debilitating fatigue in a person without a 
previous history of such symptoms that did not resolve with bed rest and that was 
severe enough to reduce or impair average daily activity to less than 50% of the 
patients premorbid activity level for at least six months.
b. Exclusion by a thorough evaluation based on history, physical examinations, and 
appropriate laboratory tests, of other clinical conditions that might produce 
similar symptoms.
Minor Criteria: - 
Symptoms
4
a, Mild fever (oral temperature between 37.6°C and 38.6°C if measured by the 
patient, or chills), b, Sore throat, c, Painful lymphadenopathy (anterior or posterior 
cervical and axillary distribution), d, Unexplained generalised muscular weakness, e, 
Muscle discomfort or myalgia, f, Prolonged (more than 24 hours) generalised fatigue 
after previously tolerated levels of physical activity, f, Headaches, g, Migratory 
arthralgia without joint swelling or redness, h, Neuropsychiatric complaints (one or 
more of the following - photopobia, transient visual scotomata, forgetfulness, 
excessive irritability, confusion, difficulty thinking, depression and inability to 
concentrate), i, Sleep disturbance, j, Main symptom complex developing over a few 
hours to a few days.
Signs:-
a, Lymphadenopathy. b, Nonexudative pharyngitis, c, Low grade fever.
For a diagnosis of CFS to be made the patient must have fulfilled two major criteria 
and either eight of the eleven symptoms or have six symptoms and two signs.
Others in Australia (Lloyd et al 1990) designed yet another definition. According to 
them this syndrome requires the presence of the following features.
a. Chronic persisting or relapsing fatigue causing significant disruption of usual daily 
activities that has been present for more than six months.
b. Postexertional fatigue.
c. Neuropsychiatric (cognitive) dysfunction including new onset of impairment of 
short term memory and concentration.
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d. No alternative diagnosis was reached by history, physcial examination or 
laboratory investigations over a six month period.
Behan and Bakheit (1991) have also given a clinical description of the illness with a 
differential diagnosis. The older clinical works on the syndrome did not set out a 
clear cut definition. For example, Acheson in his classical paper (Acheson 1959) 
while discussing the various outbreaks of this disorder, did not mention the fatigue 
but showed that all the patients shared the following characteristics: a) headaches; b) 
myalgia; c) paresis; d) symptoms or signs other than paresis suggestive of damage to 
the brain, spinal cord or peripheral nerves; e) mental symptoms; f) low or absent fever 
in most cases; h) no mortality. In addition,there was a) a higher frequency in women; 
b) a predominantly normal cerebrospinal fluid; and c) relapses were frequent in all of 
the outbreaks. Later, as knowledge of the illness grew, physicians concentrated on 
the fatiguability and muscle pain (Shelokov 1972). It is now readily accepted that the 
term “chronic fatigue syndrome” will, until more is known of its exact pathogenesis, 
be the correct term, and the CDC 1994 Working Case Definition will be used as the 
operative definition.
1.2 A CRITIQUE OF PRESENT DEFINITIONS
The working case definition for CFS is based entirely on symptoms which cannot be 
measured objectively. Complaints can be exaggerated, coloured or magnified, 
particularly if the patient is psychoneurotic. The patients have to tell the truth. 
Physical signs are not very reliable since non-exudative pharyngitis is a common 
finding in smokers, singers and those exposed to dust. Lymphadenopathy, 
particularly in the cervical region, can merely represent recent or chronic infection in 
the head and neck. Lymph node enlargement in the posterior cervical area can persist 
for a long time after exposure to rubella. Fever is the only physical criteria which can
6
be given some consideration, provided it is noted by a reliable person on more than 
one occasion: one reading at the time of examination is not sufficient.
One of the clinical characteristics of the illness is that the majority of patients have an 
acute onset with a flu-like illness, accompanied by upper respiratory tract symptoms 
or gastroenteritis (Acheson 1959; Holt 1965). The illness has also been observed in 
farmers and agricultural workers exposed to sheep dips and insecticides containing 
organophosphates (Behan and Haniffah 1994). Cases have also been reported after 
gastroenteritis due to ciguatera poisoning (Gillespie et al 1986). Despite these 
observations there is no mention of precipitating factors in the present definition.
Since the CDC diagnosis is one of exclusion, one is at loss to know which 
investigations are necessary to rule out the many diseases causing fatigue, including 
malignancy, autoimmune diseases, chronic or subacute bacterial, fungal and parasitic 
disease, disease related to HIV infection, anemia, metabolic or neuromuscular 
disease, drug dependency or abuse, and chronic pulmonary, cardiac, gastrointestinal, 
hepatic, renal or hematologic disorders.
In the present definition, the cut-off time is six months which is not long enough to 
exclude carcinoma on the basis of history alone. A rating scale should be used with 
regard to symptoms since the more symptoms that are, the less likely is the condition 
to be organic, and less extensive investigations are required.
Another charateristic of the disease is that most of these patients have a tendency to 
maintain a meticulous chronologic symptom diary and are inclined to be 
hypergraphic. Shafran (1991) feels this fact should also be incorporated into the 
definition. They also stress that a history of the patient having consulted many
7
physicians previously (as such patients are often referred from physician to physician),
should also be included.
Characteristics of exertion have not been dealt with in great detail. One should 
realise that exertion and exercise may precipitate other disorders presenting as 
fatigue, for example McArdle's disease and acid maltase deficiency. Measurement of 
exercise is of particular importance in these patients, particularly those who claim 
disability benefit and put claims to their insurance companies.
A lag period is not included in the definition. Fatigue may not appear immediately 
after exertion. Similarly where rest is referred to, its duration and quality are not 
defined (Armon and Kurland 1991).
The major criteria in the CDC 1988 definiton exclude all those who cannot afford to 
reduce their average daily activity to less than 50% due to personal and professional 
demands. Quantification of a 50% reduction is very difficult, if not impossible.
The psychiatric evaluation used to exclude previous and present psychopathology is 
not clearly defined (Armon and Kurland 1991). There is no mention of exclusion of 
those who have a history of psychiatric illness but have not consulted a psychiatrist 
for precise diagnosis. Again there is no mention of personality disorders. Is it 
necessary for every patient to be seen by a psychiatrist in order to exclude psychiatric 
disorders, when 50% of the patients have no psychiatric illness whatsoever and 
standardisation of the diagnosis among psychiatrists is so controversial (Nathan et al 
1969).
For epidemiologic purposes, where a questionnaire is used, the CDC definition does 
not work well since it refers to physical signs as well as symptoms. In order to
8
confirm such physical signs, each patient should be examined by a physician. The 
definition therefore cannot be relied on for epidemiological studies (Grufferman 
1991).
A number of papers have drawn attention to the fact that the illness begins acutely, in 
as many as 85% of cases (Komaroff and Buchwald 1991). The working case 
definition of the CDC 1988 tends to ignore this important point but it is one which 
argues strongly for an organic aetiology. Since the illness may consist of 
heterogenous groups of patients (Wessely and Thomas 1989; Lane et al 1995) one of 
the purposes of the revised CDC 1994 case definition should be to define a patient 
group whose heterogeneity is reduced.
In all four definitions, as might be expected, there are similarities. All are agreed that 
the duration of fatigue should be six months; however, as seen from Table 1 
(modified after Bates et al 1994 a) there is disagreement on the type or quality of 
fatigue severity. Fatigue, in both CDC definitions is required to be of new onset 
while in the British classification the onset is defined as “definite.” Both the CDC 
guidelines, lay emphasis on minor criteria, i.e. according to the CDC (1988) definition 
six or eight symptoms are required, although in the CDC (1994) definition, physicial 
signs are dropped, the number of symptoms are decreased from eight to four and the 
total from eleven to eight symptoms. This will certainly increase the number of 
patients who fulfil the criteria and therefore this definition has to be regarded as less 
specific.
One of the major problems with all these case definitions, is that they rely on self- 
reporting and the reliability of this can only be improved with the introduction of a 
standardised fatigue scale.
9
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Bates et al (1994 a) compared all the definitions and demonstrated that the 
percentage of the patients identified as having CFS were relatively similar when each 
of these definitions were used.
1.3 CRITERIA USED FOR DEFINING PATIENTS STUDIED IN THIS
THESIS
Patients included in the studies of this thesis fulfilled the following criteria:
1. Acute onset of fatigue, which was severe enough to prevent them continuing 
in their occupation, prevented women from carrying out their household 
duties and dramatically altered their social and personal lives. It fluctuated 
with time and was made worse by exercise.
2. At least two of the following four were present:
a. Sleep disturbance (hypersomnia or insomnia).
b. Myalgia/arthralgia.
c. Neurobehavioural complaints (inability to concentrate, difficulty
thinking, forgetfulness, anomia, atypical depression, generalised 
headaches).
d. Symptoms of irritable bowel syndrome - bloated stomach, colicky
abdominal pain, alternating diarrhoea or constipation.
3. Patients with complaints of excessive sweating, chest pains, palpitations, 
dysequilibrium and recurrent infections were also included but this was not 
mandatory for inclusion into the studies.
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4 Patients who were excluded from the studies included:
a. Patients with established medical conditions known to cause chronic 
fatigue.
b. Patients with a current diagnosis of schizophrenia, manic depressive 
psychosis or substance abuse.
In addition, all the patients incuded were seen at the Institute of Neurological 
Sciences and were hospitalized as inpatients. Detailed present and previous medical 
histories, a family, drug and occupational history were taken; physical and 
neurological examination and psychiatric evaluation were carried out. Laboratory 
tests included ESR, complete blood count and differential white blood count, protein 
electrophesis, serum electrolytes, glucose, creatine, blood urea, serum calcium and 
phosphate, liver function tests, muscle enzymes (CPK and aldolase), urinalysis, chest 
x-rays, thyroid function tests, serum cortisol and anti-nuclear antibodies screen were 
also carried out in order to exclude any other medical cause for their fatigue.
1.4 HISTORY OF CHRONIC FATIGUE SYNDROME:
Chronic fatigue syndrome is not of recent origin. It has been described in the medical 
literature since the mid 1700s under a wide variety of names, each reflecting a 
particular concept of the syndrome’s aetiology and epidemiology.
In 1750, Richard Manningham used the term “febricula” describing its features as 
including “little low, continued fever, ... little transient chilliness ... listlessness with 
great lassitude and weariness all over the body ... little flying pains ... sometimes the 
patient is a little delirious and forgetful” (Manningham 1750). He considered the
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syndrome to be common in females, the sedentary and studious and to be precipitated 
by grief, intense thought and taking cold.
In the first half of the 19th century, Austin Flint used the term nervous exhaustion to 
describe chronic fatigue.
George Beard, an American neurologist, coined the term neurasthenia (Beard 1869), 
describing its features as profound fatiguability of body and mind. He considered it to 
be an organic illness: “it is a physical not a mental state” (Beard 1881) with increased 
prevalence in the educated and professional classes. Neurasthenia was defined as a 
condition of nervous exhaustion, characterized by undue fatigue on minimal exertion, 
both physicial and mental, headache, gastrointestinal disturbances, and subjective 
sensations of all kinds (Cobb 1920) without any signs. Blocq (1894) reported that 
sufferers were well nourished, muscularly well developed and looked normal, 
although others described states of complete motor helplessness (Ferrier 1911). At 
the beginning of the 20th century these views were largely superseded by the new 
psychiatric diagnoses such as anxiety and depression, but traces of them survive in 
such conditions as chronic brucellosis, reactive hypoglycemia, chronic candidiasis and 
environmental hypersensitivity disorders. Neurasthenia itself remains a popular 
diagnosis in China, South East Asia and Eastern Europe.
Demise of Neurasthenia and Emergence of Post-infectious Fatigue Syndrome:
The first descriptions of neurasthenia included a link with febrile illness since Beard’s 
descriptions included “general and local chills and flashes of heat” (Beard 1880). 
This link was widely acknowledged by 1914 and various objective agents were held 
responsible for the illness (Robertson 1919; Craig 1922). These observations, 
however, were never confirmed scientifically and scepticism increased (Streckler 
1920). The decline in neurasthenia did not end these attempts and in 1934, Alice
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Evans tried to establish that chronic fatigue was the result of chronic brucellosis 
(Evans 1947) while chronic candidiasis was held responsible by Truss (1981) and 
Crook (1983). In the 1980’s, several studies linked chronic fatiguability to the 
Epstein Barr virus. The term “chronic Epstein Barr infection” was introduced when 
some patients with chronic fatigue were found to have raised levels of antibodies to 
EBV antigens (Straus et al 1985; Straus 1988). Further investigations revealed that 
all these organisms can cause chronic illness, but such illnesses were readily 
distinguished from chronic fatigue syndrome, the term introduced in the USA 
(Holmes et al 1988) and Australia (Lloyd et al 1988).
A series of epidemics of CFS were reported between 1930 and 1960. These have 
been called after their location or by their resemblance to neurological conditions.
Epidemics:
1934 - Los Angeles City and California State, USA
The first epidemic occurred in the summer of 1934, a few weeks after an outbreak of 
poliomyelitis and affected 198 members of the medical and nursing staff of Los 
Angeles County General Hospital (Gilliam 1938). As the outbreak developed, 
certain clinical and epidemiologic features i.e. a high attack rate with a low mortality 
rate, a low paralytic rate and a high incidence in adults, appeared making the 
diagnosis of poliomyelitis unlikely. The epidemic ended, but over 300 sporadic cases 
were seen in southern California between 1948 and 1965 (Marinacci and Von Hagen 
1965).
1937 - Erstfeld, Switzerland, Frohburg Hospital, Switzerland
In July 1937, out of 930 men stationed at Erstfeld, 130 were affected. No permanent
disability was recorded (Stahel 1938). Later in the summer, another outbreak in St
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Gall hospital at Frohburg was recorded, affecting patients and hospital staff The 
features of the epidemic included meningeal involvement, muscle paresis, prolonged 
convalescence with relapses, autonomic disturbances and marked fatiguability (Gsell 
1938).
1939 - Degersheim, St Gallen, Switzerland
In September 1939, 73 out of 800 military officers who arrived at Degersheim from 
an area in which there was a poliomyelitis epidemic, developed symptoms suggestive 
of neuromyasthenia (Gsell 1949).
1942 & 1945 - Epidemic - Harefield Sanatorium, Middlesex, England & 
Pennsylvania, USA.
At the same time there was a small outbreak among young nurses at Harefield 
sanatorium, England (Houghton and Jones 1942). In 1945 an epidemic of 
pleurodynia with prominent neurologic symptoms and no demonstrable cause 
occurred in University Hospital of Pennsylvania, USA.
1948-1949 - Epidemic in Iceland
A large epidemic, originally diagnosed as poliomyelitis, broke out in the town of 
Akureyri, in Iceland, in the winter of 1948. Four hundred and sixty-five cases were 
reported (Sigurdsson et al 1950), mainly high school children in the age group of 15- 
19 years. The disease was characterized by mild fever, muscle tenderness confined to 
small spots, fatiguability, disturbed sensations, emotional instability and irritablity. 
Paresis of one or more muscles was present in 30% of the cases. The rapid spread of 
the epidemic in the town pointed to an infectious agent but all attempts at isolation 
were negative. The only clue as to a possible infectious agent was that 5 years later a 
large epidemic of poliomyelitis due to type 1 virus occurred in Iceland, affecting all
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areas except those where Akureyri (Iceland) disease had occurred in 1948 
(Sigurdsson et al 1958). Over 50% of the school children in the areas affected by 
poliomyelitis had antibodies to type 1 virus, but those in Akureyri had no specific 
antibody. In 1956 after polio vaccination, children in Akureyri produced unusually 
high specific antibody titres, suggesting that they had been exposed to an agent 
immunologically similar, but not identical to the polio virus.
1949-1951 - Epidemic in Adelaide, South Australia
In the Adelaide epidemic, the acute illness was short, diffuse muscle weakness was 
common, fever was trivial, recovery was rapid and there was no deaths (Pellew 
1951). A recurrence of the disease, manifested as hyperacusis, depression and fatigue 
often occurred 4-8 weeks after the original illness.
1950 - Epidemic - New York State, USA
In the autumn of 1950 there was a widespread epidemic of poliomyelitis in New York 
State, USA. White and Burtch (1954) studied 19 cases and noted a close similarity 
to the description of the Icelandic outbreak. Lymphadenopathy, ulnar or sciatic nerve 
lesions, muscle tenderness and aching, paresis unaccompanied by a change in reflexes 
or muscle bulk, and depression were reported. It was concluded that the condition, 
though resembling it, was not poliomyelitis.
1952-1955
During these years different outbreaks were recorded from Middlesex Hospital, 
London (Acheson 1954), Whitley Hospital, Coventry and Coventry District, England 
( Macrae and Galpine 1954), Copenhagen, Denmark (Fog 1953), Lakeland, Florida, 
USA (Henderson and Shelokov 1959), Addington Hospital, Durban and Durban City, 
South Africa (Hill 1955), Dalston, Cumbria, England (Wallis 1955) and Royal Free 
Hospital, London (Compston 1956).
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1955 - Epidemic - Royal Free Hospital, London, England
In the summer of 1955 a dramatic outbreak was recorded in the Royal Free Hospital. 
Out of 3,500 (staff, patients and medical students) some 300 experienced an illness 
described by Crowley and others (1957) as a lymphoreticular encephalomyelopathy. 
Instances of presumed case to case infection were recorded from the onset, with an 
incubation of 5 or 6 days. The earliest symptoms were of malaise, headaches, 
dizziness, myalgia and sore throat. More than half the cases showed tenderness and 
occasional enlargement of lymph nodes, liver and spleen; morphological abnormalities 
also occurred in the circulating lymphocytes consistent with those described in 
infective and allergic diseases. Neurological symptoms and signs developed in 74 % 
of cases and included hypersomnia, nightmares, panic states, labile mood and 
amnesia. Cranial nerve lesions, motor weakness and sensory disturbances were also 
recorded in a number of patients. Laboratory investigations failed to find any agent. 
The course of the disease was prolonged with relapses of varying intensity in most 
patients, although most cases had a complete physical recovery within 2 years.
Following the Royal Free outbreak, epidemics continued to be reported and their 
nature suggested that an infectious agent with an incubation period of 8-10 days must 
be responsible. In most cases an acute illness resulted, lasting for a few weeks, but in 
others the syndrome persisted for months or even years.
These epidemics pose many problems in their own right but are of undoubted 
historical relevance to the emergence of CFS as a disease. A contagious, paralytic 
illness with neurological signs, and a good prognosis appeared to be occurring. CFS 
in current medical practice, however, is non-contagious, fatiguing, without 
neurological signs and has a relatively poor prognosis.
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1.5 GENERAL DATA
1.5.1 Prevalance
Data regarding the prevalence of CFS is variable because of the inconsistency in 
methodology as well as in case definitions in the relevant studies. Lloyd and colleauges
(1990) in Australia recorded a point prevalence of 37 per 100,000 in a population based 
study using an operational definition. The CDC estimated the prevalence of CFS by 
surveillance of selected physicians in four US cities and gave lower figures than those in 
Australia, i.e. between 2 to 7 per 100,000 (Gunn et al 1993). In a primary care practice, 
Bates et al (1993) reported a point prevalence, according to the various definitions, of 
0.3% (CDC 1988), 0.4% (UK) and 1% (Australian) respectively. Wessely et al reported 
a prevalence of CFS in the range of 0.8% (CDC 1988) to 1.8% (CDC 1994) across the 
south of England (Wessely 1995).
1.5.2 Geographical Distribution
The illness occurs both sporadically and in epidemics, with cases being reported from all 
over the United States, Alaska, Australia, Europe and South Africa (Acheson, 1959). 
Sporadic cases may continue to appear in the same geographic distribution after an 
epidemic has ended (Marinacci and Von Hagen 1965).
1.5.3 Gender
CFS has been documented in individuals of all ages, but young white females are at 
greater risk than others in the population (Parish 1978; Gunn et al 1993). In one 
community study, the relative risk of fatigue in women compared to men was 1.3 
(Pawlikowska et al 1994), whereas in primary care the relative risk for women varied 
between 1.3 and 1.7 (Bates et al 1993).
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There appears to be an unusual predispostion for persons in certain occupations to be 
affected, such as health service professsionals (Parish 1978; Ramsey 1986) primary 
school teachers and farmers (Behan and Haniffah 1994).
1.5.4 Genetics
Whether or not genetics play any role in this illness is unknown but the possibilty exists, 
as indicated by an increased history of an atopic diathesis in CFS patients, compared to 
controls (Olson et al 1986; Jones & Straus 1987). We have observed the illness in 
siblings, in father and son, or mother and daughter, and have collected a number of 
families in which related individuals lived a distance from each other but each developed 
CFS after a viral infection. We have also seen, albeit in small numbers, CFS in identical 
and dizygotic twins. In one instance, we saw the illness in three generations, each case 
having the illness precipitated by viruses and all those affected being females (POB - 
personal communication). These observations suggest a role for genetics in this illness.
Since patients with narcolepsy have a highly significant correlation with the possession 
of HLA-DR2 (Lock et al 1987), Behan and Behan (1988) looked at patients with CFS 
compared to controls: they found no difference in HLA-A, HLA-B and HLA-DR 
antigen frequences. In contrasts a limited number of studies have reported a higher than 
expected incidence of the HLA-D7 haplotype among patients with CFS (Tobi and 
Straus 1985).
1.6 AETIOLOGY
1.6.1 Infection
Chronic fatigue is a well-known clinical manifestation of systemic infections - caused by 
protozoa, fungi, rickettsia, spirochaetes, bacteria and viruses. The common protozoal
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infections associated with fatigue are giardiasis, toxoplasmosis and trypanosomiasis or 
sleeping sickness. Trypanosomes are known to cause hypothalamic disturbances 
through the interaction of cytokines with hypothalamic receptors. The hypothalamic 
neurons which are involved in trypanosomal infection, express MHC Class 1 antigens 
early (Schultzberg et al 1989). These same neurones are involved in the production of 
neuroendocrine hormones including corticotropin releasing factor (CRF), angiotensin II, 
glucagon, oxytocin, vasopresin, cholecystokinin, dynorphin, LHRH, TRH and 
somatostatin (Armstrong 1985, Silverman and Pickard 1983). Disturbances in these 
substances may therefore explain, not only the symptoms of trypanosomiasis, but also of 
CFS. How fatigue is caused by other protozoal infections awaits elucidation. Among 
fungal infections, cryptococcosis and chronic candidiasis are associated with chronic 
fatigue.
In the early 1930s, enormous attention was given to bacterial infections as a cause of 
fatigue. Tuberculosis, a chronic bacterial infection, causes fatigue as one of its non­
specific symptoms. Chronic brucellosis can be regarded as the prototype of bacterial 
infections which give rise to chronic fatigue. Dr Alice Evans, an American physician, in 
1934 reported chronic fatigue as one possible manifestation of chronic brucellosis 
(Evans 1947). Later in the century, however, Spink and Imboden and their colleagues 
ended speculation about brucellosis as a direct cause of chronic fatigue in the absence of 
continued infection (Spink 1951, Imboden et al 1959.)
The link between CFS and viral infection was provided by epidemiological studies. The 
symptoms of fatigue during the first outbreak were similar to a mild form of 
poliomyelitis, and the disorder was originally described as “a disease resembling or 
simulating poliomyelitis” or “atypical poliomyelitis” (Acheson, 1959). Major epidemics 
of chronic fatigue were reported after or during outbreaks of poliomyelitis in Los
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Angeles, Adelaide, and Durban (Gilliam 1938; Pellew 1951; Hill et al 1959). Similarly 
after the epidemic in Akureyri a widespread outbreak of poliomyelitis (Type 1 virus) 
occurred in the rest of Iceland, but interestingly none of the patients who had the fatigue 
syndrome were affected. Serologic studies showed that the patients were immune to 
poliomyelitis having already been exposed to a similar agent (Sigurdsson et al 1950;
1958).
From the analysis of such outbreaks Henderson and Shelokov were able to suggest that 
an infectious agent might have been involved, with an incubation period of 8-10 days 
and resulting in an acute febrile illness lasting up to 4 weeks (Henderson and Shelokov
1959). The evidence for viral infection is predominately anecdotal since it is a common 
observation that CFS may begin following a viral infection. The viruses implicated 
include enteroviruses, retroviruses and herpes viruses.
Enteroviruses
Behan et al reported increased neutralising antibody titres against Coxsackie B viruses in 
70% of patients compared to 4% of healthy controls (Behan et al 1985). Other studies 
revealed that 82% of patients as opposed to 10% of control subjects had increased titres 
(Fegan et al 1983). The detection of enteroviral structural protein VPI in immune 
complexes from the serum of patients with CFS provided further evidence for a possible 
aetiological role of enteroviruses (Yousef et al 1988). Later studies, however, identified 
no differences in specific anticoxsackie antibody titres between patients and controls. 
Nonetheless, using molecular hybridisation techniques Gow et al (1991), Miller et al
(1991) and Archard et al (1988) demonstrated the enteroviral sequences in muscle 
biopsies from patients with CFS. Cunningham et al (1990) reported that four out of 
eight (50%) patients' muscle biopsies were positive for enteroviral sequences and
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Bowles et al (1993) found positivity in 26% of patients with CFS compared to 25.9% of 
patients with inflammatory myopathies.
Using the more sensitive PCR technology Gow et al (1991) reported that 53% of the 
CFS muscle samples were positive for enteroviral RNA sequences. Clements et al 
(1995) suggested that enterovirus was present in 42% of CFS serum samples. In 
contrast Swanink (1994) have shown there are no significant differences between 
patients and control samples, on serological and PCR testing.
These results do not exclude a role for enterovirus in initiating the disorder but do 
suggest that its pathogenesis is not dependent upon enteroviral persistence.
Retroviruses
DeFreitas and colleagues postulated a causal relationship between human T 
lymphotropic virus type II (HTLV-H) like retrovirus and CFS and found more than 75% 
patient samples were positive for this virus compared to 0% of non-exposure controls 
(DeFreitas et al 1991). Others in the UK (Gow et al 1992), USA (Khan et al 1993; 
Gunn 1993) and Japan (Honda et al 1993) have now reported negative results. 
Therefore it appears unlikely that HTLV-II like retrovirus is present in CFS.
Herpes Viruses
All the herpes viruses have been associated with CFS i.e., Epstein Barr virus, 
cytomegalovirus, varicella zoster virus, herpes viruses 6 and 7 and herpes simplex.
Epstein Barr Virus (EBV)
This group of herpes viruses has been studied extensively in relation to CFS. Several 
workers have reported that EBV infection may be followed by a chronic fatigue-like
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syndrome, the "chronic mononucleosis syndrome" characterized by malaise, fatigue, low 
grade fever, loss of weight, and myalgia (Tobi et al 1982; Dubois 1984; Straus et al
1985). Significantly increased titres of antibodies to EBV-specific early antigen (EA) 
were reported in 20% of patients with CFS by Hotchin et al (1989). Similarly, 9% of 
CFS muscle samples were positive for EBV genome (Archard et al 1989). Despite 
these results, three seroepidemiologic surveys have indicated that EBV is unlikely to be 
the aetiologic agent (Hellinger et al 1988; Horwitz et al 1985; Lamy et al 1982) and 
others agree (Bell 1994).
Human Herpes Viruses 6 & 7 (HHV-6, HHV-7).
Buchwald and colleagues reported increased CD4/CD8 T cell ratios and replication of 
HHV-6 in the peripheral blood lymphocytes of 70% patients, as opposed to 20% of 
controls, in a well-controlled study of 259 cases at outbreaks in Lake Tahoe and 
Califoma/Nevada (Buchwald et al 1992). Dale et al (1989) detected antibodies to 
HHV-6 in 69% of patients with CFS compared with 12.5% of controls. Wakefield et al 
(1988) however, found no difference in seroprevalence between patients and controls. 
Bememan et al (1992) isolated HHV-7 from the peripheral blood mononuclear cells of 
patients with CFS but subsequently, Secchiero et al (1994) isolated the same virus from 
a patient with CFS and a healthy blood donor. The significance of these findings, 
therefore, is still unknown.
The Concept of Viral Persistence in the Pathogenesis of CFS
One of the reasons for considering the herpes viruses as possible agents is that they are 
known to persist in latent or chronic forms after an initial infection.
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In a chronic or persistent viral illness, the infected cells may not be killed and may 
reproduce, but are unlikely to carry out differentiated or specialised functions (Haywood
1986). For instance, neonatal mice infected with lymphocytic choriomeningitis virus 
(LCMV) show decreased production of neurotransmitters. Similarly, in neuroblastoma 
cells in culture infected with LCMV, although there is no cytopathic effect and cloning 
efficiency is normal, there is complete cessation of normal production of acetylcholine 
(Oldstone 1991). This idea, of persistent viral infection resulting in defective 
neurotransmitter production without evidence of cell damage, is important in 
understanding the pathogenesis of CFS. Recently McGarry et al (1994) detected 
enterovirus in the hypothalamus of a patient with CFS. Upregulation of hypothalamic 
5HT receptors has been reported in CFS (Bakheit et al 1992), suggesting a link 
between persistent virus and decreased production of neurotransmitter (5HT), leading 
to the characteristic symptoms.
1.6.2 Metabolic
Several studies show that there is generalised disturbance of muscle metabolism in CFS. 
Early studies by Cohen et al (1947) at Harvard had shown abnormal responses to 
exercise: significantly greater rises in blood lactate were found after matched exercise 
protocols in patients with neurocirculatory asthenia, a disorder considered closely 
related to CFS (Straus 1991) compared to controls. This data was the first to question 
the idea that CFS might be a functional disorder and came down strongly on behalf of an 
organic aetiology. The work was repeated by Riley et al (1990) who also found 
abnormal lactate metabolism and reduced aerobic work capacity. An important criticism 
of both studies is the selection of controls, since the ideal control is a sedentary person 
who is unfit and neither study had such controls. What was also important in these early 
studies was that hyperventilation, which had been proposed as a cause of CFS, was 
shown to be completely untenable (Saisch et al 1994).
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Arnold et al (1984) studied a case of CFS which followed chickenpox. Intracellular pH 
was measured using 3 IP nuclear magnetic resonance spectroscopy (NMR) during 
ischaemic exercise. In comparison with healthy controls, the patient developed early and 
severe intracellular acidosis. This was presumed to be due to increased lactate 
formation as a result of excessive glycolytic activity, possibly caused by a change in the 
regulation of the relative contributions of aerobic and anaerobic metabolism to exercise. 
Subsequent studies by the same researchers on six other patients, showed similar 
abnormalities in four (Arnold 1984). These results have been confirmed by the 
comprehensive studies of Montago et al (1989) whose patients showed limited exercise 
capacity characterized by an inability to achieve the target heart rate, a lower exercise 
heart rate and reduced exercise duration on graded exercise testing. In addition to 
reduced duration of exercise Wong et al (1992) reported reduced intracellular 
concentration of ATP in their patients. This data suggests defective oxidative 
metabolism with a resultant acceleration of glycosis in the working skeletal muscle. 
Finally, Lane et al (1995) using the subanaerobic threshold exercise test concluded that 
some patients with CFS have impaired muscle metabolism not explainable by physical 
inactivity or psychiatric disorder.
Defective oxidative metabolism suggests an abnormality at the cellular level probably 
involving mitochondria. In addition to nonspecific histological changes of mild to 
moderate atrophy of type 2 fibres, decreased numbers of type 1, occasional “moth- 
eaten” fibres, with increased lipid and/or glycogen deposition, Behan et al (1991) also 
reported distinctive changes in muscle mitochondria in patients with CFS: they were 
increased in number and size and showed an unusual pattern of branched cristae - called 
compartmentalisation.
Bryne et al (1985) looked at mitochondrial function in CFS by using polarographic 
techniques and found mild depression of state III respiration rates with site 1 and 2
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substrates. In a later study, however, the same workers reported that skeletal muscle 
carnitine, phosphorylase, glycolytic enzymes and mitochondrial marker enzymes were 
normal (Byrne et al 1987). Wagenmakers and colleagues (1987) also reported impaired 
mitochondrial function but at the same time suggested that these defects could be 
entirely secondary to reduced muscle use and inactivity.
Japanese workers (Kuratsune et al 1994) and ourselves (Majeed et al 1995 a) have 
reported abnormalities of carnitine metabolism is patients with CFS. Carnitine has an 
important role in energy production and in modulation of the intramitochondrial co­
enzyme A/acylcoenzyme A ratio in skeletal muscle. Carnitine also plays an important 
part in muscle metabolism during exercise by controlling the influx of fatty acids into 
mitochondria. Oxidation of long chain fatty acids takes place within the mitochondria 
and is completely dependent on carnitine. It promotes the oxidation of pyruvate and 
branched aminoacids and contributes to the protection of cells by preventing the 
accumulation of acyl coA. Furthermore carnitine and carnitine acetyl-transferase are 
involved in the metabolism of acetyl coA and pyruvate oxidation (Rebouche et al 1983, 
Bemsen et al 1991).
Preedy et al (1993) have reported loss of muscle protein synthetic potential, without loss 
of muscle bulk. These findings may contribute to the perceived muscle weakness 
associated with CFS. In summary, the evidence for a metabolic abnormality in this 
condition is strong but precise explanation awaits elucidation.
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1.6.3 Immunology
The clinical observations of the association of CFS with atopy, hayfever, asthma and 
other allergies (Straus et al 1988, Jones et al 1985), the development of 
hypersensitive/idiosyncratic reactions to certain drugs, recurrent infections, the 
symptomatology indistinguishable from that of CFS after administration of interferon to 
patients with chronic hepatitis B infection (McDonald et al 1987) may point to immune 
dysfunction in CFS. The concept of possible immune dysfunction in CFS and its 
relationship to post-viral states was first put forward by Behan et al in 1985 ( Behan et 
al 1985). Since then different investigators have reported abnormalities in different 
elements of the immune system.
Serum immunoglobulin concentration results are conflicting. Most commonly 
immunoglobulin levels have been normal (Behan et al 1985, Borysiewicz et al 1986, 
Prieto et al 1989). Others have reported decreased amounts of immunoglobulins of the 
IgG, IgA, IgM or IgD classes (Lloyd et al 1989, DuBois et al 1984, Straus et al 1985, 
Salit 1985) while a recent report revealed increased IgG levels in 20% of patients 
compared to 0% of control subjects (Bates et al 1994). Deficiencies in IgG subclasses, 
IgG 1 or IgG 3 have been reported in 45% of patients studied (Komaroff et al 1988, 
Linde et al 1988, Lloyd et al 1989).
Several studies reported low levels of circulating immune complexes in CFS patients 
(Behan et al 1985, Borysiewicz et al 1986, Bates et al 1994) and decreased levels of 
complement are found in 0-25% ( Behan et al 1985, DuBois et al 1984, Borysiewicz et 
al 1986) without any clinical manifestations of immune complex-mediated disease.
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Autoantibodies:
Various circulating autoantibodies, in particular anti-nuclear antibodies and rheumatoid 
factor, are found in 20% and 10% of CFS patients respectively without other evidence 
of lupus or rheumatoid arthritis (Salit 1985, Tobi et al 1982, Jones 1985, Straus et al 
1985).
Cytokines:
Cytokines (interferons) when administered to patients with chronic hepatitis B 
infections, resulted in symptoms described as “flu-like,” i.e., fatigue and myalgia, similar 
to those of CFS. On the basis of this observation it was postulated that the symptoms of 
CFS might result from the inappropriate production of cytokines. Later, different 
studies suggested that circulating interferons are infrequently, if ever, present 
(Borysiewicz et al 1986, Jones et al 1985, Straus et al 1985, Linde et al 1992). 
Interleukin 1 beta, interleukin 4, tumor necrosis factor and beta 2 microglobulin have not 
been detected in CFS. In contrast, higher levels of interleukin 2 (Cheney et al 1989), 
interleukin 6 and neupterin (Chao et al 1990) have been reported in some patients with 
CFS, observations which have not been confirmed.
Lymphocyte Function:
Different studies report different findings in regard to lymphocyte phenotype and 
function. In general, the number of CD4 and CD8+ cells are normal (Behan et al 1985, 
Straus et al 1985, Borysiewicz et al 1986, Tirelli et al 1993), but increases and decreases 
have been reported (Behan et al 1985, Linde et al 1988). Buchwald and co-workers
(1992) found a higher than normal CD4/CD8 ratio; whereas others demonstrated a 
normal (Landay et al 1991, Kilmas et al 1990) or decreased ratio (Hamblin et al 1983, 
DuBois et al 1984, Jones et al 1985, Linde et al 1988).
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Natural Killer Cells:
Abnormalities of natural killer (NK) cell number and functions have been reported in a 
number of studies. A reduction in the absolute number and percentage of NK cells has 
been seen from 0% to 73% of patients (Behan et al 1985, Caligiuri et al 1987). NK cell 
function has been found to be increased (Gold et al 1990), decreased (Caligiuri et al 
1987, Kilmas et al 1990) or normal (Borysiewicz et al 1986), as measured by cytolytic 
activity against a number of different target cell lines.
Overall such immunological studies suggest a host response to an infection that may be 
persistent or may have been eliminated but has led to the activation of the immune 
system. No single immunological finding has been identified as typical of CFS.
1.6.4 Psychiatry:
Two important points which suggested that CFS might be purely a psychiatric disorder 
were, first, fatigue is a major symptom of the clinical spectrum of several different 
psychiatric illnesses and secondly, physical and laboratory abnormalities could not be 
detected.
Different studies have confirmed that fatigue is the commonest somatic symptom of an 
affective disorder, occurring in the majority of patients (Mathew et al 1981, Wittenbom 
and Buhler 1979, Hamilton 1989). Beck (1973) reported increased fatigablility in 62% 
of mild, 80% of moderate and 86% of severely depressed patients, compared with 40% 
of controls. On the other hand, 80% of fatigued patients in primary care had depression 
and/or somatic anxiety (Kroenke et al 1988). In one study, Research Diagnostic Criteria 
for a major depressive disorder were satisfied in 47% of a hospital sample of CFS 
patients, after removing complicating somatic symptoms from the diagnostic criteria
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(Wessley and Powell 1989). Despite this association, the response to anti-depressant 
medication has been poor in a number of cases of CFS.
Procter (1991) explained the association between CFS and depression on the basis of a 
depression vulnerability hypothesis because of the increased prevalence of lifetime 
psychiatric disorders in the CFS group (Taerk 1987), a depression - reactivity hypothesis 
because of the reaction to a chronic state of ill health, the loss of role functioning and 
the degree of uncertainty about the diagnosis and prognosis of the disorder (Ramsay 
1986, Jones and Miller 1987) and an organic hypothesis because of changes in 
neurotransmitter neuroendocrine functions as a result of disease processes (Bakheit et al 
1992, Majeed et al 1995 b). Finally she suggested in her study that CFS depression has 
much in common with a reactive disorder secondary to medical illness.
Due to overlap between the symptoms of CFS and neurotic depression, the separation of 
these two entities is sometimes difficult, if not impossible. They share certain symptoms 
and have some common neuroendocrine abnormalities. Nonetheless CFS is now being 
recognised as a separate entity and a psychiatric aetiology would be untenable.
1.6.5 Autonomic Nervous System:
The symptoms of palpitation, diarrhoea, urinary frequency/nocturia suggest involvement 
of autonomic nervous system in CFS. Studies showing abnormal heart rate responses to 
exercise in CFS also suggest autonomic dysfunction. Rosenhall et al (1987 a & b) 
reported abnormal auditory brain stem responses in patients with chronic 
fibromyalgia/CFS and pointed out that autonomic dysfunction in these patients is 
secondary to brain dysfunction. They also documented abnormal eye movements in 
these patients and suggested that brain dysfunction was at the brain stem level. The 
dysequilibrium which is present in 30-50% of patients with CFS could be a manifestation
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of a vestibular or central nervous system disorder (Furman 1991). In order to resolve 
the issue of peripheral versus central CNS involvement, Ash Bernal et al (1995) tested 
vestibular function in eleven patients and found that abnormalities were more suggestive 
of central nervous system deficits than of peripheral vestibular dysfunction.
Sisto et al (1995) have found recently that patients breathing at specific rates, have 
diminished vagal activity in both the sitting and standing postures, compared to healthy 
controls. These abnormalities in vagal function again suggest autonomic brain 
dysfunction.
1.7 CLINICAL FEATURES 
1.7.1 Mode of Presentation
The majority of patients have an acute onset with a 'flu-like illness, accompanied by 
upper respiratory symptoms or gastro-enteritis (Acheson 1959. Holt 1965). The illness 
may occur after encephalitis, labyrinthitis, myocarditis, orchitis or prostatitis (Behan et al 
1988). These modes of presentation clearly implicate an infectious agent at the onset. 
Another common mode of presentation is with a syndrome akin to Bornholm disease, 
with anterior chest pain and myocarditis. As the disease continues, myalgia becomes 
generalised and disproportionate fatigue appears. Another presentation is with acute 
vertigo, which lasts for about a week and then leaves the patient with a constant feeling 
of unsteadiness or dysequilibrium, severe exhaustion and varying degrees of myalgia.
These presentations are not mutually exclusive and can occur in any combination.
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1.7.2 Precipitating Factors
There is evidence that infection plays a role in precipitating the illness. Many previous 
epidemics have been described and more than 80 % of the patients ascribe their illness to 
an infectious event. Indeed, the infectious element is highlighted by the other names of 
the illness, i.e. acute infective encephalomyelitis, atypical poliomyelitis, a disease 
resembling or simulating poliomyelitis, persistent myalgia following a sore throat and 
chronic infectious mononucleosis syndrome (Behan et al 1988). What is now clear is 
that infection, usually of a mild type, can precipitate the illness, but there is no direct 
evidence for persisting viruses causing the continuing disease. Enteroviruses, influenza, 
varicella-zoster, Epstein Barr virus and hepatitis virus, have all been implicated as 
precipitating agents. The illness has also been observed in farmers and agricultural 
workers exposed to sheep dips and insecticides containing organophosphates (Behan et 
al 1994). These patients often claim to have a 'flu-like illness before developing CFS. 
Patients may also develop CFS after gastro-enteritis due to ciguatera poisoning 
(Gillespie et al 1986).
1.7.3 Symptoms 
Fatigue
Human fatigue is a baffling symptom which has escaped accurate definition and 
measurement. Bartley describes the symptom in his book ‘Fatigue, Mechanism and 
Management’ (Bartley 1965) as a “sensory, cognitive syndrome which includes 
tiredness, aversion to work, body discomfort, ineffectiveness in performance ... a self­
felt assessment of inadequacy ... with the desire to escape.”
In neurophysiologocal terms fatigue can be defined as failure to maintain a required or 
expected force (Edward 1986). Muscle fatigue can be further categorised as “central” 
where there is volitional or non-volitional failure of neural drive to the muscles or
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“peripheral” where there is failure in force generation by mechanisms at or beyond the 
neuromuscular junction. In neuropsychology fatigue can refer to time related 
decrements in the ability to perform mental tasks and varies according to personality and 
social desirability (May and Kline 1988).
Fatigue as a Manifestation of Psychiatric Disorder
The great majority of patients who enter a hospital because of unexplained chronic 
fatigue and lassitude have been found to have some type of psychiatric illness. Chen 
(1986) looked at the risk of anxiety and depression in a community sample of fatigued 
patients; 46% of males and 51.1% of females, were depressed. In a hospital-based study 
however, 67% of 135 self-referrals to a special fatigue clinic were found to have 
psychiatric diagnoses (Mam et al 1988). Wessley and Powell (1989) studied 47 medical 
referrals to a specialist neurology hospital with chronic unexplained fatigue, and found 
that 72% had a psychiatric diagnosis.
Fatigue in Chronic Infections
Infection is another cause of chronic fatigue, though a much less frequent one. Infection 
should be suspected when the fatigue is out of proportion to other symptoms such as 
mood change, nervousness and anxiety, e.g. in hepatitis, tuberculosis, brucellosis or 
infectious mononucleosis.
Fatigue in Metabolic and Endocrine Diseases
Metabolic and endocrine diseases of various types may cause inordinate degrees of 
lassitude and fatigue. In Addison’s and Simmond’s diseases, fatigue may dominate the 
clinical picture. Aldosterone deficiency is another established cause of fatigue. In 
persons with hypothyroidism, lassitude and sluggishness are frequent complaints.
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Uncontrolled diabetes mellitus may be accompanied by excessive fatiguability, as may 
hyperparathyroidism, hypogonadism, and Cushing’s disease. Anemia when moderate or 
severe should be considered as a possible cause of unexplained fatigue. Among 
neurologic diseases; Parkinson’s disease and multiple sclerosis, are ones in which 
fatiguablilty is a prominent symptom and they should also be considered.
Fatigue in CFS
Fatigue in CFS varies from day to day and after exercise. Patients will claim that they 
are weary, have no energy and are unable to complete tasks that they could do formerly 
without any problem. The typical fatigue is noticed within the first few days after the 
precipitating event, i.e. infection or toxin exposure. It fluctuates, being made worse by 
muscle exercise, mental tasks or emotional stress. Further infections often aggravate the 
fatigue.
Some patients are able to carry out their normal physical activity, although feeling 
fatigued but in other patients, the fatigue progresses to such an extent that they are 
unable to care for themselves and stay in bed, needing day to day care and assistance. It 
is still not clear whether the fatigue experienced by CFS patients is peripheral in origin, 
or is a consequence of an alteration in central drive. Gibson et al (1993) studied the 
physiological function of a large muscle group before, during and after exercising 
activity in a well-defined population of patients with CFS and found normal contractile 
function. The longterm recovery of muscle was indentical to that of normal subjects and 
complete by 24 hours after exhaustive exercise, even though the patients complained of 
excessive fatigue, weakness or muscular discomfort. Differences in the perception of 
effort in relation to the physiological response (raised perceived exertion scores) to 
exercise, indicated the likely involvement of central mechanisms in limiting exercise 
performance.
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As Denman states “our understanding of chronic fatigue has reached an important stage 
and progress will only be achieved if different categories of chronic fatigue are dissected 
with scientific objectivity and therapeutic reason” (Denman 1990).
Conditions with Central Fatigue
Multiple Sclerosis
It has long been recognised that fatigue may be a central incapacitating symptom in 
patients with multiple sclerosis. In their classical treatise on multiple sclerosis, which 
has not been bettered, MacAlpine, Lumsden and Acheson point out that “fatigue usually 
arises from periods of hyperactivity but routine work and daily journey induce it, 
particularly in those whose general health is of low standard (MacAlpine et al 1972).
We have observed in young people in whom multiple sclerosis has been precipitated by 
whiplash injury, that severe disabling fatigue was the main symptom, associated with 
hypersomnia.
Post Head Injury Depression
Depression following minor closed head injury is a common phenomenon shown to be 
different clinically, in its response to treatment and in its neuroendocrine responses, to 
idiopathic depression (Dinan & Mobayed 1992).
The patients often have severe fatigue with increased somnolence as part of their 
symptom complex. Brainstem auditory-evoked responses have been reported as 
abnormal and detailed neuroendocrine responses measuring prolactin release or using 
the dexamethasone suppression test suggest a different response to that seen in 
idiopathic depression (Saran 1985). Saran found that few patients with depression after 
mild head injury were non-suppressors on the dexamethasone suppression test in
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contrast to the functional depressives. Clearly, the atypical depression that follows 
closed mild head injury bears a striking resemblance to, and should be considered in the 
differential diagnosis of, chronic fatigue syndrome.
Post-Polio Syndrome
Post-polio syndrome is a recently described disorder in which muscle weakness 
associated with a variety of other symptoms occurs in patients who have had acute 
poliomyelitis previously (Dalakas et al 1986). The new development of weakness 
occurrs many years after apparent recovery from acute paralytic poliomyelitis. Fatigue 
is the most commonly reported, most debilitating sequel affecting more than 1.63 million 
American polio survivors, with 91% reporting new or increased fatigue, 41% reporting 
fatigue significantly interfering with performing or completing work and 25% reporting 
fatigue interfering with selfcare activities (Parsons 1989, Bruno 1987).
Polio survivors differentiate between the physical tiredness and decreased endurance 
they associate with new muscle weakness and a ccbrain fatigue” that is characterized by 
problems with attention and cognition similar to those in patients with CFS. 
Neurophysiological, muscle biopsy, and cerebro-spinal fluid findings differentiate these 
patients from those with CFS but the clinical symptomatology is virtually identical to it.
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Idiopathic Cyclic Oedema
This is a well recognised condition in women who experience fluid retention in the 
absence of known causes such as hypoproteinaemia, renal, hepatic, alimentary or 
cardiac disease. The condition overlaps with the normal pre-menstrual tension and 
weight gain at the time of the menses. An abnormal amount of fluid is retained, 
affecting the face, arms and abdomen, and sometimes producing headache. The fluid 
retention can occur throughout the day and as much as four to five pounds can be 
gained between morning and evening and throughout the menstrual period when, at 
times, there can be as much as twelve to fourteen pounds in weight gain. At the time of 
maximum weight gain, the patients complain bitterly of incapacitating fatigue associated 
with difficulty in concentration and memory. The condition is exacerbated by stress and 
particularly by infections. Several of the patients that we have seen bore a striking 
clinical similarity to patients with CFS, heightened in the subgroup who also went on to 
develop diabetes mellitus.
The pathophysiology of this condition is unknown but there is evidence for a 
hypothalamic disturbance (Young et al 1983). Attention has been drawn in the past to 
the other features of this syndrome, in particular the depression, emotional lability and 
overwhelming chronic fatigue that may be experienced. Several patients studied by us 
had undisputed CFS. The finding of increased water content in these cases and in 
patients with CFS suggests an overlap between the two entities (Bakheit et al 1993). 
The underlying mechanisms appear to be aggravated by female sex hormones.
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Myalgia
Diffuse muscle pain involving large muscles such as the trapezii, muscles of the 
shoulder, chest, quadriceps and gastrocnemii often accompany infections such as 
dengue, brucellosis, influenza, measles, malaria, salmonellosis and toxoplasmosis, 
trichinosis, Weil's disease and, of course, rheumatic fever. Severe pain associated with 
coxsackie enteroviral infections and involving the chest muscles, has long been known as 
Bornholm disease. Patients with idiopathic polyneuritis may have pain in their legs at 
the onset of the disorder, as can patients with acute poliomyelitis. Shingles is a 
recognised form of segmental muscle pain. In essence, therefore, acute viral, fungal, 
bacterial infections can all be associated with pain in muscles, but the mechanism is not 
understood. Inflammation may result in the release of a number of pain producing 
substances, but it is noteworthy that in polymyositis, pain is usually absent, unless 
tendinous structures are involved. Muscle pain in polymyalgia rheumatica is another 
poorly understood syndrome, as is fibromyalgia which is a condition identical with CFS. 
Pain is common in the metabolic myopathies, and may be precipitated and made worse 
by exercise as in CFS. In CFS, the pain is usually generalised, tends to affect the larger 
muscles and is characteristically fluctuating and made worse by exercise. In some 
patients it is mild but in others, it is the overwhelming symptom. On examination, it may 
be associated with tenderness, particularly at certain points in the muscle. The cause of 
the pain is unknown, but present data suggest a metabolic type of induced myalgia 
(Behan et al 1991).
Neuropsychiatric Symptoms
Neuropsychiatric symptoms in chronic fatigue syndrome have received a lot of attention, 
but few objective studies carried out, (Smith et al 1993). Patients complain of 
disturbances of memory and concentration, of emotional lability and of irritability, of
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anomia and of a reluctance to take in and carry out mental tasks. There was no 
difference between healthy controls and patients with chronic fatigue syndrome of the 
free recall tasks, but the patients were more cautious in the delayed recognition tasks, 
i.e. they made fewer false alarms, but detected fewer target words. This study showed 
that the performance impairment in these patients could not be the result of depression 
alone (Smith et al 1993).
About 80% of patients have psychiatric symptoms, but it is important to note that 20% 
are entirely free of any history of, or present, psychiatric complaints. Phenomenological 
differences have been found in presenting psychiatric and attributional style, which 
distinguish chronic fatigue syndrome patients from psychiatric populations. In one 
study, (Powell et al 1990), chronic fatigue syndrome subjects satisfying criteria for 
depression showed depressed mood and emotional lability, often with profound 
pessimism about the future, but did not display active suicidal ideation, feelings of guilt 
or negative self referential cognitions (low self-esteem, self-depreciation), which were 
familiar among a group of psychiatric inpatients with major depression. The chronic 
fatigue syndrome subjects demonstrated significantly less loss of pleasure in comparison 
to the depressed group and attributed their illness almost exclusively to a physical (viral) 
cause, (Wessely & Powell 1989). An extraordinary feature which they do show is 
hypergraphia: the patient will bring to the clinic long descriptions of his or her 
symptoms, a phenomenon described by the late Professor Norman Geschwind in patients 
with temporal lobe epilepsy (Geschwind 1979). Patients often complain of difficulty in 
memory but this is more forgetfulness than a true loss of memory. They often have 
conspicuous anomia and it is this anomia, a common feature in virtually all 
encephalopathic processes, that they misinterpret as memory disturbances.
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Sleep Disturbance
The majority of the patients sleep excessively at the beginning of the illness. The 
hypersomnolence is a conspicuous feature and patients will complain that they can drop 
off to sleep at the slightest opportunity. Even after as much as 12-14 hours of deep 
sleep, however, they awake unrefreshed. With the passage of time, however, patients 
often develop difficulty in getting off to sleep and wake early. Whelton et al (1992) 
showed that CFS patients had more difficulty falling asleep and spent less time asleep. 
They had reduced rapid eye movement (REM) sleep and more alpha EEG in non-rapid 
eye movement (NREM) sleep than healthy controlled subjects, a sleep anomaly which is 
considered to be an indication of a physiologic arousal disorder and is accompanied by 
indicators of increased vigilance during sleep and the subjective experience of 
unrefreshing sleep (Anch 1991).
Irritable Bowel Syndrome
In our experience, the irritable bowel syndrome which occurs in CFS (though not a part 
of CFS definition) is indistinguishable from the idiopathically occurring irritable bowel 
syndrome. Patients complain of intractable constipation, alternating with diarrhoea or 
abdominal pain and loose stools throughout the day. Interestingly, we found few 
patients with nocturnal diarrhoea, but most patients complained of bloating, palpitations, 
irregularities of bowel motility and dyspepsia. The mechanisms underlying irritable 
bowel syndrome are unknown, but there is some experimental data to implicate 5-HT.
Dysequilibrium
A significant number of cases of CFS begin with sudden vertigo and dysequilibrium 
persists in 30-50% of cases. Several patients have had abnormal neuroaudiological 
findings suggestive of brain stem dysfunction (Rosenhall et al 1987). A previous study 
by Furman (1991) indicated that the dysequilibrium seen in these patients could be a
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manifestation of vestibular or central nervous system disorder. A central nervous system 
deficit rather than peripheral vestibular dysfunction was postulated (Ash Bernal et al 
1995). Epidemics of CFS with vertigo have been described in the past. Pederson found 
“intense asthenia which develops in five to ten per cent of the cases and often becomes 
the predominant symptom in the late course.” A significant number of his patients at the 
beginning had a pleocytosis in the cerebrospinal fluid and he considered the illness to be 
an infection of the brain stem (Pederson 1959).
Atopic Disorders
In our experience, large numbers of patients have a strong atopic diathesis, suffering 
from asthma or hayfever and other allergies. Strauss in a study of 27 patients who were 
entering a placebo control trial of Acyclovir for CFS found that, ‘"there was a 
remarkable correlation between patient history and skin test reactivity. Of 12 reactive 
patients, 10 had histories of allergies to food or inhalants, of 12 non-reacting patients, 
only 3 reported allergies to food or inhalants (P<0-01), however, even among individuals 
who did not identify themselves allergic to food or inhalants there was evidence of atopy 
by history. In all 11 of 12 skin test reactors and 9 of the 12 non-reactors provided 
information suggestive of atopy, such as eczema, seasonal rhinitis, hives, asthma and 
drug or food allergies.” (Straus et al 1988). While the nature of this association is 
unknown, there is little doubt that atopic allergies have some connection with CFS.
Night Sweats
Patients often complain of extreme degrees of sweating, particularly at night, although 
they may occur at any time during the day. The sweating is pathological in that they 
report not only having to change their pyjamas, but often having to change the sheets as 
well. The night sweats, the hot and cold sensations and the sudden changes in appetite, 
probably reflect subtle hypothalamic disturbances.
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1.8 EVIDENCE FOR HYPOTHALAMIC INVOLVEMENT
The clinical and laboratory data which suggests involvement of central (hypothalamic) 
mechanisms in the pathophysiology of CFS are now discussed.
1.8.1 Clinical Data
The following clinical features of this illness are suggestive of involvement of 
hypothalamus. Some patients with CFS develop a fluid retention syndrome (Behan and 
Bakheit, 1991), in which fatigue may be a prominent feature (Pelosi 1986). Although 
the pathophysiology of this syndrome is unknown, disturbance at hypothalamic level has 
been reported (Young et al 1983). Indeed, German and Stempfer (1979) have 
suggested that fatigue itself is primarily an exhaustion or malfunctioning of brain cells in 
the hypothalamic region, since they observed a good response to hypothalamic-releasing 
factor in reactive depression where prolonged stress and exhaustion had played a role. 
In panhypopituitarism after most hormones have been replaced it is known that the 
patient still complains of fatigue and this has been shown to be due to abnormalities of 
either prolactin or growth hormone (Martin 1987), again suggesting involvement of 
hypothalamus. Other complaints of night sweats, feelings of hot and cold and of a raised 
temperature, may also reflect a hypothalamic disorder (Nikitopoulou and Crammer
1976). In view of the psychological and emotional problems, sleep disturbances and 
mood changes that accompany CFS, and the fact that major depressive disorders are 
often associated with a disturbance of hypothalamic pituitary axis (Ettigi and Brown
1977), it was thought that hypothalamic functions might be impaired in this illness also. 
Finally, patients with CFS often complain of an exaggeration in their symptoms, 
especially fatigue, at the time of menstruation (Deisher 1957), emphasising the 
hormonal influence on the clinical features of this illness.
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1.8.2 Laboratory Evidence
The following laboratory investigations on patients with CFS suggest involvement of 
hypothalamus.
Impaired HPA-axis activation.
Reduced basal evening cortisols, low 24 hour urinary-free cortisol excretion and 
elevated ACTH concentration have been reported in CFS. Enhanced adrenocortical 
sensitivity to exogenous ACTH and blunted ACTH responses to CRH have been found, 
indicating central adrenal insufficiency secondary to either a deficiency of CRH or to 
some other central stimulus for the pituitary adrenal axis (Demitrack et al 1991). 
Demitrack and co-workers used corticotropin-releasing hormone (CRH) to stimulate 
ACTH release from the anterior pituitary. Tests were conducted at 2000h. A 
significant reduction in baseline cortisol levels and an elevation in baseline ACTH was 
noted. Overall the ACTH release in response to CRH was blunted. An examination of 
CRH and ACTH levels in cerebrospinal fluid revealed no abnormality. A series of tests 
using various dosage of ACTH to stimulate cortisol release from the adrenals was 
carried out. The lowest dose of ACTH produced a marked elevation in cortisol in 
patients with CFS, but no elevation in healthy controls. With higher doses patients with 
CFS showed attenuated responses, it was suggested on the basis of these results, that 
patients with CFS have a form of mild hypocortisolism, reflecting a deficit at the level of 
the hypothalamus or above.
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Disturbed Water Metabolism.
Bakheit et al (1993) studied water metabolism and the response of the neurohypophysis 
to changes in plasma osmolality during the water loading and water deprivation tests, in 
patients with CFS reported that secretion of arginine-vasopressin (AVP) was erratic, as 
shown by lack of correlation between serum and urine osmolality and the corresponding 
plasma AVP levels. Patients with CFS also had significantly lower baseline arginine- 
vasopressin levels compared with healthy subjects. It was suggested that the results 
were indicative of hypothalamic dysfunction.
Disturbed 5HT/serotonin function.
a. Prolactin responses to the 5HT1A receptor agonist were investigated by comparing
prolactin release with buspirone in patients with CFS to that with depression and 
healthy controls (Bakheit et al 1992). There was no significant difference between 
patients with chronic fatigue and healthy subjects or depressives, in terms of baseline 
prolactin concentration. The percentage difference between peak and baseline 
prolactin values was significantly higher in patients with CFS than in the controls or 
the depressives. The results were however interpreted as having supersensitivity of 
5HT1A receptors in CFS.
b. Cleare et al (1995) measured serum prolactin and cortisol concentrations hourly, 
following oral administration of the selective 5HT releasing agent d-fenfluramine in 
patients with CFS, depression and healthy controls and found cortisol levels were 
highest in the depressed and lowest in CFS. Peak cortisol responses did not differ 
between the groups. Basal prolactin values were similar in the three groups while 
peak prolactin responses were lowest in the depressed and highest in the patients
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with CFS. They concluded that defective prolactin release in CFS was due to 
increased 5HT function in hypothalamus.
McGarry et al (1994) detected enteroviral sequences in brain samples from the 
hypothalamus and brain stem region of a patient with CFS which may be significant.
45
GENERAL NEUROENDROCRINOLOGICAL DATA
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2.1 INTRODUCTION
The endocrine and nervous systems regulate almost all the metabolic and homeostatic 
activities of the organism. They interact and influence each other. The rate of most 
endocrine secretion is influenced directly or indirectly by the brain transmitters, and 
virtually all hormones can influence brain activity. The basic functional unit of the 
endocrine system is the secretory cell, releasing substances into the blood in which they 
are carried via the circulation to selective target tissues where they modify activity. The 
basic functional unit of the nervous system, the neuron, exists in anatomically distinct 
pathways and mediates its regulatory functions via electrical impulses. Nerve cells and 
endocrine cells however have many attributes in common. Neurons, in common with 
endocrine cells, secrete chemical messengers that react with specific receptors and both 
have electric potentials. Several kinds of peptides and neurotransmitters which are 
synthesized by nerve cells are identical to those secreted by endocrine glands (Roth et al
1982). Neuroendocrinology looks at the interface between the endocrine and nervous 
systems in an attempt to understand their complex relationship.
Aspects of this interface are examined in the studies of this thesis i.e. the effects of 
various neurotransmitters on the hypothalamic pituitary adrenal axis (HPA) in patients 
with CFS.
2.1.1 Hormones
A hormone is a chemical substance that is secreted into the body fluids by one cell or a 
group of cells and exerts a physiological effect on other cells of the body. All hormones 
share several characteristics. First, they are present in the circulation at low 
concentration. Second, they are directed to sites of action by specific mechanisms. This 
direction is accomplished by specific receptors with high affinity in target tissues, 
recognising and binding the hormone. Another mechanism by which hormones can be
47
directed to specific target tissues is by delivery within a restricted circulation such as the 
hypophyseal-portal system or the hepatic-portal system. A third means of targetting is 
by direct diffusion to adjacent sites. A fourth mechanism is local formation of hormone 
within a tissue from circulating precursors as with the formation of dihydrotestosterone 
from testosterone within androgen target tissues such as prostate (Wilson and Foster
1985).
Third, hormone synthesis is regulated in general by feedback control mechanism (Burgi 
1974). The regulation is accomplished by hormones produced peripherally in endocrine 
glands ‘Teeding back” on the hypothalamic pituitary system: the concentration of the 
hormone signals the need for more or less production.
Fourth, rhythms in the release of hormones are a common feature of almost all 
endocrine systems. These rhythms can vary over minutes to hours (pulsatile secretion of 
prolactin [PRL] luteinizing hormone [LH] and testosterone), days (the circadian 
variablity in cortisol secretion), weeks (the menstrual cycle), or even longer periods 
(seasonal variability in thyroxine production).
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2.1.2 Chemical Nature o f Hormones
Hormones fall into two main categories - peptides and steriods. The majority are 
polypeptides and range from very complex polypeptides such as luteinizing hormone 
[LH], through intermediate sized peptides (somatostatin), to small peptides (thyrotropin 
releasing hormone [TRH]) and dipeptides (thyroxin).
2.1.2.1 Peptide Hormones
Hormones of hypothalamus: - [corticotropin releasing hormone (CRH), thyrotropin 
releasing hormone (TRH), gonadotropin releasing hormone (GnRH), growth hormone 
releasing hormone (GHRH), somatostatin], anterior pituitary [growth hormone (GH), 
adrenocorticotropin hormone (ACTH), thyroid stimulating hormone (TSH), follicle 
stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL) and melanocyte 
stimulating hormone], posterior pituitary [antidiuretic hormone (vasopressin - AVP) and 
oxytocin] and of the pancreas - [insulin and glucagon], thyroid - [thyroxin, 
triiodothyroxin and calcitonin] and adrenal - medulla [catecholamines] - are peptide 
hormones. These water soluble hormones do not cross the lipid barrier interposed by 
the plasma membrane but interact directly with receptors located on the cell surface. 
The receptors are specific with high affinity for the corresponding hormone; binding of 
which results in activation of the second messenger system in the plasma membrane - 3’, 
5’-adenosine monophosphate (cyclic AMP) and inositol triphosphate and diacylglycerol.
Cyclic AMP System
Activation of adenylate cyclase, catalytic unit (C), catalyzes the conversion of adenosine 
triphosphate (ATP) to cyclic AMP. Cyclic AMP activates protein kinase A which 
phosphorylates proteins producing physiologic effects. Stimulatory ligands bind to the 
stimulatory receptor (Rs) and activate adenylate cyclase via Gs - the stimulatory
49
nucleotide regulatory protein. Inhibitory ligands inhibit adenylate cyclase via the 
inhibitory receptor (Ri) and inhibitory nucleotide regulatory protein (Gi). See Figure 
(2.1) for diagramatic representation of this process.
Inositol Triphosphate and Diacylglycerol System
Other peptide hormones when coupled with target receptors R activate phospholipase C 
(PLC) on the inner surface of the membrane via nucleotide regulatory protein (G). The 
resulting hydrolysis of phosphatidylinositol 4,5 diphosphate (PIP2) produces inositol 
1,4,5 triphosphate (IP3) which releases calcium from endoplasmic reticulum (ER) and 
diacylglycerol (DAG) which activates protein kinase C (PKC). Protein kinases are 
intracellular enzymes that phosphorylate proteins implicated in the production of many 
different cellular responses (Berridge 1984).
2.1.2.2 Steroid Hormones
The steroid hormones are produced by the adrenal glands, the ovaries and the testes and 
all share a characteristic chemical structure. They are large molecules derived from the 
cholesterol and have a basic steroid “nucleus” of 17 carbon atoms joined together in 
four interconnected rings. The major groups of steroids are glucocorticoids (cortisol 
and corticosterone), the mineralocorticoids (aldosterone) produced by the cortex of the 
adrenal gland and sex steroids (testosterone, oestradiol and progesterone) secreted by 
the testes and ovaries. The chemical structure of the steroid hormones is illustrated in 
Figure(2.2).
The steroid hormones are lipid soluble and traverse the lipid rich membranes of the 
targets cells mostly by diffusion. In the target cells steroid binds to macromolecules 
called receptors. These molecules are relatively large proteins that have specific binding
50

Figure 2.1
Cyclic AMP (cAMP) as a second messenger in the action of polypeptide and 
glycoprotein hormones.
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Figure 2.2
Biosynthetic pathways for steroid hormones and their chemical structures.
sites for the hormone and are found in both the cytoplasmic and nuclear fractions of the 
cell. The delivery of steroid hormone to receptor is heavily dependent on the 
concentration of carrier proteins: proteins that bind steroids and transport them in the 
circulation to target tissue. Once in the cell and bound to receptor, the hormone 
receptor complex translocates to the nucleus and binds to DNA (Rousseau 1973), 
activating transcription of target genes. The messenger RNA (mRNA) is translated into 
new proteins that express the biological activity of the glucorticoid. See Figure (2.3). 
Steroid hormones also have membrane receptors and can act directly upon the cell to 
produce an immediate effect such as altering the firing rate of the neurone.
Steroid Hormone (Glucorticoid) Receptors
Two types of central adrenal steroid receptor have been described - first observed by 
McEwen et al (1968) after they injected a tracer dose (0.5-1 microgr) of [H] 
corticosterone into adrenalectomized (ADX) rats.
Type 1 are mineralocorticoid receptors (MR-receptors); and Type 2 are glucocorticoid 
receptors (GR-receptors). The type 1 receptors have tenfold higher affinity for 
corticosterone than do glucocorticoid receptors in the rat brain (Reul et al 1985) and are 
found in high concentrations in extrahypothalamic limbic neurons of the septo- 
hippocampal complex, whereas in the pituitary, relatively low levels are found (Reul and 
Dekloet 1986). They also have a high affinity for aldosterone and have been described 
by Beaumont and Fanestil (1983) as mineralocorticoid-like receptors.
Type 2 (GR-receptors) resemble physiochemically the classical GR system in the 
periphery and have the highest affinity for synthetic glucocorticoids such as 
dexamethasone with a lower affinity for binding naturally occuring glucocorticoids (Reul 
and Dekloet, 1986; Sutanto and Dekloet, 1987). They are found in both neuronal and 
glial cells. They are present in high quantities throughout the forebrain, particularly in
53

Figure 2.3
The mechanism of action of a steroid hormone (H) on the target cells.
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cortical, thalamic, hypothalamic (paraventricular, arcuate, supraoptic nucleus) and 
septohippocampal (dorso-lateral septum, dentate gyrus) regions. (Reul and Dekloet,
1986). In immunocytochemical studies using a monoclonal antibody against rat liver 
glucocorticoid receptor, Van Eckelen et al (1987) found strong reactivity in CA1 and 
CA2 pyramidal cells in the hippocampus. They found that the activity was highest in the 
parvocellular neurones of the paraventricular nucleus of the hippothalamus and in the 
tractus solitarius and nucleus locus coeruleus in brainstem nucleii.
More recently Reul et al (1989) used 32p-labelled cRNA probes directed against type 1 
and type 2 receptor messenger RNA to examine the distribution of these receptors in the 
rat. Among the nervous tissues, mRNA coding for mineralocorticoid receptors was 
highest in the hippocampus. Moderate to low levels were found in the hypothalamus 
and cerebellum respectively. In situ hybridization histochemistry revealed that in the 
brain mineralocorticoid receptors appear to be expressed exclusively in neurons (Arriza 
et al, 1988 and Van Eckelene et al 1988). Heavy labelling occured in the pyramidal 
neurons of Ammon’s horn with the CA3 cell field exhibiting the highest 
mineralocorticoid receptor mRNA levels. The distribution of GR mRNA was rather 
evenly distributed over the brain. Nevertheless, hypothalamus tissue contain more GR 
mRNA than did hippocampus and cerebellum. In situ hybridization showed 
glucocorticoid receptor mRNA within the hippocampus to be primarily present in the 
neurons of the CA1 and CA2 field (Aronsson et al 1988). Very low concentration of 
glucocorticoid receptors mRNA were found in the CA3 and CA4 cell field. Apart from 
the hippocampal formation, increased labelling of glucocorticoid receptor mRNA was 
present over the granular layer of the cerebellum, in the subdivision of the amygdala, and 
in the arcuate nucleus and parvocellular region of the parventricular nucleus of the 
hypothalamus (Aronsson et al 1988). Further profound labelling was found over the 
aminergic cell groups of the locus coeruleus and raphe nuclei. Moderate glucocorticoid
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receptor mRNA concentrations were present in well defined layers of the cortex, central 
nucleus of the amygdala, thalamic regions, and most of the preoptic and hypothalamic 
nuclei. Glucocorticoid receptor mRNA was low in the caudate nucleus, putamen, septor 
region, and substantia nigra.
Studies involving measurement of glucocorticoid receptor mRNA and binding sites have 
revealed that glucocorticoid receptors are subject to autoregulation. After 
adrenalectomy (ADX), glucocorticoid receptor concentration increases but it is reduced 
after chronic stress, chronic adminstation o f glucocorticoids, and at senescence. A 
diminished glucocorticoid receptor concentration may compromise the negative 
feedback action exerted by glucocorticoid after stress. After ADX, mineralocorticoid 
receptor binding is upregulated acutely and reaches its maximum between 7 and 24 
hours post-ADX. Long-term ADX has no effect on the mineralocorticoid receptor 
concentration, but, interestingly chronic dexamethasone treatment results in an up- 
regulation of mineralocorticoid receptors. Functionally, mineralocorticoid receptors and 
glucocorticoid receptors are involved in different aspects of the organisation of the 
stress response and in conjunction they control the response to stress of the animal.
2.2 HYPOTHALAMIC-HYPOPHYSEAL AXIS
The classical endocrine system is regulated by the hypophysis which in turn is regulated 
by the neurosecretory cells of the hypothalamus. These neurosecretory neurons, in turn, 
are regulated by neurotransmitters whose cell bodies originate both within and without 
the hypothalamus. A brief outline of the anatomy and physiology of the structure is 
necessary to understand the outline and aims o f the studies that follow.
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2.2.1 The Hypothalamus
The hypothalamus is situated at the base of the diencephalon, beneath the thalamus and 
on each side of the third ventricle. The basal surface is defined by the optic chiasm 
anteriorly and the mamillary bodies posteriorly. In between is a grey swelling called the 
tuber cinereum which tapers ventrally into the infimdibulum which, together with the 
infundibular part of the adenohypophysis, forms the hypophyseal stalk. This 
infundibular region at the base of the hypothalamus is frequently called the median 
eminence. It is the site at which hypothalamic nerurones that regulate the anterior 
pituitary release their secretions in an anatomic relation to the primary plexus of the 
hypophyseal-portal system. This region is also the site through which neurones that end 
in neural lobe and intermediate lobe of the pituitary pass (Flerko 1980, Lechan 1987). 
Three components of this structure can be identified: neural, consisting of nerve
terminals and neurones in passage; vascular, consisting of the primary capillary plexus 
and portal veins and epithelial, consisting of the pars tuberalis of the anterior pituitary 
gland. This primary capillary plexus formed by the hypophyseal branch of the internal 
carotid artery drains into portal vessels which pass into the adenohypophysis. These 
vessels are the conduit through which the secretions of the tubereroinfimbibular 
neurones reach the pituitary (Page 1983). There the portal vessels break up to form a 
second capillary bed which bathes the endocrine cells and drains finally into the 
cavernous sinus.
It is customary to divide the hypothalamus into three regions: anterior (supraoptic), 
middle (tuberal) and posterior (mamillary). The preoptic, supraoptic, superchiasmatic, 
paraventricular and anterior nuclei are located in the anterior region. Themiddle region 
contains the arcuate, tuberal, lateral, dorsal, dorsomedial, ventromedial, posterior and 
periventricular nuclei. The mamillary and posterior nuclei are situated in the posterior 
region (see Figure 2.4).
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Figure 2.4
Diagram of the nuclei within the hypothalamus.
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Hypophyseotropic Hormones o f the Hypothalamus
The currently used term, releasing factor, is applied to hypothalamic substances of 
unknown chemical nature, whereas substances with established chemical identity are 
referred to as releasing hormone. The cells of each releasing hormone have distinct 
distributions but they all converge on the median eminence where they come into 
contact with the capillaries of the hypophyseoportal plexus. The cells projecting to the 
median eminence have been demonstrated by retrograde transport methods (Lechan,
1982) and it is within the cell bodies of these neurones that the hypothalamic 
neurohormones are synthesised.
The chemical structures of all of the classic releasing factors have now been established. 
All (thyrotropin releasing hormone [TRH], gonadotropin releasing hormone [GnRH], 
somatostatin, growth hormone releasing hormone [GHRH] and corticotropin releasing 
hormone [CRH]) are peptides with one important exception, dopamine, which is the 
principal prolactin release inhibitory factor.
Certain hypothalmic factors exert significant inhibitory actions on anterior pituitary 
function. Inhibitory factors interact with the respective releasing factor to exert dual 
control of the secretion of prolactin (PRL) growth hormone (GH) and thyroid 
stimulating hormone (TSH). Further the actions of hypophyseotropic hormones are not 
limited strictly to a single pituitary hormone; for example thyroid releasing hormone 
(TRH) is a potent releaser of prolactin (PRL) as well as of thyroid stimulating hormone 
(TSH) and, under certain circumstances, may release ACTH and GH (Borges et al
1983). LHRH releases both LH and FSH. Somatostatin inhibits the secretion of GH, 
TSH and a wide variety of other non-pituitary hormones. The principal inhibitor of PRL 
secretion, dopamine, also inhibits TSH, gonadotropin and, under certain conditions, GH 
secretion.
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Secretion of releasing hormone is regulated by local neurotransmitters and 
neuropeptides which interact with the effects of circulating hormone such as 
glucocorticoid, gonadal steroids and thyroid hormones. There is also evidence for 
feedback effects of anterior pituitary hormone (short loop feedback control) and of 
hypophyseotropic factors themselves (ultrashort loop feedback control).
Many of these hypophyseotropic factors are distributed and sometimes synthesized in 
sites beyond the hypothalamus or the CNS. There are extensive aggregations of 
hypothalamic CRH cell bodies and terminal CRH neurones in the limbic system, cortex, 
striatal and hippocampal areas and in close association with the locus coeruleus. TRH 
has been identified by immunoassay or immunohistochemistry in virtually all parts of the 
brain including the cerebal cortex, basal ganglia, neurohypophysis and spinal cord; as 
well as in pancreatic islet cells and various parts of the gastrointestinal tract (Engler et al 
1981; Jackson 1982). GnRH is found outside the hypothalamus in a number of regions 
of the limbic system (Hsueh and Jones 1981). GHRH is not present in the normal gut or 
pancreas and within the CNS is largely limited to the tuberoinfimdibular nervous system. 
Somatostatin is the most widely distributed of the hypothalamic peptides within both the 
nervous system and many extra neural tissues, including the gut and pancreas.
2.2.2 The pituitary
Anatomy
The pituitary is located in the sella turcica or hypophyseal fossa of the skull, under the 
brain (Goddyer 1989). It is protected by the sphenoid bone, which surrounds it bi­
laterally and inferiorly, and enclosed in the dura that lines the sella turcica. Superiorly it 
is covered by the diaphragma sellae, a dural sheath that forms the roof of the sella. The 
diaphragma sellae has a central opening that is penetrated by the hypophyseal stalk. The 
pitutitary is an oval , bean shaped, bi-laterally symmetrical, brownish-red organ. The
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weight of the pituitary varies in adults, averaging 0.6 gm and weighing somewhat more 
in women than in men. During pregnancy it enlarges and may reach 0.9-1.0 gm 
(Scheithauer 1990). The anterior lobe is larger than the posterior lobe and constitutes 
80% of the gland. The anterior lobe is composed of three divisions: pars distalis, pars 
intermedia, and pars tuberalis (Goodyer 1989). The pars distalis is the largest and is the 
site of the hormone-producing cells. The pars intermedia is poorly developed in the 
human, consisting of a few dilated cavities filled with an amorphous proteinacious 
material. The pars tuberalis is the upward extension of the anterior lobe, attached to the 
pituitary stalk. It contains a few small groups of cells including squamous cells and 
produces mainly glycoproteins. The structure of the pituitary gland is shown in Figure 
2.5.
The neurohypophysis or posterior pituitary consist of three parts (Sheehan and Kovacs 
1982): the median eminence of the tuber cinereum, the infundibular stem or
hypophyseal stalk, and the posterior lobe or neural lobe. The dominant features of the 
neurohypophysis are the large cell tracts (hence called magnocellular) which originate in 
the supraoptic and paraventricular nuclei, descend through the infundibulum and the 
neural stalk and terminate in dilated endings in the neural lobe (as shown in Figure 2.6). 
The principal biologically active substances secreted here are vasopressin (anti-diuretic 
hormone) and oxytocin. Anterior pituitary homones are listed in Table (2). The studies 
of this thesis measure some hormones from the anterior pituitary; namely GH and 
prolactin and the adrenal steroid cortisol, whose release is stimulated by the anterior 
pituitary ACTH. A brief account of the regulation of the hormones is given below.
Regulation of Growth Hormone
Human growth hormone is a non-glycosylated, single chain, 191 amino acid, 22 kd 
protein with two intramolecular disulfide bonds. Approximately 75% of the pituitary
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Figure 2.5
The structure o f the pituitary gland as seen in sagittal view.
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Figure 2.6
The posterior pituitary or neurohypophysis, stores and secretes hormones (vasopressin 
and oxytocin) produced in neuron cell bodies within the supraoptic and paraventricular 
nuclei of the hypothalamus. These hormones are transported to the posterior pituitary 
by nerve fibres of the hypothalamo-hypophyseal tract.
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TABLE 2
Anterior pituitary hormones and their regulation.
HORMONE TARGET
TISSUE
STIMULATED 
BY HORMONE
REGULATION OF 
SECRETION
ACTH
(adrenocorticotro 
phic hormone)
Adrenal cortex Secretion of 
glucocorticoids
Stimulated by CRH; 
inhibited by 
glucocorticoids.
TSH (thyroid
stimulating
hormone)
Thyroid gland Secretion of 
thyroid hormones
Stimulated by TRH; 
inhibited by thyroid 
hormones.
GH (growth 
hormone)
Most tissue Protein synthesis 
and growth; 
lipolysis and 
increased blood 
glucose.
Inhibited by 
somatostatin; 
stimulated by growth 
hormone - releasing 
hormone.
FSH (follicle- 
stimulating 
hormone) and LH 
(luteinizing 
hormone)
Gonads Gamete production 
and sex steroid 
hormone secretion.
Stimulated by GnRH; 
inhibited by sex 
steroids.
Prolactin Memory glands 
and other sex 
accessory organs
Milk production Inhibited by PIH
(prolactin-inhibiting
hormone).
64
GH is in this form and 5-10% is in a 20 kd form. The somatotrope cells that secrete GH 
make up about 50% of the hormone producing cells of the anterior pituitary and occupy 
the lateral wings of the pituitary. The human adenohypophysis contains 5-10 mg of GH, 
synthesised and stored in the somatotropes. The gene for human GH is on chromosome 
17 (Owerbach 1980).
The pulsatile secretion of GH is regulated by two hypothalamic regulatory hormones - 
GHRH and somatostatin (SRIF, somatotropin release - inhibiting factor), as shown in 
Figure 2.7. GHRH controls GH synthesis by regulating transcription of GH mRNA via 
control of cAMP levels (Barinaga 1983). Somatostatin appears to determine the timing 
and amplitude of GH pulses but has no effect on GH synthesis. In addition to the 
hypothalamic influences, the somatotrope is regulated by negative feedback by 
circulating somatomedins such as insulin-like growth factor (IGF, also called 
somatomedin - C) at the pituitary and hypothalamic levels and by short loop feedback by 
GH itself on the hypothalamus. The pattern of GH secretion depends upon a number of 
factors including stage of development, nutritional state, sleep stage, stress and exercise. 
Exercise, stress and some neurogenic factors stimulate GH secretion. Central alpha- 
adrenergic agonists (norepinephrine) stimulate GH secretion; clonidine, a central alpha- 
adrenergic agonist, stimulates GH secretion in this manner. Beta-adrenergic antagonists 
augment the efficacy of various stimuli for GH secretion. Dopamine agonists stimulate 
GH secretion in normal subjects by stimulating dopamine receptors. Acetylcholine 
agonists stimulate and agents that lower acetylcholine tone suppress GH release.
Growth Hormone Releasing Hormone
This polypeptide was sequenced (Rivier et al; 1982 and Guillemin et al 1982) using 
extracts of human pancreatic tumours which had caused acromegaly. Three molecular 
forms of human GHRH exist: a 40 amino acid linear peptide with a free caboxyl
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Figure 2.7
Control of growth hormone secretion and its actions. The diagram displays analogues 
of growth hormone and growth hormone-releasing factor (GHRF). Synthetic peptides 
with GHRF activity consist of 1-29, 1-40 and 1-44 amino acid residues.
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terminal (GHRH 1-40 OH), a 44 amino acid sequence with an amidated carboxyl 
terminal (GHRH 1-44 NH2) and a 37 amino acid peptide (GHRH 1-37-OH). GHRH is 
cleaved from a larger precursor molecule of approximately 13,000 Daltons 
(preprosomatocrinin) (Mayo et al 1983). GHRH-containing cell bodies are largely 
confined to the arcuate and to a lesser extent, the ventromedial nuclei of the 
hypothalamus. Bundles of axons project down from these cells to end in close proximity 
with the portal vessels in the posterior area of the median eminence.
Somatostatin
Somatostatin was first characterised as a hypothalamic tetradecapeptide (SS-14) which 
inhibited the secretion of GH. It is cleaved from a precursor molecule, a 116 amino acid 
peptide called preprosometostatin (Shen et al 1982). The highest concentration of SS in 
the nervous system is found in nerve terminals adjacent to the primary capillaries of the 
hypophyseal portal blood vessels in the median eminence (Krisch 1978; Johansson et al
1984). These nerve terminals have their origin in a concentrated group of SS producing 
cell bodies which lie close to the third ventricle (periventricular nucleus) and extend 
from the preoptic area to the rostral pole of the median eminence. SS-containing cell 
bodies are abundant in a number of other hypothalamic nuclei, notably the arcuate, 
ventromedial and suprachiasmatic nuclei. There is good evidence indicating that the 
actions of somatostatin on the pituitary are mediated by binding to a single population of 
high affinity somatostatin receptors. Somatostatin produces cAMP accumulation in 
anterior pituitary tissue which is paralleled by progressive decreases in GH and TRH 
release. This suggests that somatostatin may exert inhibitory effects by blocking cAMP 
formation. There is substantial evidence that neurosecretary SS neurons in the 
hypothalamus receive a catecholaminergic (probably dopaminergic) input (Arimura and 
Fishback 1981). Thus intraventricular dopamine stimulates SS secretion and inhibits the 
release of GH. However, circulating GH levels were increased following peripheral
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adminstration of L-DOPA or dopaminergic agonists. This paradoxical effect suggests 
that both SS and GHRH may be regulated by dopaminergic stimuli, and that the effects 
of dopaminergic agents on pituitary GH secretion may reflect a delicate balance between 
the effects of the release of these two regulatory factors. GH can exert negative 
feedback on its own secretion both directly, by stimulating the release of SS from the 
hypothalamus and indirectly by stimulation of hepatic somatomedin-C synthesis. 
Somatomedic-C has been shown to stimulate hypothalamic SS release and to inhibit GH 
secretion. Substance P and glucagon stimulate SS secretion whereas VIP inhibits its 
secretion.
Prolactin
Regulation of Prolactin Secretion
Human prolactin consists of 199 amino acids and it has three intramolecular disulphide 
bonds, one more than human growth hormone (GH). It is synthesized, stored and 
secreted by the lactotrophic cells of the adenohypophysis. The number of lactotroph 
cells is widely variable (10-30%); it is lowest in men and highest in multiparous women 
(Asa et al 1982). Normal pituitary contains 100 micrograms of prolactin, only one- 
fiftieth of the pituitary content of the growth hormone (GH). Thus the pituitary 
prolactin pool turns over more rapidly than the GH pool. Its secretion is regulated by 
the hypothalamic prolactin-inhibiting hormone dopamine and by various prolactin 
releasing factors as shown in Figure 2.8. Prolactin is unique among the anterior pituitary 
hormones in that it is under tonic hypothalamic inhibition by dopamine produced by 
tuberoinfiindibular dopamine neurons. Dopamine acts by stimulating the lactotroph D2 
receptors to inhibit adenylate cyclase and consequently inhibits both prolactin release 
and prolactin synthesis. Prolactin releasing factors include thyrotropin releasing
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Control of prolactin secretion. (TRH=thyrotrophin releasing hormone; PRF=prolactin- 
releasing factor; PRIF=prolactin release-inhibiting factor.)
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hormone (TRH) and vasoactive intestinal peptide (VIP). Prolactin synthesis is also 
regulated by the effect of estrogen on prolactin gene expression, although that serum 
prolactin levels are higher in pre-menopausal women than in men.
Regulation of Glucocorticoids (Cortisol) Secretion
Glucocorticoid secretion is regulated by hormone interaction among the hypothalamus, 
pituitary, adrenal glands (as shown in Figure 2.9) and by neural and other stimuli (Taylor 
& Fishman 1988; Antoni 1986). Neural stimuli from the brain, as in the response to 
stress, cause the release into the hypothalamic hypophyseal portal blood of CRH, AVP, 
and the other agents from the hypothalamic neurons. They are carried to the pituitary, 
where they stimulate ACTH secretion into the systemic blood. ACTH acts on the 
adrenal cortex to cause secretion of cortisol and other steroids. The negative feedback 
loop is completed by the inhibitory effects of glucocorticoids on CRH, AVP, and ACTH 
synthesis and secretion.
ACTH
ACTH, a 39 amino acid peptide, is sythesized as part of a large, 241 amino acid 
precursor molecule, propiomelanocortin (POMC). Human POMC gene is located on 
chromosome 2. Human pituitary contains approximately 250 micrograms of ACTH, 
synthesized and stored in corticotroph cells, which are a sub-type of POMC-producing 
cell line. CRH stimulate ACTH secretion by binding to high affinity CRH receptors on 
the corticotrophs and by stimulating the accumulation of cyclic AMP (cAMP) which 
activates protein kinase A. AVP alone is a weak secretogogue of ACTH but acts 
synergistically with CRH to regulate ACTH release (Debold 1984). The actions of 
ACTH on the adrenals are mediated through specific high affinity membrane receptors 
and activation of adenylate cyclase leads to intracellular accumulation of cAMP and thus
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Figure 2.9
Regulation of synthesis and secretion of adrenal corticosteroids. ACTH has only a 
minimal effect on mineralocorticoid production (indicated by dotted line). 
(ACTH=adrenocorticotrophic hormone; ADH=antidiuretic hormone (vasopressin); 
CRF=corticotrophin-releasing factor)
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increased protein kinase A activity and phosphorylation of a number of important 
proteins increase steroidogenesis.
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2.3 ASSESSMENT OF NEUROTRANSMITTER (BRAIN RECEPTOR) 
FUNCTIONS
2.3.1 Neurotransmitters
2.3.1.1 Acetylcholine:
Anatomy & physiology of cholinergic neurones:
In the spinal cord all anterior horn cells supplying nerves to voluntary muscle and all 
lateral horn cells supplying preganglionic nerves to autonomic ganglia are cholinergic. 
Ganglion cells giving rise to postganglionic parasympathetic fibres are all cholinergic. 
Cranial nerves containing voluntary motor fibres and those containing preganglionic 
parasympathetic fibres also have cholinergic cell bodies. The sympathetic postganglionic 
fibres to sweat glands are also cholinergic.
The well established cholinergic pathways so far within the brain are neostriatal 
intemeurones, the habenulo-interpeduncular train, septal-hippocampal pathways and 
corticol neurons.
Central cholinergic neurones have an important role in promoting learning, stimulating 
thirst, increasing body temperature, promoting aggressiveness and in desynchronizing 
the EEG in paradoxical sleep and in alert state.
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Chemistry of Acetylcholine Synthesis:
Acetylcholine (ACh) is synthesized by the reaction of acetyl-coenzyme A and choline 
under the influence of the enzyme choline acetyl transferase (CAT).
After synthesis in the cell bodies, it is transported by axoplasmic flow to nerve endings. 
The substrate for ACh synthesis - i.e. choline, is produced in the liver and is 
concentrated in cholinergic nerve endings by a high affinity uptake system. Acetyl Co A 
is a general substrate used in many metabolic reactions, also being generated by 
cholinergic cells themselves. It is also produced by pyruvate dehydrogenase and 
glucose. Choline acetyl transferase (CAT) has a molecular weight of about 67,000 and 
is derived from human neostriatum (Singh & McGeer 1974).
Storage, Release & Turnover and Destruction of Acetylcholine:
After synthesis in the nerve terminals acetylcholine is sequestered from 
acetylcholinesterase (AChE) by vesicular binding. It is released in a quantal fashion 
from vesicles and crosses the synaptic cleft. It can be degraded into choline and acetate 
directly by AChE or reach a receptor site. This sequence of synthesis -* storage -*• 
release is shown in Figure 2.10.
Cholinergic Receptors:
Two types of cholinergic receptors are well recognised: - 
1. Nicotinic. 2. Muscarinic.
Nicotinic receptors include all ganglionic receptors, all receptors of the musculoskeletal 
system and a few central receptors. Muscarinic receptors occur in smooth muscle
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[Synthesis, storage, release and destruction of acetylcholine.
innervated by postganglionic fibres of the parasympathetic system. This also includes 
cardiac muscle and certain exocrine glands. Most areas of the brain other than thalamus 
and cerebellar cortex have muscarinic receptors.
Nicotinic receptors are excitatory and operate by opening ionic channels and hence the 
action of acetylcholine is rapid through these receptors. Muscarinic receptors operate 
by the formation of second messenger cyclic guanocine 3', 5' - monophosphate (cGMP) 
for the action of acetylcholine (Greengard 1976) and hence the action is relatively slow 
and prolonged.
2.3.1.2 Gamma-Aminobutyric Acid (GABA):
Gamma-Aminobutyric Acid (GABA) is widely known as one of the major inhibitory 
neurotransmitters in the mammalian central nervous system (Obata and Takeda 1969) 
and is used by at least 40% of neurons (Guidotti et al 1983).
Anatomical distribution of GAB A Pathways:
The brain content of GAB A is 200 to 1,000 fold greater than that of other 
neurotransmitters such as dopamine, noradrenaline, acetylcholine and serotonin. It is 
widely distributed in the CNS particularly in the cerebellar purkinje cells, golgi and 
basket cells, hippocampal basket cells, pallidonigral neurons, spinal cord intemeurons, 
corticol and hypothalamic intemeurons.
Unlike 5HT or noradrenaline which are projected diffusely from their discrete brain stem 
and midbrain nuclei, GAB A is primarily a transmitter of local inhibitory circuits within 
the brain. Through these local circuits GAB A can rapidly alter the excitability of
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primary output neurones and thus regulate neural excitability (Zorumski and Isenberg 
1991).
Synthesis, Release and Destruction:
GABA is synthesised from glutamate in nerve endings, probably in vesicles, until it is 
released, by nerve stimulation. Its destruction is in mitochondria of glial cells, 
postsynaptic processes as well as nerve endings. The destruction of GABA causes a 
new molecule of glutamate to form from a-ketoglutarate. The newly synthesised 
glutamate may be converted to glutamine before it re-enters the nerve ending.
GABA-T
Glutamine -» Glutamate «>a-ketoglutarate SSADH
GAD I succinic semi-aldehyde -» succinic acid dehydrogenase
GABA
GAD - glutamic acid decarboxylase
GABA-T - GABA a  - oxoglutarate transaminase
SSADH succinic semi-aldehyde dehydrogenase
GABA Receptors:
The inhibitory action of GABA is mediated by GABA receptors, which are divided into 
two types - GABA (A) and GABA (B). It was initially thought that GABA (A) 
receptor, a bicuculline - sensitive type, forms the GABA - gated chloride ion channel, 
and that the activation of GABA (A) receptor induces the fast inhibitory postsynaptic 
potential (IPSP). Subsequently, the presence of GABA (B) receptor which is insensitive 
to bicuculline and sensitive to baclofen was revealed (Hill & Bowery 1981), and it was 
found that this receptor is one of the metabotropic types that couple with G-protein.
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GABA (B) receptors are located pre and/or post synaptically, and are coupled to various 
K+ & Ca+2 channels through a pathway involving second messengers. Therefore 
activation of GABA (B) receptor induces slow inhibitory post synaptic potential (IPSP).
In summary both GABA (A) and GABA (B) receptors have inhibitory roles in the CNS, 
although these actions are mediated by different molecular mechanisms.
2.3.1.3 Serotonin - [5hydroxytryptamine (5-HT)]:
Anatomy of serotonergic neurons.
Cell bodies of 5HT neurons are located in the raphe and reticular systems of the brain 
stem. The neurons of the caudal raphe nuclei project into this spinal cord, and those of 
the rostral raphe nuclei give rise to ascending pathways to the diencephalon and 
telencephalon as shown in Figure 2.11a & 2.11b (Fuxe & Johnsson 1974). There are 
important functional as well as anatomical differences among different rostral raphe 
nuclei and their projection systems which provide dual innervation of different brain 
regions, sometimes with opposing functional effects (Blier et al 1990, Murphy 1991). 
The divergence of terminals suggests that the role of serotonin neurons is to exert a 
generalised tonic effect rather than to have a highly selective action on a limited group of 
neurons.
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Figure 2.11a
Horizontal projection of ascending serotonin pathways, (Adopted from Fuxe and 
Johnsson 1974)
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Figure 2.1 lb
Schematic diagram of central serotonergic cell groups and projections in sagittal 
sections from rat brain. (Adopted from Fuxe and Johnsson 1974)
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Metabolism:
The sequence of reactions by which serotonin is created and destroyed is following.
The dietary amino acid tryptophan is converted to 5-hydroxytryptophan (5HTP) by the
enzyme tryptophan hydroxylase. 5HTP decarboxylase then converts this intermediate
amino acid to serotonin. Serotonin is metabolised both pre and post synaptically by the
enzyme monoamine oxydase (MAO) which produces the inactive metabolite 5-
hydroxyindolacetic acid (5HIAA).
Tryptophan hydroxylase L-aromatic acid decarboxylase
Tryptophan > > > > > 5-Hydroxytryptophan (5HTP) > > > > > >Serotonin (5HT)
Pteridine cofactor Pyridoxal phosphate (B5) 1
MAO-> I 
5-Hydroxyindoleacetic acid 
(5HIAA)
5-HT Receptors:
Serotonin (5HT) receptors exist in many different tissues (brain, gut, blood vessels and 
many others) and on many different cell types (e.g. neurons, platelets, smooth muscle 
cells). Two types of brain serotonin receptors, 5HT1 and 5HT2 were defined in 1979 
(Peroutka & Snyder). Subsequently, additional subtypes were recognised and classified 
according to their second messenger associations. (Humphrey et al 1993). This approach 
has led to the division of 5HT receptors into those linked to adenylate cyclase (5HT1 A, 
5HT1B, 5HT1D, 5HT4), those linked to phosphatidyl inositol system (5HT2A, 
5HT2B, 5HT2C), and those linked directly to ion channels (5HT3). 5HT play a role in 
thermoregulation. 5HT1A agonist produces hypothermia whereas 5HT1B and 5HT2 
agonists appear to produce hyperthermia (Martin et al 1988, Gudelsky et al 1988). 
Others have also reported involvement of 5HT1B receptors in sexual behaviour (Olivier 
et al 1987, Mendleson 1988). Cardiovascular effects of 5HT depends upon the species
81
of animal, the vascular bed understudy and the dose of drug (Saxena et al 1987). 5HT2 
mechanisms may be involved in peripheral vasoconstriction whereas coronary and 
cerebral vasoconstriction is 5HT1 mediated (Van Houtte 1987). Hypotensive effect of 
serotonin is mediated via inhibition of central vasomotor loci, which involves 5HT1 
receptors and inhibition of release of norepinephrine from postganglionic symphathetic 
neurons which also involve 5HT1 like receptors (Van Zwieten 1987). 5HT can also 
release vasodilator substances from vascular endothelium (Van Zweiten 1987) and also 
regulates sleep-waking cycle (Koella 1988), and plays a part in the aetiology of anxiety 
disorders (Iverson 1984, Eriksson 1987), depression (Coppen & Doogan 1988) and 
migraine (Fozard & Gray 1989).
2.3.1.4 Dopamine:
Anatomy of dopamine neuron:
Dopaminergic neuronal system arises from a series of cell bodies in the brain stem and 
gives rise to three dopaminergic pathways, i.e. nigrostriatal (Dahlstrom and Fuxe 1964 
a,b), mesolimbic - mesocortical as shown in Figure 2.12a & 2.12b (Ungerstedt 1971) 
and tuberoinfundibular (Dahlstrom and Fuxe 1964 a,b). These pathways are shown in 
horizontal and sagittal projections in figure 2.12a & 2.12b. In addition, there are 
dopaminergic intemeurons in the brain stem superior cervical ganglion (Bjorklund et al 
1970), hypothalamus (Lindvall & Bjorklund 1974), retina (Ehinger 1977), olfactory bulb 
(Halasz et al 1977) and carotid body (Bolme et al 1977).
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Figure 2.12a
Sagittal projection of dopamine pathways in rats. Striped areas indicate dense terminal 
fields. (Adopted from Ungerstedt 1971).
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Figure 2.12b
Horizontal projections of the ascending dopamine and noradrenaline pathways. 
(Adopted from Ungerstedt 1971).
Dopamine synthesis, storage, release and destruction:
The synthesis of dopamine takes place in the cytoplasm of the nerve endings from 
tyrosine under the action of two enzymes, tyrosine hydroxylase and 3-4, 
dihydroxydecarboxylase. The synthesised dopamine is either stored in vesicles or 
destroyed presynaptically by intrasynaptosomal monoamine oxydase (MAO) or released 
into the synaptic cleft. After release it can be recaptured by the nerve ending or 
destroyed by MAO or catechol-o-methyl transferase (COMT).
Tyrosine hydroxylase L-Aromatic Amino Acid
3-4 Dihydroxydecarboxylase 
Tyrosine »>-» »>-> DOPA >■■»->■> > > Dopamine
Pteridine Cofactor Phenylalanine Pyridoxal Phosphate
Physiological effects of dopamine:
Dopamine is associated with initiation and execution of movements, plays an important 
role in thought organisation and has been implicated in a number of behaviours including 
stereotype, eating and drinking. It also has an important governing influence on the 
endocrine system, particularly in promoting the release of GH and inhibiting the release 
ofPRL.
Dopamine receptors:
At present three types of dopamine receptors have been identified in the brain, namely 
D l, D2 and D3. The D1 type stimulates adenylate cyclase whereas the D2 type inhibitis 
this enzyme (Stoof & Kebabian 1981). The D3 receptor has recently been cloned with
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higher concentrations in limbic regions and ventral striation (Sokoloff et al 1990). D2 
receptors are located on the striatal cells and terminals of the corticostriate projections 
but also on the synaptic terminals, soma and dendrites of the dopaminergic neurons of 
the substantia nigra pars compacta (Aghajanian & Bunney 1977).
2.3.1.5 Noradrenaline:
Anatomy of noradrenaline neuron:
Ungerstedt (1971) with histofluorescence methods described two main ascending 
noradrenalergic pathways, a dorsal and a ventral bundle as shown in Figure 2.12b & 
2.13. Ventral noradrenalergic pathway gathers fibres from the cell bodies in the medulla 
oblongata and pons. The axons ascend in the midreticular formation and turn 
ventromedially along the medial lemniscus and continue rostrally mainly within the 
medial forebrain bundle. In its route it gives rise to noradrenalergic nerve terminals in 
the lower brain stem, mesencephalon, and diencephalon. The dorsal ascending 
noradrenalergic pathway has its cell bodies in the locus coeruleus. Their axons ascend in 
the dorsal tegmentum and at the diencephalic level turn ventrally to join the ascending 
dopamine axons in the medial forebrain bundle. Terminals are found in diencephalon, 
limbic system, and cortex. The locus coeruleus also gives rise to noradrenalergic 
terminals in the cerebellum and lower brain stem nuclei. There are also descending 
pathways to ventral and dorsal horn, and sympathetic lateral columns.
In the peripheral nervous system noradrenalergic fibres are the postganglionic gray rami 
arising from the paravertebral ganglia which contain their cell bodies. They receive their 
preganglionic fibres from the 12 thoracic and upper 2 lumbar segments.
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Figure 2.13
Noradrenaline projections by histochemistry; sagittal projection of the ascending NA 
pathways traced by fluorescent histochemical method. Striped areas indicate major 
nerve terminal fields. (Adopted from Ungerstedt 1971)
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Synthesis, storage, release and inactivation:
Noradrenalergic neurons contain dopamine /3-hydroxylase which hydroxylates the
ethylalmine side chain of dopamine and converts it into noradrenaline.
dopamine /3-hydroxylase 
Dopamine -* > > > Noradrenaline
++
Ascorbate, Cu
Noradrenaline is metabolised by MAO and COMT. The peripheral products of its 
metabolism are normetanephrine, 3-4-dihydroxymandelic acid, and vanillylmandelic acid 
(MHMA or VMA) and of central metabolism are 3-4-dihydroxyphenylglycol and 3- 
methoxy 4-hydroxyphenylglycol (MHPG). After synthesis it is stored in storage 
vesicles, released by nerve stimulation into synaptic cleft and inactivated by reuptake 
into the nerve endings.
Adrenoceptors:
Two types of adrenoceptors are well recognised:-
1. Alpha (a) 2. Beta(/3).
Alpha receptors are further subclassified into a ]  and likewise Beta receptors are 
subsubdivided into (3\ and 02.
cq adrenoceptors are located post-junctionally and c^-receptors which are mainly 
located pre-junctionally on noradrenergic nerve terminals functions as autoreceptors by 
regulating the release of noradrenaline (NE) through a negative feedback mechanism 
(Nyback et al 1975; Langer et al 1980). Whereas a2 postsynaptic receptors on
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activation may result in the stimulation of growth hormone release (Terry and Martin 
1981).
All adrenoceptors are members of the receptor superfamily which are coupled to G 
proteins. Each adrenoceptor consists of a single polypeptide chain of 400-560 amino 
acids which crosses the cell membrane 7 times. The amino terminal (NH2) *s 
extracellular and the carboxyl terminal intracellular. Each transmembrane segment 
forms a hydrophobic-a-helix. All receptors interact with G. proteins at an intracellular 
site. Different receptors interact with different G. proteins, for example are
coupled to Gs, «2 coupled with Gi/Go and o l\ to Gq proteins. Both Gs and Gi act to 
modulate the activity of adenylate cyclase. Gs stimulate whereas Gi inhibit the activity 
of this enzyme. Activated Gq activates Inositol 1 4, 5-triphosphate system. In a number 
of tissues Gi proteins can also modulate the activity of certain ion channels without 
involvement of intracellular second messengers. c*2-adrenoceptors also contraction of 
vascular smooth muscle by increasing calcium influx through L-type calcium channels 
without activating second messengers.
2.3.2 Neuroendocrine Challenge Tests
With the development of the radioimmunoassay during the late 1950s and the 1960s it 
became possible to measure endocrine function in quantitative terms in an accurate way. 
The basis of a radioimmunoassay is competitive inhibition of the binding of labelled 
hormone to antibody by unlabelled hormone contained in standards or in unknown 
samples (Yalow 1985). The broad normal range for some plasma hormone 
concentrations makes the interpretation of one value in an individual unreliable, if the 
previous normal value for that person is unknown. In addition, there are subtle degrees 
of endocrine organ dysfunction that can be compensated for under basal conditions.
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Thus the cortisol levels in plasma and the cortisol secretion rates can be normal in 
patients with partial adrenocorticol insufficiency as the result of increased secretion of 
corticotrophin (ACTH). Dynamic endocrine tests provide additional information to that 
obtained from measurements of a single hormone and can uncover these less obvious 
abnormalities in endocrine function. Such tests are based on either the stimulation or 
suppression of endogenous hormone production.
Stimulation tests are used when hypofunction of an endocrine organ is suspected and are 
designed to perturb the endogenous control mechanisms so as to assess the reserve 
capacity to form and secrete hormone. This assessment is done in either of two general 
ways. A trophic hormone can be administered to test the capacity of the target organ to 
increase hormone production. The trophic hormone can be a hypothalamic-releasing 
factor, for example TRH, and the capacity of the target organ is assessed by measuring 
TSH. Alternatively, a stimulatory test may be performed by causing an increase in the 
secretion of an endogenous trophic hormone or stimulatory factor in measuring the 
effect of the procedure on a target hormone.
For the studies in this thesis we utilised stimulatory tests that were designed to increase 
the endogenous trophic factors in the hypothalamus through central neurotransmitter 
activation and to measure specific aspects of pituitary reserve. These hormonal 
responses to drug challenge provide an important bioassay for the evaluation of 
neurotransmitter function for evaluating the integrity of its pathway and the sensitivity of 
its receptor systems. Included in this group are the growth hormone responses to 
pyridostigmine, bromocriptine, dexamethasone, desipramine and baclofen; and prolactin 
responses to buspirone. This neuroendocrine approach to assess neurotransmitter 
function is heavily dependent on the development of selective drugs for challenging 
specific receptor systems.
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Pharmocological Criteria For Neuroendocrine Tests Of Neurotransmitter Function:
When the following criteria are satisfied it is reasonable to assume that the hormone 
response to a particular drug results from the stimulation of a specified receptor: Firstly, 
a similar hormonal response should result from administration of other drugs that 
stimulate the specified neurotransmitter system. Secondly, it should be possible on each 
occasion to block this response with drugs which selectively block receptors of this 
system. Thirdly, antagonists at other neurotransmitter systems should not inhibit the 
hormonal response. Fourthly, the response must be produced either by drugs that only 
cross the blood brain barrier or if mediated at peripheral sites can be shown by animal 
studies to be at the median eminence (Checkley, 1980). Pharmocological probes can 
stimulate either receptor sites or alter the release of reuptake of neurotransmitter. In 
this thesis an attempt is made to analyse the regulation of different neurotransmitter 
systems and their influence on the functional integrity of the HPA axis in patients with 
CFS.
2.4 OUTLINE AND AIMS OF STUDIES
Due to overlap between the symptoms of CFS and depression, the separation of these 
two entities is sometimes difficult if not impossible. Abnormalities in the hypothalamic- 
pituitary-adrenal axis (HPA), in addition to disturbed neurotransmitters function, have 
been the most consistently demonstrated biological markers in depressive illness (Dinan 
1995); whereas very few studies have been conducted into the biology of CFS.
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The objective of these studies was to examine neuroendocrine aspects of monoaminergic 
(serotonergic, adrenergic, dopaminergic), GABAergic and cholinergic function in an 
attempt to explore the underlying neurobiological mechanisms in this illness.
The first study was designed to test the hypothesis that serotonergic neurotransmission 
is enhanced in CFS (Bakheit et al 1992). Hormonal responses to 5-HT1A agonist 
buspirone were examined in CFS, compared to a healthy control group. In the second 
study HPA function was examined by looking at ACTH and cortisol responses to 5- 
HT1A receptor agonist ipsapirone.
In a subsequent study to assess the function of cerebral steroid receptors, 
dexamethasone-induced growth hormone release was measured in two phases, before 
and after the administration of metyrapone. Responses to this battery of tests were 
compared to responses in healthy and depressed individuals.
Next, to assess the functioning of acetylcholine and adrenaline neurotransmission we 
measured hormonal (GH) responses to the anticholinesterase pyridostigmine and the 
monoamine reuptake inhibitor-desipramine respectively in patients with CFS and healthy 
subjects.
Finally, dopaminergic and GABAergic function was examined by measuring growth 
hormone responses to the dopamine agonist bromocriptine and the GABA (B) agonist 
baclofen respectively, in patients with CFS compared with healthy controls.
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GENERAL SUBJECTS AND METHODS:
3.1 SUBJECTS
Group 1: Patients with Chronic Fatigue Syndrome.
All patients with chronic fatigue syndrome were seen at the Institute of Neurological 
Sciences CFS out-patient clinic, Glasgow, and were hospitalised as in-patients. All 
patients were selected according to the criteria outlined in the introduction of this thesis 
and they also fulfilled the CDC criteria laid down by Fakuda et al in 1994. Those with 
co-existing depression were excluded. Essentially, patients meeting the CDC criteria 
had to have persisting or relapsing, debilitating fatigue for at least six months in the 
absence of any medical diagnosis which would explain the syndrome. Laboratory tests 
which include ESR, complete blood count and differential, protein electrophoresis, 
serum electrolytes, glucose, creatinine, blood urea, serum calcium and phosphate, liver 
function tests, muscle enzymes, urinalysis, chest x-rays, thyroid function tests, 
antinuclear antibodies screen were carried out to exclude any other medical cause for 
their fatigue.
Group 2: Patients with major depressive illness.
All patients with major depression were seen at St. Bartholomew's Hospital, psychiatric 
out-patient clinic and were admitted to the hospital for neuroendocrine studies. All 
patients were seen by psychiatrists and fulfilled the criteria for major depression as 
defined by the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, 
Revised (DSM-III-R). Depression was rated using the Hamilton Rating Scale for 
Depression (Hamilton 1960) and those with a score greater than 17 were included. 
These patients like those in Group 1, were extensively studied as were in-patients.
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Group 3: Healthy controls.
These were age and sex matched staff and student volunteers from both hospitals. All 
subjects had a full physical examination and psychiatric interview. None had a past or 
current history of chronic fatigue, psychiatric illness, neurological, endocrine, 
cardiovascular, renal, hepatic or cerebrovascular disease. None had a history of any 
alcohol consumption or elicit drug use.
All patients and control subjects were medication free for at least three months. Females 
were tested in the early follicular phase of menstrual cycle. All patients gave written, 
informed consent, and the studies were approved by the Ethics Committees in the 
Southern General Hospital, Glasgow, and St. Bartholomew's Hospital, London.
3.2 PROCEDURE
Subjects were given all tests at the same time of the day, i.e. 9.00 am. The tests were 
performed in the morning after an overnight fast. They had a cannula inserted in a 
forearm vein at 8.30 am and they were allowed to relax for 30 minutes. The cannula 
was kept patent by flushing with heparin. Serial samples were taken for estimation of 
either growth hormone, prolactin, cortisol or ACTH at 0, +30, +60, +90, +120 and 
+180 minutes after the administration of different pharmacological agents in different 
studies. Details are given in the relevant sections. The samples were immediately 
centrifuged and stored at -80° C until analysis. Blood pressure and heart rate were 
measured at 15 minute intervals throughout.
3.3 HORMONAL ASSAYS
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Growth hormone was measured in the Department of Biochemistry, Royal Infirmary, 
Glasgow using an "in house" immunoradiometric assay employing UK9 as primary 
working HGH standard. The sensitivity of the method is 0.2 mU/1 (CV <22%) with a 
between batch variation of 5% over the working range 5 to 40 mU/1.
Prolactin concentrations were also measured by immunoradiometric assay. The assay 
was standardised against the National Institute for Biological Standards and Control 3d 
International Standard 84/500, and the within and between batch coefficients of 
variation were 3% and 6% respectively over the concentration range 200-3000 mU/1.
ACTH was measured using a commercially available 2-site immunoradiometric assay. 
Intra and interassay coefficients of variation were 6% and 10% respectively. The 
reliable lower limit of detection was 4.4 Pmol/1 (20 ng/1). Cortisol was measured by 
double antibody RIA, The sensitivity of the method is 30 nmol/1 with a between batch 
variation of <10% over the range 100 to 1200 nmol/1.
3.4 STATISTICAL ANALYSIS
Unless stated otherwise the results are expressed as mean + SEM and statistically 
analysed by means of statgraphics (Statistical Graphics Corporation 1987). Endocrine 
responses over time to drug were evaluated by analysis of variance (ANOVA) with 
repeated measures and Tukey’s post hoc comparisons were applied. This analysis was 
performed to assess statistical significance of the main effects of group (patients vs 
controls), and time (changes over several time points). To evaluate whether the patients 
with chronic fatigue syndrome and controls reacted differently to drug, the interaction of 
group x time was examined.
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The comparisons of basal and drug induced hormone release [Delta A = difference 
between baseline and maximum subsequent increase after drug administration] were 
done by student's t-test and one-way analysis of variance.
3.5 DRUGS ADMINISTERED
Ipsapirone
Ipsapirone, a centrally acting pyrimidinyl piperazine derivative, is a selective 5HT1A 
agonist with only negligible affinity for IB, 1C, ID, 2 and 3 subtypes and only moderate 
affinities to a-adrenergic and dopamine D2 sites.
It has been shown to produce a dose dependent increase in ACTH and cortisol which is 
blocked by 5HT1A antagonists (Lesch et al 1990 and Koenig et al 1988). Ipsapirone 
induced ACTH and cortisol release appears to be mediated through 5HT1A receptor 
sites on the CRH-synthesizing neurons in the paraventricular nucleus of the 
hypothalamus because selective surgical or neurotoxic lesions of ascending serotonergic 
fibres or the raphe nuclei do not prevent the ACTH and corticosterone response to 5HT 
releasing compounds or 5HT agonists in rats (Van de Kar et al 1985).
Baclofen
Baclofen is a selective GABA (B) receptor agonist which freely crosses the blood brain 
barrier (Naik et al 1976). It has both pre and post synaptic effects. Pre synaptic effects 
comprise the reduction of the release of both excitatory and inhibitory transmitters, 
whereas post synaptic GABA (B) receptor mediated inhibition occurs by activating 
potassium channels through a second messenger pathway involving arachidonic acid.
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Hypothalamic GABA (B) receptors are involved in the modulation of human growth 
hormone secretion (Koulu et al 1979, Passariello et al 1982, Monteleone et al 1988). 
Therefore measurement of GH responses to acute administration of baclofen is an 
important tool to assess GABAergic function.
Buspirone
Buspirone is a piperazinyl compound which has diverse behavioural effects in animals 
and humans and is now being used in the management of anxiety disorders. It is a 
5HT1A agonist as well as dopamine antagonist, releases prolactin in a dose dependent 
manner (Meltzer et al 1983). It can also cause dizziness, nervousness, headaches and 
nausea.
Dexamethasone
Dexamethasone is a synthetic glucocorticoid with a higher affinity (7 fold) than cortisol 
for the intracellular type 2 glucocorticoid receptors. In contrast, the type 1 receptor 
mediated activities are negligible compared with their glucocorticoid activities. It is 
absorbed within 30 minutes after oral administration and its half life is 4 hours with 
considerable interindividual variation. It is widely used for both diagnostic and 
therapeutic purposes.
Despiramine
Despiramine is a tricyclic antidepressant, is a monoamine - reuptake inhibitor and thus 
indirectly stimulate the alpha 2 adrenoceptor and hence produce an increase in GH
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levels. This effect od despiramine is blocked by the alpha 1 and alpha 2 antagonist 
phentolamine but not by alpha 1 antagonist prazocin (Laakmann et al 1986).
Pyridostigmine
Pyridostigmine is an anticholinestrase and is mainly used in the treatment of myasthenia 
gravis to increase neuromuscular transmission. It inhibits the cholinestrase enzyme 
which breaks down acetylcholine in the synaptic cleft, thus increasing both the amount 
and duration of action of the transmitter at the receptor sites. It can cause nausea, 
salivation, diarrhoea and colic. Pyridostigmine brings about an increase in growth 
hormone secretion from somatotrophs by inhibiting somatostatin release (Ross et al 
1987).
Bromocriptine
Bromocriptine is an ergot derivative, stimulates D2 receptors and antagonises D1 
receptors. It is used in the treatment of Parkinson's disease, acromegaly and 
hyperprolactinemia. The common side effects of this drug are nausea, postural 
hypotension, dizziness, headache and vomiting.
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3.6 STUDY 1: 5-HT mediated prolactin release
Methods and subjects 
Subjects
60 subjects participated in this study; 30 healthy subjects and 30 patients with CFS. All 
patients fulfilled the strict criteria for the CDC revised case definition. The CFS group 
consisted of 15 males, mean age 42 years, and 15 females, mean age 44 years.
15 men, mean age 40, and 15 women, mean age 46 years, were included in this control 
comparison group. None had a personal or family history of psychiatric disorder. All 
females were tested in the follicular phase of their menstrual cycle. All subjects gave 
fully informed consent.
Procedure
The test was carried out at 9.00 am following an overnight fast. A cannula was inserted 
into the antecubital vein at 8.30 am and blood samples for baseline prolactin estimation 
taken 30 minutes later. A standard dose of buspirone 60 mgs was given orally at 9.00 
am to all subjects. Further blood samples were taken hourly for four hours. Blood 
samples were centrifuged immediately and stored at - 80° C until analysis.
Hormonal assay
Prolactin concentrations were also measured by immunoradiometric assay. Assay were 
standardised against the National Institute for Biological Standards and Control 3d
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International Standard 84/500, and the within and between batch coefficients of 
variation were 3% and 6% respectively over the concentration range 200-3000 mU/1.
Statistical analysis
Results were expressed as mean ± SEM and statistically analysed as follows. To 
calculate differences in baseline prolactin and A prolactin (difference between baseline 
and maximum value after buspirone administration) levels between patients with chronic 
fatigue syndrome and healthy volunteers, student's t-test was employed.
Two-way ANOVA with repeated measure and post hoc Tukey comparisons were 
applied to compare prolactin response curves to buspirone in healthy subjects and 
patients with chronic fatigue syndrome.
3.7 STUDY 2: Serotonin mediated activation of the hypothalamic-pituitaiy- 
adrenal axis in CFS:
Subjects
14 patients - 6 males, mean age 34 years, and 8 females, mean age 36 years, fulfilling the 
revised CDC criteria for CFS together with 14 age and sex matched healthy compairson 
subjects were recruited. The latter had a full physical examination and psychiatric 
interview. None had a personal or family history of psychiatric illness. Pre-menopausal 
females were tested in the follicular phase of the cycle. All subjects were medication 
free for at least 6 weeks before the study. None had a history of alcohol consumption or 
illicit drug use.
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Procedure
The test was carried out at 9.00 am following an overnight fast. They had a cannula 
inserted in an antecubital vein at 8.30 am and they were then allowed to relax for 30 
minutes. Baseline blood for ACTH and cortisol estimation was drawn. The cannula was 
kept patent by flushing with heparinse. A standard dose of ipsapirone 20 mgs was 
administered orally at 9.00 am. Further blood for ACTH and cortisol estimation was 
drawn at +30, +60, +90, +120 & +180 minutes. The samples were immediately 
centrifuged and stored at -80° C until analysis. Blood pressure and heart rate were 
measured at 15 minute intervals throughout.
Hormonal assay
ACTH was measured using a commercially available two site immunoradiometric assay. 
This is a non-extraction assay supplied by the Nichols Institute, San Juan Capistrano, 
CA. Intra and interassay coefficients of variation were 6% and 10% respectively. The 
reliable lower limit of detection was 4.4 pmol/L (20 ng/L). Cortisol was measured by 
double antibody RIA. The sensitivity of the method is 30 nmol/L with a between batch 
variation of less than 10% over the range 100 to 1200 nmol/L.
Statistical analysis
ACTH and cortisol responses were measured as the maximum level post ipsapirone 
relative to baseline (A ACTH and A cortisol). Two-tailed student t-test were used to 
compare means. A two-way repeated measures ANOVA with planned comparisons was 
used to compare the hormone responses over time.
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3.8 STUDY 3: Dexamethasome - induced growth hormone release: Evidence 
for cerebral steroid receptor resistance.
Subjects
36 subjects participated in this study: 12 healthy control, 12 with major depression and 
12 with CFS. Group 1 - Patients with CFS fulfilled the strict criteria for the Centres of 
Disease Control (CDC) revised case definition. All known causes of fatigue were 
eliminated, and patients had an extensive clinical work-up at in-patients. This group 
consisted of 6 men, mean age 38 years, and 6 women, mean age 40 years. Group 2 - 
Patients with major depressive illness fulfilled the DSM - 111-R criteria for their 
diagnosis and all had a Hamilton Depression Rating Score greater than 17. This group 
also consisted of 6 males, mean age 43 years, and 6 females, mean age 40 years. Group 
3 - Healthy comparison subjects: This group also included 6 males, mean age 35 years, 
and 6 females, mean age 33 years. All subjects had a full physical examination together 
with routine haematology, biochemistry and thyroid function screening. No subject was 
admitted to the study who was taking any medication. Females were tested in the early 
follicular stage of menstrual cycle. All patients gave written informed consent.
Procedure
The test was carried out in two phases and commenced in the morning at 9.00 am 
following an overnight fast. They relaxed for 15 minutes following the insertion of a 
cannula and heparin bung in a forearm vein. In the first phase dexamethasome 4 mgs 
was given orally at 0 minute and blood samples were drawn at 0, +60, +120, +180 & 
+240 minutes for growth hormone estimation. In the second phase of the study after a
103
week interval the same subjects were given metyrapone - 500 mgs, 6 hourly for 24 hours 
and then the dexamethasone test repeated as in the first phase.
Hormonal assay
Growth hormone was measured in the Department of Biochemistry, Royal Infirmary, 
Glasgow using an "in house" immunoradiometric assay employing UK9 as primary 
working HGH standard. The sensitivity of the method is 0.2 mU/1 (CV <22%) with a 
between batch variation of 5% over the working range 5 to 40 mU/1. Cortisol was 
measured by double antibody RIA. The sensitivity of the method is 30 nmol/1 with a 
between batch variation of < 10% over the range 100 to 1200 nmol/1.
Statistical analysis
One-way analysis of variance was used to compare baseline growth hormone, A GHj 
(difference between baseline values and maximum increase post DEX in phase 1), A 
GH2 (difference between baseline and maximum increase post DEX in phase 2 after 
metyrapone) values in patients with chronic fatigue syndrome, depression and healthy 
volunteers. Two-way ANOVA with repeated measures and post hoc Tukey comparison 
were applied to compare GH response curves to DEX during phase 1 and 2 in healthy 
subjects and patients with chronic fatigue syndrome and depression.
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3.9 STUDY 4: Desipramine induced GH release
Subjects
Fourteen patients and fourteen healthy controls gave fully informed consent to 
participate in this study. CFS group consisted of six male, mean age 46 years, and eight 
females, mean age 35 years, who fulfilled the revised CDC criteria for chronic fatigue 
syndrome. All known causes of chronic fatigue were eliminated, and the the patients 
had an extensive clinical work up as in-patients. This included routine haematology, 
biochemistry and thryoid function screening.
Our control group, six men and eight women (mean age 43 and 38 years respectively) 
were physically healthy and had no family or personal history of psychiatric disorder.
Premenopausal female subjects were tested in the follicular phase of menstrual cycle. 
None of the patients or controls was on any medication for at least six weeks before the 
study.
Procedure
Test was carried out at 9.00 am following an overnight fast. They relaxed for 15 
minutes following the insertion of a cannula and herparin bung in a forearm vein. 
Baseline sample was taken at 0 minute and thereafter at +60, +90, +120 and +180 
minutes for estimation of growth hormone. A standard dose of desipramine 75 mgs was 
administered orally at 0 minute. All subjects remained in a supine position throughout 
the procedure. The samples were immediately centrifuged and stored at -80° C until 
analysis.
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Hormone analysis
Growth hormone was measured in the Department of Biochemistry, Royal Infirmary, 
Glasgow using an "in house" immunoradiometric assay employing UK9 as primary 
working HGH standard. The sensitivity of the method is 0.2 mU/1 (CV <22%) with a 
between batch variation of 5% over the working range 5 to 40 mU/1.
Statistical data
Growth hormone responses over time to desipramine challenge were evaluated by 
analysis of variance (ANOVA) with repeated measures and Tukey's post hoc 
comparisons were applied. A growth hormone (difference between baseline values and 
the maximum increase post desipramine administration) measures were also used to 
compare responses in both groups. Two-tailed student's t-tests were used. Results 
were expressed as mean ± SEM.
3.10 STUDY 5: Pyridostigmine induced growth hormone release:
Subjects
Twenty eight subjects participated in this study: sixteen healthy subjects and twelve 
patients with CFS. All patients fulfilled the strict criteria for the Centres of Disease 
Control (CDC) revised case definition. The CFS group consisted of six men mean age 
31 years and six women mean age 36 years.
Eight men, mean age 32 years and eight females mean age 33 years, were included in the 
control subjects. None had a personal or family history of psychiatric disorder.
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All female subjects were tested within the first ten days of menstrual cycle. All patients 
and healthy control subjects gave fully informed consent.
Procedure
All patients were hospitalised the night before the test. The test was commenced in the 
morning following an overnight fast. An intravenous cannula was inserted into a 
forearm vein at 8.30 am and they were allowed to relax for 30 minutes. Baseline blood 
for growth hormone estimation was drawn at 9.00 am. The cannula was kept patent by 
flushing it with heparinse (0.5 ml, 50 units) after samples of blood were taken and the 
first 2 mis extracted at each time point was discarded. Pyridostigmine 120 mgs orally 
was admistered at 0 minute, i.e. at 9.00 am and further blood for GH estimation was 
drawn at +60, +90, +120 and +180 minutes. The subjects remained in a supine position 
throughout the procedure.
The samples were immediately centrifuged and stored at -80° C until analysis. Analysis 
was held out in batches and blind to subjects status.
Assays
Growth hormone was measured in the Department of Biochemistry, Royal Infirmary, 
Glasgow using an "in house" immunoradiometric assay employing UK9 as primary 
working HGH standard. The sensitivity of the method is 0.2 mU/1 (CV <22%) with a 
between batch variation of 5% over the working range 5 to 40 mU/1.
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Statistical evaluation
Student's t-tests were employed to compare baseline growth hormone values in patient 
with CFS and healthy controls. The same tests were applied comparing A GH 
(difference between baseline values and the maximum increase post pyridostigmine 
administration) values in two groups.
Growth hormone responses over time were compared by repeated measures two-way 
ANOVA and Tukey's post hoc comparisons were applied. Results are expressed as 
mean + SEM.
108
3.11 STUDY 6: Growth hormone release in response to dopamine agonist - 
bromocriptine:
Subjects
24 subjects participated in this study, 12 healthy subjects and 12 patients with CFS. All 
patients and healthy subjects gave written consent for their participation. All patients 
fulfilled the strict criteria for CDC revised case definition. All had an extensive clinical 
work-up as in-patients to exclude all known causes of chronic fatigue. CFS group 
consisted of 6 males, mean age 39 years, and 6 females, mean age 37 years.
6 men and 6 women, both with mean age of 35 years, were included in the control 
subjects. None had a personal or family history of psychiatric disorder. All females 
were tested within the first ten days of menstrual cycle.
Procedure
All patients were hospitalised the night before the test. The test was commenced in the 
morning following an overnight fast. An intravenous cannula was inserted into a 
forearm vein at 8.30 am and they were allowed to relax for 30 minutes. Baseline blood 
for growth hormone estimation was drawn at 9.00 am. The cannula was kept patent by 
flushing it with heparinse (0.5 ml, 50 units) after samples of blood were taken and the 
first 2 mis extracted at each time point was discarded. Bromocriptine 2 mgs orally was 
admistered at 0 minute, i.e. at 9.00 am and further blood for GH estimation was drawn 
at +60, +90, +120 and +180 minutes. The subjects remained in a supine position 
throughout the procedure.
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The samples were immediately centrifuged and stored at -80° C until analysis. Analysis 
was held out in batches and blind to subjects status.
Assay
Growth hormone was measured in the Department of Biochemistry, Royal Infirmary, 
Glasgow using an "in house" immunoradiometric assay employing UK9 as primary 
working HGH standard. The sensitivity of the method is 0.2 mU/1 (CV <22%) with a 
between batch variation of 5% over the working range 5 to 40 mU/1.
Data analysis
Results were expressed as mean ± SEM and statistically analysed as follows.
Baseline GH and A GH (measured by substracting the baseline from the peak value after 
bromocriptine) values were compared in patients with CFS and controls by using two- 
tailed student's t-tests. Two-way ANOVA with repeated measures was employed to 
compare GH response curves to bromocriptine in healthy subjects and patients with 
CFS.
3.12 STUDY 7: Baclofen induced growth hormone release:
Subjects
Twenty four subjects - twelve patients and twelve healthy controls - gave fully informed 
consent to participate in this study. The CFS group consisted of six men and six women 
between the ages of 33 and 53 years. All fulfilled the revised CDC criteria for chronic
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fatigue syndrome. Healthy comparison group also consisted of six men and six women 
between the ages of 22 and 51 years. They had a full physical examination and 
psychiatric interview. None had a past or present history of chronic fatigue, psychiatric 
illness, neurological, endocrine, cardiovascular, renal or cerebrovascular disease. None 
had a history of heavy alcohol consumption or elicit drug. All females were tested in the 
follicular phase of their menstrual cycle.
Experimental procedure
The experiment was performed in the morning after an overnight fast. Between 8.30 am 
and 9.00 am a butterfly needle was inserted into an antecubital vein. Baseline blood 
samples were taken at 0 minute and thereafter at +60, +90, +120 and +180 minutes for 
the estimation of growth hormone (GH). All subjects received 20 mgs of baclofen orally 
at 0 minute after baseline blood samples were drawn. Samples were immediately 
centrifuged and stored at -80° C until analysed for GH.
Assay
Growth hormone was measured in the Department of Biochemistry, Royal Infirmary, 
Glasgow using an "in house" immunoradiometric assay employing UK9 as primary 
working HGH standard. The sensitivity of the method is 0.2 mU/1 (CV <22%) with a 
between batch variation of 5% over the working range 5 to 40 mU/1.
Statistical data
GH responses were measured as the maximum level post baclofen relative to baseline (A 
GH). Two-tailed student's t-tests were used to compare baseline and A GH means. A
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two-way repeated measures ANOVA with planned comparisons was used to compare 
the hormone responses over time.
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RESULTS
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4.1 STUDY 1
Results: The prolactin responses to buspirone challenge were considerably augmented 
in patients with CFS. The change in prolactin (A prolactin) level was taken as the 
difference between the baseline value and the maximum value after buspirone. There 
were no differences in basal prolactin levels between two groups: CFS 367.27 ±21.17 
mU/L; healthy controls 362.93 ± 23.86 mU/L, (P = 0.8). A Prolactin levels differed 
significantly between patients with chronic fatigue syndrome and controls (unpaired t- 
test: t = 2.7, d .f= 58, P < .009) (see fig. 4.1.1).
Using a repeated measures two-way ANOVA to compare responses over time between 
CFS and controls yields a significant group x time interaction (F = 3.59; d.f = 4 , 295; P 
= .007). Tukey comparisons reveal differences (P < 0.05) between the groups at +60, 
and +120 minutes (see fig. 4.1.2).
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Figure 4.1.1
Prolactin (PRL) responses (A prolactin) to buspirone challenge in chronic fatigue 
syndrome (CFS) - O - and in healthy controls - ♦  Results are expressed as the 
mean ± SEM with 95% confidence limit in control subjects to compare with mean + 
SEM (-) of CFS group.
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Figure 4.1.2
Mean plasma prolactin responses (± SEM) as a function of time after buspirone 
administration to 30 patients with CFS and matched controls. Post hoc Tukey 
following ANOVA was used to compare changes at different time points.
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4.2 STUDY 2
Results: Baseline ACTH levels did not differ significantly between the two groups:
CFS 18.6 ± 2.3 ng/L, healthy controls 20.7 ±1.9 ng/L; t = 0.74, d.f = 27, P = 0.46 (see 
fig. 4.2.1). Neither did baseline cortisol levels differ significantly: CFS 433.5 ± 49.3 
nmol/L, healthy subjects 453.7 ± 65.1 nmol/L (see fig. 4.2.2).
Thirteen of the fourteen healthy volunteers elevated ACTH in response to ipsapirone 
challenge. Eight of the CFS patients failed to show a response. The mean ± SEM A 
ACTH values for both groups were: CFS 4.4 ± 0.6 ng/L, healthy subjects 14.6 ±1 . 6  
ng/L. Overall CFS patients release less ACTH than do the healthy comparison subjects 
(t = 5.9, d.f = 27, P < 0.01) (see Figure 4.2.3). A repeated two-way ANOVA yields a 
significant group x time interaction (F = 2.4; d.f = 5 ,  155; P = 0.038). Tukey 
comparisons reveal differences (P < 0.05) between the groups at +60, +90 and +120 
minutes (see fig. 4.2.4). Cortisol responses to ipsapirone challenge were inconsistent 
with only 6 healthy subjects and 5 chronic fatigue patients showing clear increases from 
baseline. The overall mean ± SEM response was 50.6 ± 58.4 nmol/L in CFS and 39.2 ± 
60.3 nmol/L in healthy subjects. These differences were not significant.
Overall ipsapirone was well tolerated, though mild nausea and lightheadedness was 
reported by subjects in both groups.
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Figure 4.2.1
Basline ACTH levels in patients with chronic fatigue syndrome (CFS) (n=14) and in
healthy comparison subjects (CONT) (n=T4). Results are expressed as the mean ±
SEM.
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Figure 4.2.2
Baseline cortisol levels in patients with chronic fatigue syndrome (CFS) (n=14) and in
healthy comparison subjects (CONT) (n=14). The results are expressed as the mean +
SEM.
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Figure 4.2.3
ACTH responses to ipsapirone challenge in chronic fatigue syndrome (CFS) (-) and in 
healthy comparison subjects ( ♦ ). Ipsapirone (20 mg orally) was administered at time 0 
minute. Results are expressed as the mean ± SEM.
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Figure 4.2.4
ACTH responses (A ACTH) to ipsapirone challenge in chronic fatigue syndrome (CFS)
and in healthy comparison subjects (CONT). Results are expressed as the mean + SEM.
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4.3 STUDY 3
Results: Using one-way ANOVA baseline GH values (control group 1.4 ± 0.31 mU/L; 
CFS 0.73 ± 0.16 mU/L; depressives 1.07 + 0.25 mU/L) did not differ significantly 
between the three groups [F (2,33) = 2.23, P = 0.123].
The overall growth hormone levels rose in response to dexamethasone (DEX) challenge. 
Growth hormone responses to dexamethasone (A GH) were calculated as the maximum 
GH level post-DEX relative to baseline. In the first phase A GH values (control 19.17 ±
3.8 mU/L; CFS 4.8 + 1.52 mU/L; depressives 3.44 + 1.07 mU/L) were significantly 
different [ F (2,33) = 29.34; P < .0001] but CFS and depressives were not significantly 
different from each other (see fig. 4.3.1).
Metyrapone treatment resulted in a nearly significant drop in cortisol in all three groups. 
In depressives it dropped from 820.9 + 159.5 nmol/L to 355.6 + 101.2 nmol/L; in 
healthy controls from 453.7 + 65.1 nmol/L to 298.7 + 87.6 nmol/L and CFS from 501.4 
± 102.26 nmol/L to 342.4 ± 98.4 nmol/L (see fig. 4.3.5).
A GH values after metyrapone treatment in three groups (control 26.98 + 4.12 mU/L; 
CFS 6.33 + 2.03 mU/L; depressives 4.33 + 1.03 mU/L) were different significantly [F 
(2,33) = 17.65, P < 0.0001] (see fig. 4.3.3). Of the three groups healthy volunteers 
increased A GH from 19.17 + 3.8 mU/L to 26.98 + 4.12 mU/L (P = 0.09) after 
dexamethasone following metyrapone treatment compared to CFS and depressives (P = 
0.5).
Tukey comparisons following repeated measures two-way ANOVA to compare 
responses over time between controls, CFS and depressives reveal differences (P < 0.05)
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at 60, 120 and 180 minutes in phase 1 and at 120, 180 and 240 minutes in phase 2 (see 
fig. 4.3.2 & 4.3.4).
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Delta Growth Hormone (mll/l)
Figure 4.3.1
Phase 1. Growth hormone responses (A GH) to dexamethasone (DEX) in controls, 
patients with chronic fatigue syndrome (CFS) and in patients with depression. Results 
are expressed as mean ± SEM with 95% confidence limit in controls to compare with 
mean + SEM of patients with chronic fatigue syndrome and depressives.
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Figure 4.3.2
Phase 1. Mean plasma GH responses (± SE) as a function of time after DEX to patients 
with chronic fatigue syndrome, depressives and matched controls. Results are expressed 
as the mean + SEM.
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Figure 4.3.3
Phase 2. Growth hormone responses (A GH) to dexamethasone (DEX) in controls, 
patients with chronic fatigue syndrome (CFS) and in patients with depression. Results 
are expressed as mean + SEM with 95% confidence limit in controls to compare with 
mean ± SEM of patients with chronic fatigue syndrome and depressives.
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Figure 4.3.4
Phase 2. Mean plasma GH responses (+ SE) as a function of time after DEX to patients 
with chronic fatigue syndrome, depressives and matched controls. Results are expressed 
as the mean + SEM.
127
Serum Cortisol (nmoI/L)
□B
efore
Figure 4.3.5
Mean cortisol levels in patients with chronic fatigue syndrome (CFS), depressives and
healthy comparison subjects (CONT) before and after metyrapone.
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4.4 STUDY 4
Results: Basline GH levels did not differ significantly between the two groups; CFS
1.82 ± 0.15 mU/L, healthy controls 2.04 + 0.2 mU/L; t = 0.22, d.f = 26, P = 0.73.
All healthy volunteers elevated GH in response to desipramine. Two of the chronic 
fatigue patients failed to show a response. A mean A GH in CFS group of 3.26 + 0.51 
mU/L was significantly lower compared to a mean A GH of 7.33 + 1.38 mU/L in healthy 
controls (t = 2.8, d.f = 26, P < 0.013) (see fig. 4.4.1).
A repeated measures two-way ANOVA used to assess differences over time between 
CFS and healthy controls demonstrates a significant effect for group [F (1,138) = 
18.165, P = .0001]; time [F (4,135) = 14.98, P = .0001] and the group x time interaction 
[F (4,135) = 4.4, P = 0.002]. Post-hoc Tukey comparisons show these responses to be 
significantly different at +120 (P < 0.05) and +180 minutes (P < 0.05) (see fig. 4.4.2).
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Desipramine challenge (delta GH)
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Figure 4.4.1
Growth hormone responses (A GH) to desipramine in controls - ♦  - and patients with 
chronic fatigue syndrome (CFS) -0-. The results are expressed as the mean ± SEM 
with 95% confidence limit in controls to compare with mean ± SEM of CFS group.
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Figure 4.4.2
Growth hormone responses (mean ± SEM) as a function of time after desipramine 
challenge in patients with CFS and matched controls.
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4.5 STUDY 5
Results: All but one healthy individual responded to pyridostigmine with an increase in 
plasma growth hormone. There were no differences in baseline GH levels between CFS 
and control groups (CFS 0.63 ± 0.28 mU/L, control 0.71 ±0.11 mU/L; t = 0.22, d.f = 
26, P = 0.78).
A mean A GH in CFS group of 17.07 ± 2.57 mU/L was significantly higher compared 
to a mean A GH of 6.84 ± 1.26 in healthy controls (t = 3.5, d.f = 26, P < 0.002) (see fig.
4.5.1).
Using a repeated measures two-way ANOVA to compare responses over time between 
CFS and controls yields significant effect for group [F (1,138) = 14.178, P = .0003] and 
time [F (4,135) = 8.84, P = .0001]. Tukey post-hoc analysis indicates that GH 
responses at +60, +120 and +180 minutes are significantly different (P < 0.05) (see fig.
4.5.2).
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Figure 4.5.1
Growth hormone responses (A GH) to pyridostigmine in controls - ♦  - and patients with 
chronic fatigue syndrome (CFS) -0-. Results are expressed as the mean + SEM with 
95% confidence limit in controls to compare with mean ±  SEM of CFS group.
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Figure 4.5.2
Plasma growth hormone responses (mean ± SEM) as a function of time after 
pyridostigmine in patients with chronic fatigue syndrome (CFS) and matched controls. 
Post-hoc Tukey comparisons were used to compare changes over time in both groups.
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4.6 STUDY 6
Results: The overall GH levels rose in response to bromocriptine in both healthy
subjects and patients with CFS. In fact, two-way ANOVA with repeated measures 
disclosed no signficant differences between the two groups [F = 0.080, NS] and no 
significant group x time interaction (F = 0.308, NS) but it showed a significant effect for 
time (F = 12.44, P = .0001). Tukey's post-hoc analysis indicates that responses at +60, 
+120, +180 and +240 minutes are not different in both groups (see fig. 4.6.1).
No significant difference in mean A growth hormone (Peak GH after bromocriptine - 
baseline GH) is seen in CFS (8.93 + 1.32 mU/L) compared with the control group (8.53 
+ 1.95 mU/L) [unpaired t-test: t = 0.1, d.f = 22, P = 0.86] (see Figure 4.6.2).
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Figure 4.6.1
Plasma growth hormone responses (mean ± SEM) as a function of time after 
bromocriptine (2 mg orally) to patients with CFS and matched controls. Post-Tukey 
following ANOVA compared changes after bromocriptine in controls and patients.
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Figure 4.6.2
Growth hormone responses (A GH) to bromocriptine in controls - ♦  - and patients with 
chronic fatigue syndrome (CFS) -0-. Results are expressed as mean ± SEM with 95% 
confidence limit in controls to compare with mean ± SEM of CFS group.
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4.7 STUDY 7
Results: All patients and healthy volunteers responded to baclofen with an increasing
plasma GH. There were no differences in basal GH levels between two groups 
(unpaired t-test: t = 0.1, d.f = 22, P = 0.80). Similarly no significant difference in A GH 
(Peak GH post-baclofen - basline GH) is seen in CFS compared to controls [CFS 12.70 
± 2.18 mU/L, control 11.05 ± 1.98 mU/L, unpaired t-test: t = 0.686, d.f = 22, P = 0.58) 
(see fig. 4.7.1).
ANOVA with repeated measures disclosed no significant difference between two groups 
(F = 0.060, NS) and no significant group x time interaction (F = 0.26, NS) but it showed 
a significant effect for time (F = 14.28, P < .0001). Tukey post-hoc analysis indicates 
that responses at +30, +60, +90, +120 and +180 minutes are not different in both groups 
(see fig 4.7.2).
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Figure 4.7.1
Growth hormone responses (A GH) to baclofen in controls and patients witht
chronic fatigue syndrome (CFS) -0-. Results are expressed as mean ± SEM with 95% 
confidence limit in controls to compare with mean ± SEM of CFS group.
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Figure 4.7.2
Growth hormone responses (mean ± SEM) as a function of time after baclofen (20 mg 
orally) to patients with CFS and matched controls. Post-Tukey following ANOVA was 
used to compare changes over time after baclofen challenge in both groups.
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DISCUSSION AND CONCLUSION
DISCUSSION
Chronic fatigue syndrome is an important disease posing enormous health problems that 
urgently need elucidation. Research has been hampered in this illness by the fact that 
there is no diagnostic test and the present definitions mentioned earlier in this thesis have 
not been specific. The definition which I used in the studies of this thesis met the CDC 
(Holmes et al 1988; Fukuda et al 1994), UK (Sharpe et al 1991) and Australian (Lloyd 
et al 1990) criteria for defining this illness. In addition, as stated in methods, all the 
patients were hospitalised as in-patients and fully investigated to exclude any medical or 
psychiatric causes of their fatigue.
Analysis of the reported clinical symptoms and signs i.e. debilitating fatigue, mood and 
sleep disturbances, subjective feeling of hot and cold, emotional lability and temperature 
fluctuations - has strongly suggested that central/hypothalamic mechanisms are involved. 
Other reported data on chronic fatigue has further suggested hypothalamic involvement. 
Poteliakhoff (1981) found lower levels of plasma cortisol in patients suffering from 
chronic fatigue and suggested this to be due to decreased stimulation of the pituitary - 
adrenal axis secondary to exhaustion or malfunctioning of brain cells in the hypothalamic 
region. Asthenia and tiredness in post-hepatitis syndrome has also been attributed to 
impaired steroid metabolism (Mims 1969).
Initial studies in patients with CFS of impaired water metabolism (Bakheit et al 1993), 
augmented prolactin responses to 5HT1A agonist buspirone (Bakheit et al 1992) and 
abnormal adrenal corticol sensitivity to exogenous ACTH and CRH with blunted ACTH 
responses to CRH (Demitrack et al 1991) has pointed to abnormalities of the 
hypothalamus and its activation of the pituitary - adrenal axis. Activation of the 
hypothalamic - pituitary - adrenal axis is brought about by the release of CRH from the 
paraventricular nucleus which is under the control of a wide array of neurotransmitters.
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For this reason we decided to analyse the regulation of different neurotransmitter 
systems and their influence on the functional activity of hypothalamic - pituitary - 
adrenal (HPA) axis, hypothalamic somatotroph axis and hypothalamic prolactin axis.
Dynamic neuroendocrine challenge tests provide one of the only methods for examining 
neurotransmitter function in vivo in humans (Checkley 1980). This neuroendocrine 
approach is heavily dependent on the development of selective drugs for challenging 
specific receptor systems. The resultant hormonal response to drug challenge provide 
an important bio-assay for the evaluation of neurotransmitter function - integrity of it's 
pathway and the sensitivity of it's receptor systems. The various neurotransmitter 
systems which were studied in this thesis include dopamine (DA), noradrenaline (NA), 
5-hydroxytryptamine (5-HT), gamma aminobutyricacid (GABA) and acetylcholine 
(ACh).
5-HT mediated prolactin release:
In the first study we extended the original work of Bakheit et al (1992) on buspirone 
induced prolactin (PRL) release. Our data confirmed augmented PRL release in 
response to buspirone in patients with CFS compared with healthy controls. We did not 
look at depressives in this study but our data confirmed that there was an increased 
response as compared to the blunted response reported in patients with depression 
(Bakheit et al 1992).
In general prolactin secretion from the anterior pituitary is likely to be mediated by many 
different pathways but is primarily under tonic dopaminergic (DA) inhibitory control 
(Kato et al 1985). Dopamine is released from the terminals of the tuberoinfundibular 
dopaminergic neurones into the pituitary portal circulation (MacLeod 1976; Gudelsky
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and Porter 1979) and exerts its inhibtory effect on PRL secretion via DA2 receptors 
located on pituitary lactotrophs. Consequently dopamine agonist inhibit the release of 
prolactin (Meltzer and Fang 1976) and neuroleptics t b a t  block the DA receptors 
(dopamine antagonists) augment prolactin release (Meltzer et al 1978). In contrast to 
dopamine, the effect mediated by serotonin (5HT) is stimulatory and indirect as there are 
no 5HT receptors on the lactotrophs (Lambarts and MacLeod 1978).
It is generally accepted that serotonergic neurons in the dorsal raphe nucleus stimulate 
the secretion of prolactin (Advis et al 1979, Barofsky et al 1983, Kitts and Johnson 
1986, Van De Kar and Bethea 1982, Van De Kar et al 1985) probably through secretion 
of prolactin releasing factor (PRF) in the paraventricular nucleus of the hypothalamus 
(Minamitani et al 1987). Whether 5-HT can also release prolactin by a direct action on 
the pituitary gland is at present controversial (Stobie and Shin 1983; Lopez et al 1987). 
A large number of different 5-HT receptors have been discovered on neurons in the 
human brain. These include 5-HT1A, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2C 
(previously called 5-HT 1C receptor). The role of different 5-HT receptor subtypes in 
stimulating the secretion of prolactin are less clear. Some studies indicate that prolactin 
response to 5-HT stimulation is mediated predominantly by 5-HT1 rather than 5-HT2 
receptors (Charig et al 1986) whereas Jahn and Deis (1988) report some evidence that 
there is stimulatory action of serotonin on prolactin release by 5-HT2 receptors. In rats 
evidence exists that 5-HT IB receptors are involved in the stimulation of the secretion of 
prolactin by endogenously released 5-HT (Van De Kar 1989). As the human brain lacks 
5-HT IB recognition sites (Hoyer et al 1986) it can be concluded that the regulation of 
prolactin secretion in humans is mediated by 5-HT 1A or 5-HT2 receptors or as yet 
undefined 5-HT receptor subtypes.
144
The exact mechanisms of buspirone induced prolactin release in humans and animals are 
unknown but several pieces of evidence suggest that on balance, prolactin release is 
mediated by 1. 5-HT receptors, 2. dopamine receptors, 3. non-specific stress factors 
such as induction of nausea. The latter is highly unlikely as none of our subjects 
reported any feelings of nausea. Animal studies indicate that buspirone produce a dose 
dependent increase in rat plasma prolactin levels (Meltzer et al 1982) through central 
dopaminergic mechanisms. A number of studies indicate that buspirone interacts with 
central dopaminergic mechanisms, e.g. it disrupts the conditioned avoidance response 
(Wu et al 1972; Allen et al 1974) and blocks apomorphine induced stereotypy in rats 
and emesis in dogs (Allen et al 1974; Stanton et al 1981). Radiolabelled ligand binding 
studies also indicate that buspirone can interact with dopamine (DA) receptors (Stanton 
et al 1981). It was also proposed that, in low doses, it may also act as dopamine agonist 
(Taylor et al 1980, Riblet et al 1981) however, enhancement, rather than a reversal by 
buspirone of alpha-methyl-Para-tyrosine (AMPT) induced increase in prolactin secretion 
strongly argues against the hypothesis that buspirone acts as a dopamine agonist at the 
pituitary gland (Meltzer et al 1982).
If this increase in prolactin release is mediated through DA receptors it can be 
hypothesised that dopaminergic inhibitory tone on anterior pituitary lactotrophs for the 
release of prolactin is higher in patients with CFS compared with controls. This 
postulated altered DA neurotransmitter function in CFS was further tested by giving the 
patients dopamine agonist - bromocriptine and measuring growth hormone release, no 
difference was found between patients and controls. It is therefore unlikely that the 
increase in prolactin release in response to buspirone in patients with CFS is through 
dopaminergic receptors.
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The involvement of 5-HT receptors in buspirone induced prolactin release is supported 
by the observation that 5-HT antagonist - methysergide (Kato et al 1974) and 
metergoline (Gregory et al 1990) significantly reduced prolactin release in response to 
buspirone.
Finally, it is concluded that prolactin release in response to buspirone is mediated 
through 5-HT la receptors in the hypothalamus and an augmented response suggest 
upregulation/increased sensitivity of central 5-hydroxytryptamine receptors in CFS. 
Other studies which support the idea of increased sensitivity of central 5-HT receptors in 
this illness are those of Cleare et al (1995). They found similar augmentation in 
prolactin release when 5-HT- releasing agent d-fenfluramine was used. It assesses "net" 
5-HT activity as it is not clear which 5-HT receptor subtypes are involved in mediating 
these responses. Demitrack et al (1992) in their study also provide evidence of 
disturbed 5-HT functioning in the periphery. In 19 patients with CFS they found 
increased plasma 5-hydroxyindole acetic acid (HIAA) the major metabolite of 5-HT. An 
increase in peripheral turnover might explain the heightened allergic responsiveness, as 
well as the musculoskeletal pain seen in these patients, whilst altered central 5-HT may 
explain the cognitive fatigue, poor concentration and sleep disturbance.
As stated in the method section, we tested pre-menopausal women in the early follicular 
phase of menstrual cycle. Dinan et al (1990) reported that prolactin responses to 
buspirone vary widely throughout the menstrual cycle in healthy women with a three 
fold increase pre-menstrually probably through upregulation of 5HT receptors following 
ovulation when gonadal steroid levels are high (Biegon et al 1980 and Ladisich 1977).
The view that chronic fatigue syndrome is a form of depressive disorder is not supported 
by the findings of this study. In depression, prolactin responses to 5HT1A agonist
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buspirone (Bakheit et al 1992), 5-HT reuptake inhibitor clomipramine (Anderson et al 
1992) and to d-fenfluramine (Cleare et al 1995, O'Keane and Dinan 1991) are blunted 
and reflect decreased 5HT neurotransmission whereas we suggest that CFS may be 
associated with increased 5HT function.
Serotonin mediated activation of hypothalamic-pituitary-adrenal (HPA) axis in 
CFS:
Many of the clinical manifestations of chronic fatigue syndrome - debilitating fatigue, an 
abrupt onset precipitated by a stress , arthralgia, myalgia, exacerbation of allergic 
responses, mood and sleep disturbances - are reminiscent of mild glucocorticoid 
deficiency (Baxter and Tyrell 1981). Patients with hypothyroidism (Kamilaris et al 
1987) and seasonal affective disorder (Joseph et al 1991) who present with fatigue, 
lethargy and atypical depression, show evidence of impaired activation of hypothalamic 
CRH. Bruno et al (1995) has reported impaired activation of HPA axis to a fasting 
stressor in patients with post-polio fatigue, a condition that bears striking similarities to 
CFS. In their study they measured plasma concentration of cortisol and ACTH 
following a mild stressor effect (fasting) which is known to stimulate the HPA axis 
(Dallman et al 1993) and found that there was no ACTH elevation in subjects reporting 
severe fatigue. They suggested that hyposecretion of ACTH may be secondary to 
decreased production of the hypothalamic secretogue CRH and vasopressin. Thus post­
polio fatigue may be attributable to a polio virus lesion not only in the brain activating 
system but also in the paraventricular nucleus which reduces the secretion of 
neuromodulators that stimulate this system (HPA axis). Similarly in patients with CFS, 
Demitrack et al (1991) conducted a comprehensive dynamic assessment of the 
hypothalamic-pituitary-adrenal axis and suggested mild central adrenal insufficiency 
secondary to either a deficiency of CRH or some other secretogue.
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The release of CRH from the paraventricular nucleus is under the control of several 
classic neurotransmitters, including serotonin (Dinan 1996). These neurotransmitters 
may influence the receptor content of steroid sensitive cells, and this may constitute an 
important mechanism by which neurotransmitters modulate steroid dependent processes 
(Nock et al 1981 Angelucci et al 1981). For example 5HT plays an important role in the 
negative feedback by glucocorticoids on central HPA-axis function: (a) depletion of 
5HT in hippocampal structures may attenuate the negative feedback effects on the axis 
through downregulation of glucocorticoid (GR) or mineralocorticoid (MR) receptors 
(Brady et al 1992: Seckl and Fink 1991); and (b) depletion of 5HT causes an 
enhancement of the negative feedback effects of glucocorticoids on hypothalamic CRH 
(Feldman and Weidenfeld 1992).
The serotonergic receptor system is complex and evidence is now available to link 
ACTH release with stimulation of 5HT1A receptor (Gilbert et al 1988). Ipsapirone is a 
selective 5HT1A agonist and has been shown to produce a dose dependent increase in 
ACTH and cortisol which is blocked by 5HT1 Atagonists (Lesch et al 1990 and Koenig 
et al 1988). That 5HT might be involved in the pathophysiology of CFS, as suggested in 
the first study, it was therefore decided to examine 5HT activation of the hypothalamic- 
pituitary axis in this syndrome. The study is based on the hypothesis that the 
abnormalities in hypothalamic-pituitary-adrenal axis function arise from disturbance in 
serotonergic inputs.
Blunted release of ACTH in response to ipsapirone challenge was demonstrated. This 
blunting is similar to that previously reported when CRF was administered to subjects 
with chronic fatigue syndrome (Demitrack et al 1991). The abnormality may be 
attributed to a number of possible factors: 1. decreased responsivity of 5HT1A receptors 
at a hypothalamic level. 2. decreased responsivity of CRH receptors on the anterior
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pituitaty corticotrophs. 3. underactivity of anterior pituitary corticotrophs leading to 
decreased production and release of ACTH. In order to resolve the site of abnormality, 
simultaneous measurement of cerebrospinal fluid CRF is required. In case of decreased 
responsivity of 5HT1A receptors at a hypothalamic level CRF levels would be low 
compared with healthy controls. A deficiency of CRH could also theoretically 
contribute to lethargy and fatigue that are cardinal symptoms of CFS. In case of the 
second and third possibilities levels of CRF are increased. It is unlikely that 
abnormalities in cortisol feedback either at a pituitary or hypothalamic level are 
responsible as baseline cortisol levels in the current study were normal. To rule out such 
a possibility definitely would require monitoring of 24 hours cortisol production in such 
subjects.
Demitrack et al (1991) reported elevated ACTH levels whilst we were unable to find 
differences between patients and comparison subjects in terms of baseline ACTH. A 
detailed 24 hour study of ACTH release is required to throw further light on these 
differences. Similar blunting of ipsapirone-mediated ACTH release was reported by 
Lesch et al (1990 b) in a patient with unipolar depression but such blunting was found in 
the presence of high cortisol levels and they postulated that cortisol might have 
produced a decreased sensitivity of the postsynaptic 5HT1A receptor. In our study 
patients were excluded if they had depressive symptoms and we found that cortisol 
levels did not differ from those found in control subjects.
The view that chronic fatigue syndrome is a masked form of depression therefore, is not 
supported by our findings. In the first study we examined buspirone induced prolactin 
release, assuming this to be a measure of 5HT1A receptor responsivity and found an 
augmented prolactin release in comparison to healthy controls. Similar augmentation in 
such patients has been reported by Bakheit et al (1992) and in other studies when d-
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fenfluramine was used to stimulate prolactin release (Cleare et al 1995). This might 
indicate that 5HT1A responses show anatomic differences with some responses 
enhanced and other attenuated in CFS. It is however possible that the differences may 
be due to differing drug selectivity. If 5HT1A receptors show different anatomic 
responses such differences could be demonstrated using d-flenfluramine to release both 
prolactin and ACTH. If differences exist one would expect enhanced prolactin and 
decreased ACTH release in chronic fatigue syndrome.
The view that the syndrome is simply a variant of affective disorder is not borne out by 
this study. First, all patients underwent a full psychiatric assessment and none had 
evidence of significant depressive symptoms or had a past history of major depression. 
Secondly, patients with major depressive illness show elevations in cortisol levels (Dinan 
1994; Checkley 1992), whilst patients here had serum cortisol levels which did not differ 
significantly from healthy comparison subjects. In fact when 24 hour urinary free 
cortisol is monitored, cortisol output is seen to be reduced in chronic fatigue syndrome 
(Demitrack et al 1991). Adrenalectomy in rats increased 5HT1A receptor binding in 
both the hippocampus and raphe neurones (DeKloet et al 1986). Furthermore the 5HT1 
receptor is G-protein linked and the G-proteins are known to be significantly influenced 
by glucocorticoids (Saito et al 1989). It is therefore possible that the alterations in 
5HT1A receptors are partly mediated through differences in cortisol output.
In summary, in patients with CFS, we found no differences in baseline ACTH or cortisol 
levels but significant attenuation of 5HT1A mediated ACTH responses, using ipsapirone 
as challenged agent.
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Dexamethasone induced growth hormone release: evidence for cerebral steroid 
receptor resistance:
In chronic fatigue syndrome impaired activation of HPA-axis has recently been reported 
(Demitrack et al 1991). How chronic fatigue might result from such abnormalities is 
unknown but it is noteworthy that in patients with panhypopituitarism in whom all 
hormonal replacements have been made, they still suffer from apathy, lack of drive and 
chronic fatigue. The basis of this fatigue is unknown and has been suggested to be due 
to either a deficiency of growth hormone or prolactin (Martin and Reichlin 1987). Some 
of the features of chronic fatigue syndrome are similar to those seen in adult growth 
hormone deficiency (Lamberts et al 1992). We therefore studied functional integrity of 
hypothalamic-pituitary-somatotroph axis and its interaction with HPA-axis as 
physiological level of corticosteroids is a prerequisite for the normal functioning of 
hypothalamic-pituitary growth hormone axis (Giustina et al 1989).
Growth hormone is secreted by specific anterior pituitary cells, the somatotrophs, which 
are influenced by a number of factors. Growth hormone (GH) secretion is stimulated by 
growth hormone releasing hormone (GHRH) and is inhibited by somatostatin. Negative 
feedback control is brought about at the pituitary level by somatomedin C, while 
somatomedin may also act at a high level that is at the hypothalamus to stimulate the 
secretion of somatostatin. A number of diverse factors act on the release of growth 
hormone releasing hormone and on somatostatin. Interestingly, exercise and stress, 
together with /3-adrenergic stimuli reduce growth hormone secretaion by increasing 
somatostatin tone while acetylcholine/dopaminergic stimuli and a-adrenergic stimuli 
increased growth hormone release. The exact role of glucocorticoids in the regulation 
of growth hormone secretion is unclear. Contrasting with the generally accepted idea 
that glucocorticoids inhibit growth hormone secretion in man, Casanueva & colleagues
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(1990) have been able to demonstrate that dexamethasone alone administered acutely 
can result in a stimulation of growth hormone release, presumably through alteration in 
somatostatinergic tone at the level of hypothalamus (Nakagawa et al 1987; Wehrenberg 
et al 1990). This study is designed hypothesising that abnormalities in hypothalamic 
pituitary-GH axis stem from impaired activation of HPA axis. We made use of the fact 
that dexamethasome, the synthetic glucocorticoid when administered acutely stimulates 
type 2 cerebral steroid receptor and promotes growth hormone release (Casanueva et al 
1990).
In this study abnormalities in growth hormone level have been found between healthy 
controls and patients with both chronic fatigue syndrome and depression. Baseline 
growth hormone levels in patients with chronic fatigue syndrome and depression were 
not significantly different but consistent with a trend towards lower level of GH. This 
findings is in agreement with that of Bennett et al (1992) who described lower levels of 
growth hormone mediator-somatamedin C (IGF-1) taken at random in 70 women with 
fibromyalgia/CFS compared with controls.
Another condition which bears a striking similarlity to CFS, is the post-polio syndrome. 
In this condition, in which there is new weakness and incapacitating fatigue developing 
in patients who have had previous polio, low levels of somatomedin C and GH have 
been found (Gupta et al 1992). Growth hormone levels decline following puberty 
although the spontaneous growth hormone secretion rate does not differ significantly 
over the age range 20-40 years (Finkelstein et al 1972). Whilst the mean age of healthy 
controls was a little below that of the other two groups, we do not feel that this is 
important or that the differences found are a result of age. Furthermore in Bennett's 
study (1992) the patient and control groups were well matched for age and the 
differences in somatomedin C were still observed. It is not apparent whether these
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changes are components of a primary pathological process or are acquired secondary to 
some of the behavioural aspects of CFS and depression such as reduced physical 
activity. We did not collect data on current physical activity levels in this study, 
although reduced physical activity is a criteria for CFS. It is important to extend this 
work to include control subjects who are more closely age matched to the patients and 
to ascertain levels of activity in all subjects.
We also observed abnormal responses in growth hormone production to administered 
steroids in both patients with CFS and depression. Acute administration of 
dexamethasome (DEX), a synthetic glucocorticoid, by acting on glucocorticoid 
receptors (GR) in the brain, reduces somatostatin tone and increases serum levels of 
growth hormone. How steroids are administered, e.g. acutely or chronically, will have 
an effect on how steroid receptors on certain neurones in the cortex, particularly the 
limbic system, and the periventricular nucleus of hypothalamus, react. There is receptor 
plasticity, i.e. changes can occur in neuronal anatomy, physiology or biochemistry of 
such receptors in response to a variety of stimuli and this plasticity leads to a different 
response to acute or chronically administered steroids (Casanueva et al 1988).
In this study, the effects of acute administration of dexamethasone on GH release are 
shown to be markedly reduced in patients with CFS and depression. This abnormality is 
compatible with a decreased responsivity of cerebral glucocorticoid receptors and fits 
well with the hypothesis that CFS may be a form of Addison's disease of the brain 
(Demitrack et al 1991). The high baseline cortisol levels seen in depression may explain 
the blunted responses by increasing somatostatic tone, (Wehrenburg et al 1990, Lima et 
al 1993) whereas in patients with CFS cortisol levels did not differ significantly from the 
healthy comparison group (as measured in the previous study) and low levels have been 
reported by Demitrack and co-workers (1991) in their studies. It can therefore be
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hypothesised that decreased responsivity of steroid receptors is independent of the 
serum cortisol level (disturbance of HPA system) and receptors have lost their plasticity 
and become resistant.
In order to confirm this, in the second phase of the study metyrapone, inhibitor of 11/3- 
hydroxylation was administered prior to dexamethasome challenge in order to block 
glucocorticoid synthesis and upregulate brain steroid receptors (Chao and McEwan 
1989). Despite reduction in cortisol levels in patients with CFS and depression after 
metyrapone administration, there was no further rise in the production of GH compared 
with controls. These findings confirm the assumption of cerebral steroid receptor 
resistance in CFS as does the single case reported by Bronnegard et al (1986), who 
presented with intermittent fatigue and a tendency for hypotension and was found to 
have primary cortisol resistance associated with a thermolabile glucocorticoid receptor. 
Similarly mutations within the glucocorticoid receptor (GR) gene can cause the clinical 
syndrome of familial glucocorticoid resistance (Hurley et al 1991). Although we cannot 
explain the mechanisms involved in the pattern of glucocorticoid sensitivity observed in 
patients with CFS and depression, the genetic influences that determine the sensitivity to 
glucocorticoid (Becker et al 1976) appear to be superseded by disturbances of the HPA 
system.
Desipramine induced GH release:
To date little is known about the central noradrenergic functioning in this syndrome. 
However in a comprehensive study of monoamine metabolism in CFS, Demitrack et al 
(1992) found lower levels of plasma norepinephrine metabolite - 3 methoxy - 4 
hydroxyphenethyleneglycol (MHPG) in CFS patients compared with controls. Plasma 
free MHPG was used as an index of central noradrenergic (NE) turnover because it has
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been shown to reflect brain MHPG, the major metabolite of brain NE (Maas et al 1979). 
Although the proportion derived from central noradrenergic activity is controversial, 
with estimates ranging from 20% (Blombery et al 1980) to 60% (Maas et at 1979). On 
this assumption is can be hypothesised that central noradrenergic function is impaired in 
patients with CFS. The most widely studied test of central noradrenergic a l  receptor 
functioning in man is the clonidine/GH challenge test, a l  adrenergic receptor is found 
both presynaptically and postsynaptically on noradrenergic neurones in a variety of brain 
regions (U'Prichard et al 1979; Morris et al 1981). Growth hormone release in response 
to clonidine is mediated by postsynaptic a l  adrenergic receptors (Terry and Martin 
1981). Dinan and Barry (1990), in their study in depressives used desipramine, a 
monoamine reuptake inhibitor, to assess the function of postsynaptic a l  adrenergic 
receptors. Desipramine by blocking the reuptake of noradrenaline and indirectly 
stimulating a l  adrenal receptors brings about growth hormone release (Laakmann et al 
1986).
We used the same neuroendocrine challenge test to assess the central noradrenergic 
function in patients with CFS. Blunted release of growth hormone in response to 
desipramine challenge was demonstrated in a cohort of patients with chronic fatigue 
syndrome. The abnormality may be attributed to a number of possible factors: 1.
presynaptic noradrenaline (NE) hypersecretion resulting in postsynaptic a l 
adrenoceptor downregulation. 2. reduced sensitivity of somatotroph to GHRH 
stimulation as desipramine induced GH secretion involves intermediate stimulation of 
the growth hormone releasing hormone (GHRH). 3. somatomedin C resulting in 
negative feedback on the production of GH. It is unlikely that the sensitivity of 
somatotroph is affected as in two preliminary studies (unpublished data), in patients with 
CFS, administration of GHRH produced an increase in GH release. On the other hand, 
somatomedin-mediated feedback inhibition is not possible in the presence of the well
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documented lower level of somatomedin C in this syndrome (Bennett et al 1992). 
Moreover, in order to exclude interference by fluctuations of ovarian hormones during 
menstrual cycle, all patients and controls were tested during the early follicular phase 
when ovarian secretion is minimal. Finally, we concluded that blunted growth hormone 
response to desipramine is due to a2 postsynaptic adrenoceptor downregulation 
secondary to a hypemoradrenergic state.
This result is consistent with the previous reports of lower levels of plasma 3 methoxy 4 
hydroxyphenethyleneglycol (MHPG) in patients with CFS (Demitrack et al 1992) 
suggesting a decrease in NE turnover. Norepinephrine turnover is determined by NE 
neuronal impulse flow and the amount of NE released and metabolised per nerve 
impulse (McMillen et al 1980). Due to increased synaptic NE (hyper-noradrenergic 
state) neuronal impulse flow is reduced and hence NE turnover is decreased. These 
results are in keeping with the previous reports of blunted growth hormone responses in 
depressed patients (Checkley et al 1981; Chamey et al 1982; Checkley et al 1984; 
Dinan and Barry 1990). Similarly, postsynaptic a2 adrenoceptors subsensitivity, as 
revealed by the blunted growth hormone response to colonidine stimulation is reported 
in patients with panic disorder (Chamey and Heninger 1986; Curtis et al 1989; Nutt et al 
1989).
In summary, growth hormone responses to desipramine are significantly attenuated in 
patients with CFS indicating o l2  -  postsynaptic adrenoceptor downregulation secondary 
to hyperadrenergic state and a decrease in central noradrenergic function. These 
findings are nor specific to CFS as in patients with depression (Dinan and Barry 1990) 
and panic disorder (Curtis et al 1989; Nutt et al 1989) they are similarly blunted. This 
test therefore cannot be used by itself as a specific diagnostic test for CFS.
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Pyridostigmine Induced Growth Hormone Release:
CFS is relatively common in farmers and agricultural workers exposed to sheep dips and 
insecticides containing organophosphates (Behan and Haniffah 1994). Psychiatric 
sequelae has also been reported due to chronic exposure to these insecticides (Gershon 
and Shaw 1961). Pharmacologically organophorphorus insecticides are cholinesterase 
inhibitors which prolong and intensify the effects of acetylcholine. There is convincing 
evidence for the role of acetylcholine in the regulation of mood, psychomotor activity 
and sleep (Schuberth 1978; Janowsky and Davis 1979). It has also been reported that 
centrally acting cholinergic drugs produce sleep changes characteristic of major 
depression (Sitaram et al 1977).
We therefore hypothesised that sleep disturbances and neurobehavioural symptoms in 
patients with CFS might be due to central acetylcholine neurotransmitter function 
abnormalities. We tested this hypothesis using a neuroendocrine challenge paradigm. 
The same approach has been used in two previous studies to assess central ACh 
neurotransmitter function. Risch (1982) found that physostigmine caused significantly 
greater increases in /3-endorphin in depressed as compared to normal subjects. In the 
second study O'Keane et al (1992) reported augmented GH release in response to 
another cholinesterase inhibitor pyridostigmine in depressive illness. We used the same 
pharmacological probe as it is well tolerated and its mechanism of action in the release 
of growth hormone is well understood. ACh promotes GH secretion by activating 
central muscarinic receptors, rather than nicotinic receptors as stimulation of nicotinic 
receptors by nicotine failed to alter the GH releasing ability of the potent cholinergic 
agonist eserine (Casanueva 1983). Along with its central action, it may also act at the 
level of the median eminence or the pituitary, as shown by the finding that 
methscopolamine, a cholinergic antagonist incapable of crossing the blood brain barrier,
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inhibits sleep and insulin-related growth hormone release (Mendleson et al 1978). The 
inhibition of GRH-induced GH release in man by the muscarinic cholinergic antagonist 
pirenzepine could also be explained by a pituitary site of action.
Pyridostigmine, by enhancing ACh neurotranmission, causes increased secretion of GH 
from the somatotrophs by reducing somatostatin release from the somatostatin 
containing neurones in the periventricular nucleus of hypothalamus (Ross et al 1987). In 
this study we found an augmented growth hormone response to pyridostigmine in 
patients with CFS compared to healthy controls. Pyridostigmine is a cholinesterase 
inhibitor and thereby prolongs and intensifies the effects of acetylcholine, an important 
neuromodulator of growth hormone release. Growth hormone secretion is primarily 
regulated by two hypothalamic peptides, GH releasing hormone (GHRH) and 
somatostatin with stimulating an inhibitory influence on the anterior pituitary 
somatotrophs respectively, with a negative feedback effect exerted by GH on its own 
secretion. Ross et al (1987) suggested that this negative feedback effect is mediated 
through hypothalamic somatostatin release and this stomatostatin secretion is under 
inhibitory cholinergic control. This is confirmed by studies in rats demonstrating a 
complete inhibition of GH responses to cholinergic drugs if hypothalamic somatostatin is 
selectively depleted (Locatelli et al 1986).
This increased growth hormone secretion seen in a group of patients with CFS may be 
attributed to a number of factors. 1. Increased sensitivity of somatotrophs to GHRH 
stimulation as pyridostigmine induced growth hormone secretion involves intermediate 
stimulation of GHRH. 2. Hyperresponsivity of cholinergic receptors as hypothalamic 
level, resulting in greater decrease in somatostatin tone and a bigger surge in GH release 
from the anterior pituitary. It is unlikely that the sensitivity of somatotroph is affected in 
CFS as in two preliminary studies (unpublished data) administration of GHRH produced
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normal increase in GH release. Acetylcholine hyperresponsivity at hypothalamic level is 
the most likely explanation for the increased growth hormone secretion and could be 
caused by presynaptic autoreceptor sub sensitivity; upregulation or hyperresponsivity of 
post-synaptic receptor or abnormalities in intracellular second messenger systems 
coupled to the ACh receptor. This finding of ACh hyperresponsitivity in patients with 
CFS may be partly responsible for sleep disturbances and neurobehavioural symptoms of 
this syndrome and is in keeping with the clinical observation that anticholinesterase 
administration (Bowers et al 1964) and physostigmine, a cholinominetic, produce 
behavioural changes and anergic symptoms, very much similar to that of CFS.
As stated in the methods section we tested all premenopausal women in the early 
follicular phase of menstrual cycle as growth hormone responses to pyridostigmine are 
profoundly influenced by the menstrual cycle phase due to changes in sex steroid 
hormones (O'Keane and Dinan 1992).
In summary, growth hormone responses to pyridostigmine are significantly enhanced in 
patients with CFS and reflect increased sensitivity of ACh neurotransmitter function. 
These findings are not specific to CFS as increased cholinergic sensitivity has also been 
reported in depression (O'Keane et al 1992). This cholinergic overdrive in CFS is 
probably due to monoamine (NE) depletion which as reported in the previous study is 
consistent with the cholinergic-adrenergic balance hypothesis of depression (Janowsky 
et al 1972) it may be the reason why a few of the symptoms of both disorders overlap.
CFS is also known as post-viral fatigue syndrome. Over the years several viruses have 
been postulated to be of aetiological significance, including EBV and enteroviruses such 
as the coxsackie B group. Other viruses implicated include herpes simplex, human 
herpes virus type 6, varicella zoster and rubella (for detail see under section aetiology).
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None of these viruses has been definitively linked to this disorder, although viral 
genomic material has been found in the brain of a fatal case (McGarry et al 1994), 
suggesting that selective cerebral involvement could contribute to altered neurological 
and neuroendocrine function. Animals infected with viruses, for instance, neonatal mice 
with neuronal infection by lymphocytic choriomeningitis virus (LCMV) show decreased 
production of neurotransmitters. In neuroblastoma cells chronically infected with 
LCMV, there is no cytopathic effect, cloning efficiency is normal, but there is however, 
a complete cessation of the normal production of acetylcholine (Oldstone et al 1991). 
This hypothesis of persistent viruses causing altered cellular function, without cytopathic 
effect has been proposed as a possible mechanism to explain chronic fatigue syndrome 
(De La Torre et al 1991). Therefore it can be postulated that the hypersensitivity of 
ACh receptors in patients with CFS is due to decreased production of ACh 
neurotransmitter as a result of viral persistence.
Growth hormone release in response to dopamine agonist, bromocriptine.
There is considerable evidence to suggest that brain monoamines including 
noradrenaline (NE), dopamine (DA) and serotonin (5-HT) are significant determinants 
of mood and behaviour (Bunny et al 1971). Behavioural alterations in patients with 
basal ganglia lesion has also been reported (Bowen 1976). Bruno et al (Lui 5*) described 
the role for the basal ganglia in the generation of fatigue in patients with post-polio 
syndrome, a condition that bears striking similarities to CFS. In the first study we also 
postulated dopaminergic involvement in enhanced prolactin release to buspirone (5- 
HT1A agonist & dopamine antagonist) in patients with chronic fatigue syndrome. To 
test this hypothesis further we studied the dopamine agonist, bromocriptine induced 
growth hormone release in patients with chronic fatigue syndrome.
160
There is considerable evidence that dopamine is an important modulator of growth 
hormone release in man (Camanni et al 1977). Apomorphine and bromocriptine and 
potent GH secretogue (Wass 1983), and both enhance GHRH induced GH release 
(Delitala et al 1987), probably by inhibiting the release of endogenous somatostatin from 
the median eminence (Vance et al 1987). Others have suggested an inhibitory effect of 
DA on growth hormone release (Arce et al 1991) probably by decreasing noradrenergic 
mediated GH (Kuchel et al 1987). Therefore exact mechanism (s) of action for 
dopaminergic agents in stimulating the release of growth hormone in man are not 
entirely clear and requires further investigations.
We studied the post-synaptic DA receptor by means of a neuroendocrine strategy by 
quantitatively examining a DA mediated post-synaptic function. We have done this by 
determining the GH responses to a standardised dose of the DA agonist bromocriptine 
which acts both centrally and peripherally. We found no differences between patients 
with CFS and healthy controls. The results, of normal GH release, are in keeping with 
the previous reports of apomorphine induced GH release in depressed patients (Caspar 
1977; Jimmerson and Post 1984), whereas enhanced responses were reported in acute 
schizophrenia (Hirschowitz et al 1982, 1986). On the basis of this, we concluded that 
buspirone-induced enhanced prolactin release as previously reported is mediated through 
serotonergic transmission rather than dopamine mediated.
Bromocriptine produced no severe side effects and was in general very well tolerated. 
Four subjects reported slight dizziness, headache and nausea.
To summarise, we found that plasma GH responses to bromocriptine challenge were 
normal and hence DA neurotransmitter function in patients with CFS is unaffected.
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Baclofen Induced Growth Hormone Release:
Gamma-aminobutyric acid (GABA) is one of the major inhibitory neurotransmitter in the 
human brain (Sieghart 1989). The inhibitory action is mediated by GABA receptors, 
activation of GABA (A) receptor induces the fast inhibitory post-synaptic potential 
(IPSP) and GABA (B) slow inhibitory post-synaptic potential (IPSP) because of 
different underlying molecular mechanisms.
Involvement of GABA neurons in the control of affect and emotion has recently been 
proposed. Many studies have implicated GABA in the pathophysiology of depressive 
illness (Sanger et al 1986) and trials have shown that the selective GABA agonist 
progabide and fengabine display a therapeutic action in depressive disorders (Musch 
1986). The view that CFS is a form of depressive disorder, the sensitivity of GABA (B) 
receptors was assessed via the growth hormone response to baclofen to find out the 
role, if any, of GABAergic mechanisms in the pathophysiology of CFS.
Hypothalamic GABA (B) receptors have been shown to be involved in the modulation 
of human GH secretion (Koulu et al 1979; Pasariello et al 1982; Monteleone 1988). 
The exact mechanism by which this occurs is still unknown. Murakami et al (1985) have 
observed that passive immunisation with anti-GHRH antibodies abolishes the 
stimulatory influence of GABA on the somatotroph axis, implying that GHRH is 
essential for the GABA induced release of GH. Others have claimed that GABA's GH 
releasing capabilities are due to its ability to inhibit somatostatin release (Steardo et al 
1986; Twery & Gallagher 1990). On the basis of these observations it is concluded that 
GABA induced GH release may be a consequence of increased GHRH or reduced
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somatostatin (SS) activity. Baclofen, a direct GABA (B) agonist crosses the blood brain 
barrier (Naik et al 1976) and acts centrally to increase GH release.
In the present study, plasma GH response to baclofen was evaluated in a sample of 
healthy volunteers and CFS patients. Acute baclofen administration induced a clear cut 
increase in plasma GH in both healthy subjects and patients with CFS in agreement with 
previous reports by different groups (Koulu et al 1979; Monteleone et al 1988). There 
was a difference in the GH response to baclofen between males and females, the latter 
had a greater response due to augmented effect of oestradiol on growth hormone release 
(Lucey et al 1991).
No difference was found between healthy subjects and CFS patients with regard to GH 
response to acute GABAergic challenge. These findings suggest that GABAergic 
mechanisms are not involved in the pathophysiology of CFS. Similarly, in depression 
Monteleone et al (1990) found no difference between patients and control subjects. 
Other investigators (OTlynn and Dinan 1993) have reported blunted responses in 
depressed patients on the basis of high cortisol levels as chronic steroid exposure inhibit 
growth hormone release by enhancing somatostatin tone.
The view that chronic fatigue syndrome is a form of depressive disorder is not supported 
by the findings of this study. In depression GH responses to baclofen were blunted 
indicating lower than normal responsivity of type B-7 -aminobutyric acid receptors 
whereas we suggest non-involvement of GABAergic mechanisms in CFS.
CONCLUSION:
In the first study we examined serotonin function in CFS using 5-HT 1A receptor agonist 
buspirone. Prolactin responses to this agent were augmented in a group of patients with
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CFS compared to healthy controls. In the second study we looked at the interaction 
between serotoninergic neurotransmission and the function of the HPA axis. We found 
no difference in baseline ACTH and cortisol levels in CFS but a significant attenuation 
of ACTH release in response to the 5-HT1 agonist, ipsapirone.
In the third study, GH responses to dexamethasone were examined in two phases, 
before and after metyrapone administration. Blunted responses were recorded in each 
phase, considered to be due to cerebral steroid receptor resistance. Growth hormone 
responses to the anticholinesterase pyridostigmine and the monoamine reuptake inhibitor 
desipramine were examined and found to produce augmented and blunted responses 
respectively in patients with CFS compared with healthy subjects. Finally, growth 
hormone responses to the dopamine agonist bromocriptine and the GABA (B) agonist 
baclofen were measured and found to be normal.
In summary, in CFS, 5-HT receptors are upregulated and 5-HT function is increased. 
Cerebral steroid receptors are resistant and activation of HPA-axis to serotoninergic 
input is impaired. a 2-post-synaptic adrenoceptors show decreased sensitivity with a 
decrease in central noradrenergic function while cholinergic receptors are hypersensitive. 
Dopamine (DA) and GABA neurotransmitter systems are not involved in the 
pathophysiology of chronic fatigue syndrome. These neuroendocrine abnormalities may 
help to explain some of the pathophysiological features of CFS.
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